No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3bc5A, 1.0000, 0.00, 1.000, 263, 262, X-RAY CRYSTAL STRUCTURE OF HUMAN PPAR GAMMA WITH 2-(5-(3-(2- (5-METHYL-2-PHENYLOXAZOL-4-YL)ETHOXY)BENZYL)-2-PHENYL-2H-1 23-TRIAZOL-4-YL)ACETIC ACID
2, 4xldA, 0.9873, 0.44, 0.992, 263, 260, CRYSTAL STRUCTURE OF THE HUMAN PPARG-LBD/ROSIGLITAZONE COMPLEX OBTAINED BY DRY CO-CRYSTALLIZATION AND IN SITU DIFFRACTION
3, 1wm0X, 0.9831, 0.84, 0.996, 272, 262, PPARGAMMA IN COMPLEX WITH A 2-BABA COMPOUND
4, 2zvtA, 0.9783, 0.89, 0.992, 274, 261, CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
5, 2zk6A, 0.9777, 0.86, 0.989, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY
6, 3adwA, 0.9771, 0.88, 0.996, 274, 261, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID
7, 2zk2A, 0.9766, 0.89, 0.989, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
8, 2zk1A, 0.9760, 0.90, 0.992, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214- PROSTAGLANDIN J2
9, 3wmhA, 0.9755, 0.71, 1.000, 264, 259, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT75
10, 2zk4A, 0.9754, 0.93, 0.992, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO- EICOSATETRAENOIC ACID
11, 3adxA, 0.9751, 0.96, 0.989, 274, 261, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233
12, 2zk3A, 0.9751, 0.93, 0.992, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO- EICOSATETRAENOIC ACID
13, 2zk5A, 0.9747, 0.95, 0.989, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233
14, 3prgA, 0.9741, 0.65, 0.988, 267, 258, LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR
15, 3vspA, 0.9730, 0.81, 1.000, 265, 259, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28
16, 1knuA, 0.9722, 0.90, 0.985, 265, 260, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
17, 3ty0A, 0.9708, 1.17, 0.992, 277, 262, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3- ((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-23-DIHYDRO-1H- BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-24-DIONE
18, 1zgyA, 0.9702, 0.95, 0.985, 272, 259, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
19, 5ji0D, 0.9690, 0.92, 0.969, 269, 259, PPARGAMMA-RXRALPHA(S427F) HETERODIMER IN COMPLEX WITH SRC-1 ROSIGLITAZONE AND 9-CIS-RETANOIC ACID
20, 2om9C, 0.9683, 0.70, 0.992, 270, 257, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
21, 2om9A, 0.9682, 0.70, 0.992, 270, 257, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
22, 1fm9D, 0.9676, 1.03, 0.988, 272, 259, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
23, 3kduB, 0.9672, 1.30, 0.617, 271, 261, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE
24, 4a4vA, 0.9663, 0.91, 0.992, 264, 258, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
25, 5ugmB, 0.9662, 0.86, 0.992, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH EDAGLITAZONE
26, 3an3A, 0.9662, 1.08, 0.996, 263, 258, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S
27, 2yfeA, 0.9662, 0.77, 1.000, 264, 257, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1
28, 3gbkA, 0.9661, 0.91, 0.977, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST
29, 2f4bA, 0.9661, 0.89, 0.984, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST
30, 5ugmA, 0.9660, 0.86, 0.992, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH EDAGLITAZONE
31, 2athA, 0.9660, 0.89, 0.984, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST
32, 4xuhA, 0.9659, 0.89, 0.996, 264, 258, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH SULINDAC SULFIDE
33, 3vsoA, 0.9659, 0.77, 1.000, 263, 257, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21
34, 3noaA, 0.9658, 0.90, 0.984, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST
35, 1fm6D, 0.9658, 1.12, 0.988, 272, 259, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
36, 5gtoA, 0.9657, 0.88, 0.996, 267, 258, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH S35
37, 3e00D, 0.9656, 1.12, 0.981, 363, 260, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH GW9662 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
38, 5dwlA, 0.9650, 1.08, 0.988, 271, 260, HUMAN PPARGAMMA LIGAND BINDING DMAIN IN COMPLEX WITH SR1664
39, 3sp6A, 0.9648, 1.34, 0.632, 270, 261, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
40, 3kdtB, 0.9646, 1.40, 0.625, 271, 261, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE
41, 2g0gB, 0.9645, 0.96, 0.981, 271, 258, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
42, 2g0gA, 0.9645, 0.92, 0.981, 271, 258, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
43, 3adsA, 0.9643, 0.84, 1.000, 262, 257, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
44, 5gtnA, 0.9640, 1.30, 1.000, 271, 260, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH R35
45, 3r5nA, 0.9640, 0.45, 1.000, 256, 254, CRYSTAL STRUCTURE OF PPARGAMMALBD COMPLEXED WITH THE AGONIST MAGNOLOL
46, 3advA, 0.9638, 0.84, 1.000, 262, 257, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN
47, 2znoA, 0.9638, 1.11, 0.996, 266, 258, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
48, 4r6sA, 0.9637, 0.83, 0.992, 262, 257, CRYSTAL STRUCTURE OF PPARGAMMMA IN COMPLEX WITH SR1663
49, 3an4A, 0.9633, 0.74, 1.000, 262, 256, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R
50, 4a4wA, 0.9628, 0.90, 1.000, 263, 257, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
51, 3noaB, 0.9626, 0.98, 0.984, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST
52, 3dzuD, 0.9626, 1.08, 0.981, 359, 259, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH BVT.13 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
53, 2zk0A, 0.9626, 0.89, 0.984, 270, 257, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN
54, 5twoA, 0.9623, 0.82, 0.977, 270, 256, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGNAD BINDING DOMAIN IN COMPLEX WITH A NOVEL SELECTIVELY PPAR GAMMA-MODULATING LIGAND VSP- 51
55, 2f4bB, 0.9621, 1.01, 0.981, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST
56, 3po9A, 0.9620, 0.77, 0.996, 261, 256, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN
57, 4yt1A, 0.9619, 0.77, 1.000, 261, 256, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT76
58, 2hfpA, 0.9619, 1.09, 0.996, 272, 259, CRYSTAL STRUCTURE OF PPAR GAMMA WITH N-SULFONYL-2-INDOLE CARBOXAMIDE LIGANDS
59, 3b0qA, 0.9618, 1.10, 0.996, 262, 257, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555
60, 6an1A, 0.9617, 0.78, 0.992, 261, 256, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND AM-879
61, 3gbkB, 0.9616, 1.07, 0.977, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST
62, 2athB, 0.9615, 1.03, 0.988, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST
63, 5u42A, 0.9614, 0.95, 0.640, 271, 258, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 11
64, 5u3qB, 0.9613, 0.96, 0.640, 270, 258, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 1
65, 3vjhA, 0.9613, 0.82, 0.996, 261, 256, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35
66, 3pbaA, 0.9613, 0.79, 0.996, 262, 256, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA)
67, 2g0hB, 0.9613, 1.05, 0.977, 271, 258, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
68, 1k74D, 0.9613, 1.16, 0.969, 272, 259, THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES.
69, 2xkwA, 0.9612, 0.81, 0.996, 261, 256, LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
70, 5u3sA, 0.9611, 0.96, 0.640, 271, 258, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 3
71, 3tkmA, 0.9610, 1.19, 0.633, 270, 259, CRYSTAL STRUCTURE PPAR DELTA BINDING GW0742
72, 2prgA, 0.9609, 1.07, 0.981, 271, 258, LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
73, 2g0hA, 0.9608, 0.99, 0.965, 271, 258, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
74, 3vjiA, 0.9605, 1.11, 0.988, 262, 257, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53
75, 3r8iB, 0.9605, 1.03, 0.992, 270, 257, CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86)
76, 3b0rA, 0.9603, 0.84, 1.000, 262, 256, HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM
77, 3cs8A, 0.9601, 1.26, 0.973, 269, 259, STRUCTURAL AND BIOCHEMICAL BASIS FOR THE BINDING SELECTIVITY OF PPARG TO PGC-1A
78, 3kduA, 0.9599, 1.11, 0.634, 264, 257, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE
79, 2i4pA, 0.9596, 1.06, 0.988, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS.
80, 5y2oA, 0.9594, 1.05, 0.996, 262, 256, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN-PIOGLITAZONE COMPLEX
81, 2i4zA, 0.9592, 1.05, 1.000, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS.
82, 3lmpA, 0.9590, 0.87, 0.996, 264, 256, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
83, 5gtpA, 0.9588, 0.88, 0.977, 261, 256, THE AGONIST-FREE STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN THE PRESENCE OF THE SRC-1 COACTIVATOR PEPTIDE
84, 2i4jA, 0.9587, 1.07, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE)
85, 5dv6A, 0.9584, 0.87, 0.988, 261, 256, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1404 IN A COVALENT BONDED FORM
86, 4xumA, 0.9584, 0.78, 0.996, 260, 255, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
87, 3r8iA, 0.9584, 1.07, 1.000, 270, 257, CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86)
88, 3osiA, 0.9581, 0.77, 1.000, 260, 255, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA)
89, 3oswA, 0.9580, 0.77, 1.000, 261, 255, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA)
90, 3kdtA, 0.9580, 1.10, 0.630, 264, 257, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE
91, 5dv3A, 0.9579, 1.07, 0.973, 263, 258, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1405 IN A COVALENT BONDED FORM
92, 3v9yA, 0.9579, 0.90, 0.980, 261, 256, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
93, 3d6dA, 0.9577, 1.11, 0.981, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER)
94, 4f9mA, 0.9576, 0.97, 0.988, 261, 256, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
95, 3cdpA, 0.9573, 1.11, 0.984, 270, 257, CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST ANALOGUE OF CLOFIBRIC ACID
96, 3b1mA, 0.9573, 0.81, 0.992, 260, 255, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR CERCO-A
97, 3hodA, 0.9571, 1.12, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
98, 3cdsA, 0.9570, 1.10, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE)
99, 5ttoA, 0.9569, 0.81, 1.000, 260, 255, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1643
100, 5u3tA, 0.9568, 0.97, 0.642, 270, 257, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 4
101, 5u5lA, 0.9567, 0.71, 0.992, 259, 254, X-RAY CRYSTAL STRUCTURE OF THE PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH RIVOGLITAZONE
102, 3h0aD, 0.9567, 1.29, 0.988, 265, 258, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID CO-ACTIVATOR PEPTIDE AND A PARTIAL AGONIST
103, 1fm6X, 0.9566, 1.31, 0.969, 272, 258, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
104, 5dvcA, 0.9564, 1.18, 0.985, 268, 259, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1453 IN A COVALENT BONDED FORM
105, 2vstA, 0.9563, 0.82, 1.000, 260, 255, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)- HODE
106, 3b3kA, 0.9562, 1.14, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175
107, 3vn2A, 0.9554, 0.75, 1.000, 261, 254, CRYSTAL STRUCTURE OF PPARGAMMA COMPLEXED WITH TELMISARTAN
108, 2om9B, 0.9554, 0.89, 0.984, 260, 255, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
109, 2om9D, 0.9553, 0.89, 0.984, 260, 255, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
110, 1prgA, 0.9552, 1.15, 0.981, 270, 257, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
111, 3gwxB, 0.9551, 1.12, 0.636, 271, 258, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
112, 3et3A, 0.9549, 0.95, 0.984, 260, 255, STRUCTURE OF PPARGAMMA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
113, 5u3wA, 0.9546, 0.94, 0.645, 266, 256, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 7
114, 2hwrA, 0.9545, 1.24, 1.000, 261, 256, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
115, 5u43A, 0.9543, 0.95, 0.645, 266, 256, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 12
116, 1gwxB, 0.9542, 1.16, 0.636, 271, 258, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
117, 5azvA, 0.9540, 0.92, 0.996, 259, 255, CRYSTAL STRUCTURE OF HPPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 17-OXODHA
118, 5dv8A, 0.9538, 1.28, 0.992, 269, 259, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1451 IN A COVALENT BONDED FORM
119, 3v9tA, 0.9535, 0.82, 0.996, 258, 254, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
120, 3qt0A, 0.9532, 1.08, 0.984, 267, 257, REVEALING A STEROID RECEPTOR LIGAND AS A UNIQUE PPARGAMMA AGONIST
121, 2hwqA, 0.9532, 1.00, 0.984, 261, 255, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
122, 3adtA, 0.9531, 0.82, 0.996, 259, 254, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE
123, 3g9eA, 0.9527, 0.74, 1.000, 258, 253, ALEGLITAAR. A NEW. POTENT AND BALANCED DUAL PPARA/G AGONIST FOR THE TREATMENT OF TYPE II DIABETES
124, 2vv0A, 0.9526, 0.84, 0.996, 259, 254, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA
125, 6f2lA, 0.9524, 0.84, 0.984, 259, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570: STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 15 DAYS.
126, 4jl4A, 0.9524, 1.06, 0.988, 268, 255, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID]
127, 4r2uA, 0.9523, 1.06, 0.992, 260, 256, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1664
128, 3ho0A, 0.9523, 1.20, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
129, 3aduA, 0.9523, 0.83, 1.000, 259, 254, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE
130, 4y29A, 0.9522, 0.62, 0.992, 257, 252, IDENTIFICATION OF A NOVEL PPARG LIGAND THAT REGULATES METABOLISM
131, 3sz1A, 0.9521, 0.73, 0.996, 258, 253, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID
132, 1gwxA, 0.9521, 1.10, 0.634, 270, 257, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
133, 5u3rA, 0.9520, 1.18, 0.638, 270, 257, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 2
134, 4e4qA, 0.9520, 1.05, 0.988, 268, 255, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214
135, 1i7iA, 0.9520, 0.73, 0.992, 258, 253, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
136, 5u3vB, 0.9519, 1.18, 0.638, 267, 257, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 6
137, 3wj5A, 0.9519, 1.22, 0.980, 258, 255, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN
138, 3t03A, 0.9515, 1.00, 0.984, 265, 255, CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A NOVEL PARTIAL AGONIST GQ-16
139, 3s9sA, 0.9514, 0.99, 0.976, 258, 254, LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH A BENZIMIDAZOLE PARTIAL AGONIST
140, 3fejA, 0.9513, 0.78, 0.996, 258, 253, DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL PPARA/G AGONISTS
141, 5wqxA, 0.9512, 0.77, 0.996, 257, 253, COVALENT BOND FORMATION OF SYNTHETIC LIGAND WITH HPPARG-LBD
142, 3u9qA, 0.9512, 0.65, 0.992, 257, 252, LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH DECANOIC ACID AND PGC-1A PEPTIDE
143, 1zeoA, 0.9509, 1.06, 0.984, 263, 255, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST
144, 3et2A, 0.9508, 1.07, 0.645, 266, 256, STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
145, 5wr0A, 0.9507, 0.78, 0.996, 257, 253, HUISGEN CYCLOADDITION FOR PPARG-LBD LABELING BY SOAKING METHOD
146, 5wr1A, 0.9506, 0.78, 0.996, 257, 253, COVALENT BOND FORMATION OF BIFUNCTIONAL LIGAND WITH HPPARG-LBD
147, 2vv3A, 0.9505, 0.79, 0.996, 257, 253, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA
148, 2npaC, 0.9502, 1.35, 0.636, 267, 258, THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID
149, 4bcrB, 0.9500, 1.31, 0.633, 265, 256, STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643
150, 5y2tA, 0.9499, 0.94, 1.000, 261, 254, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN - LOBEGLITAZONE COMPLEX
151, 3v9vA, 0.9498, 0.82, 0.996, 258, 253, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
152, 3et0A, 0.9498, 0.95, 0.988, 259, 254, STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)- PROPIONIC ACID
153, 4e4kA, 0.9497, 1.09, 0.988, 268, 255, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21
154, 3x1iA, 0.9497, 0.81, 0.992, 257, 253, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXO- TETRACOSAHEXAENOIC ACID
155, 5u3zA, 0.9496, 0.97, 0.643, 268, 255, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 10
156, 3gwxA, 0.9496, 1.16, 0.638, 270, 257, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
157, 3dzyD, 0.9496, 0.97, 0.984, 354, 254, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH ROSIGLITAZONE 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
158, 4jazA, 0.9494, 1.11, 0.988, 268, 255, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS- RESVERATROL
159, 3cwdB, 0.9492, 1.05, 0.988, 260, 254, MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA
160, 2b50B, 0.9491, 1.39, 0.647, 263, 258, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2
161, 4em9A, 0.9490, 0.83, 0.992, 259, 253, HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS
162, 2vsrA, 0.9490, 0.71, 1.000, 257, 252, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE
163, 2gtkA, 0.9487, 0.85, 0.984, 258, 253, STRUCTURE-BASED DESIGN OF INDOLE PROPIONIC ACIDS AS NOVEL PPARAG CO-AGONISTS
164, 1nyxA, 0.9484, 0.95, 0.992, 260, 254, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST
165, 3et2B, 0.9482, 1.13, 0.648, 267, 256, STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
166, 4ci5A, 0.9478, 1.08, 0.988, 260, 255, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR GAMMA AGONIST
167, 2xyjA, 0.9473, 1.03, 0.639, 263, 255, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
168, 5y7xB, 0.9472, 1.23, 0.637, 262, 256, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DELTA IN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST 
169, 3et1B, 0.9471, 1.40, 0.632, 270, 258, STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
170, 2fvjA, 0.9469, 0.87, 1.000, 258, 253, A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR-GAMMA (PPARG) RECRUITS PPARG-COACTIVATOR-1 ALPHA (PGC1A) BUT POTENTIATES INSULIN SIGNALING IN VITRO
171, 5u46A, 0.9466, 0.95, 0.642, 264, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH GW501516
172, 5u3tB, 0.9464, 1.10, 0.647, 265, 255, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 4
173, 3k8sB, 0.9462, 0.89, 0.996, 258, 253, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384
174, 5u3yA, 0.9461, 1.32, 0.637, 263, 256, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 9
175, 4prgC, 0.9458, 1.29, 0.965, 270, 257, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
176, 6enqA, 0.9457, 0.70, 1.000, 256, 251, STRUCTURE OF HUMAN PPAR GAMMA LBD IN COMPLEX WITH LANIFIBRANOR (IVA337)
177, 5u45B, 0.9456, 1.01, 0.642, 265, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 14
178, 5dshA, 0.9456, 0.90, 0.996, 258, 253, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1406 IN A COVALENT BONDED FORM
179, 3ty0B, 0.9456, 1.46, 0.961, 277, 258, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3- ((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-23-DIHYDRO-1H- BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-24-DIONE
180, 2vv1A, 0.9454, 0.83, 0.992, 256, 252, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA
181, 4fgyA, 0.9453, 1.14, 0.984, 265, 255, IDENTIFICATION OF A UNIQUE PPAR LIGAND WITH AN UNEXPECTED BINDING MODE AND ANTIBETIC ACTIVITY
182, 2vv2A, 0.9453, 0.83, 0.992, 256, 252, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA
183, 3x1hA, 0.9451, 0.71, 1.000, 256, 251, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-OXO- TRICOSAHEXAENOIC ACID
184, 2znqB, 0.9451, 1.34, 0.637, 260, 256, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP401
185, 5u46B, 0.9450, 0.98, 0.642, 264, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH GW501516
186, 4prgA, 0.9450, 1.32, 0.961, 270, 257, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
187, 2pobA, 0.9449, 0.99, 0.996, 255, 253, PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709
188, 5u3qA, 0.9445, 1.13, 0.643, 265, 255, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 1
189, 4emaA, 0.9445, 0.74, 0.984, 256, 251, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE
190, 3kmgA, 0.9445, 0.86, 0.996, 259, 252, THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR GSK538 AND AN SRC-1 PEPTIDE
191, 1y0sA, 0.9443, 1.17, 0.639, 260, 255, CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331
192, 2q61A, 0.9441, 0.76, 0.984, 256, 251, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145
193, 4pvuA, 0.9440, 0.85, 0.996, 257, 252, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE R ENANTIOMER OF MBX-102 (METAGLIDASEN)
194, 2znpB, 0.9438, 1.53, 0.640, 262, 258, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP204
195, 2npaA, 0.9437, 1.40, 0.638, 269, 257, THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID
196, 3wj4A, 0.9431, 1.26, 0.980, 256, 253, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN
197, 5lsgA, 0.9429, 0.78, 0.996, 256, 251, PPARGAMMA COMPLEX WITH THE BETULINIC ACID
198, 3wj4B, 0.9426, 1.50, 0.953, 260, 256, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN
199, 5y2tB, 0.9424, 1.34, 0.945, 263, 254, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN - LOBEGLITAZONE COMPLEX
200, 5u42B, 0.9424, 0.98, 0.640, 263, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 11
201, 2xyxB, 0.9424, 0.97, 0.656, 263, 253, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
202, 3wj5B, 0.9419, 1.60, 0.953, 258, 256, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN
203, 3kmgD, 0.9418, 0.80, 0.996, 256, 251, THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR GSK538 AND AN SRC-1 PEPTIDE
204, 3gz9A, 0.9416, 1.27, 0.645, 262, 256, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPARD) IN COMPLEX WITH A FULL AGONIST
205, 3furA, 0.9415, 0.82, 0.980, 256, 251, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH INT131
206, 2gwxB, 0.9415, 1.12, 0.642, 267, 254, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
207, 2vv4A, 0.9414, 0.88, 0.992, 254, 251, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE
208, 1i7gA, 0.9414, 1.10, 0.642, 259, 254, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ 242
209, 5u3sB, 0.9410, 1.02, 0.640, 263, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 3
210, 2q5sA, 0.9410, 0.85, 0.988, 256, 251, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA
211, 2yfeB, 0.9409, 1.03, 0.968, 264, 252, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1
212, 4xuhB, 0.9407, 1.13, 0.960, 258, 253, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH SULINDAC SULFIDE
213, 3sz1B, 0.9406, 1.06, 0.964, 258, 252, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID
214, 4a4vB, 0.9404, 1.05, 0.968, 265, 252, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
215, 2q5pA, 0.9404, 0.84, 0.996, 256, 251, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24
216, 2xywB, 0.9402, 1.02, 0.652, 263, 253, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
217, 2p54A, 0.9401, 1.41, 0.643, 267, 255, A CRYSTAL STRUCTURE OF PPAR ALPHA BOUND WITH SRC1 PEPTIDE AND GW735
218, 1prgB, 0.9401, 1.16, 0.949, 270, 253, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
219, 4a4wB, 0.9398, 1.05, 0.968, 264, 252, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
220, 5y2oB, 0.9391, 1.34, 0.957, 257, 253, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN-PIOGLITAZONE COMPLEX
221, 2znqA, 0.9391, 1.39, 0.643, 262, 255, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP401
222, 3d6dB, 0.9387, 1.21, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER)
223, 5u43B, 0.9385, 0.97, 0.643, 262, 252, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 12
224, 3cdpB, 0.9382, 1.21, 0.953, 270, 253, CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST ANALOGUE OF CLOFIBRIC ACID
225, 3ia6A, 0.9381, 0.69, 0.988, 254, 249, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
226, 3hodB, 0.9381, 1.22, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
227, 5u45A, 0.9380, 0.98, 0.643, 262, 252, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 14
228, 5u3xA, 0.9380, 1.22, 0.638, 262, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 8
229, 3cdsB, 0.9380, 1.21, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE)
230, 3b3kB, 0.9380, 1.23, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175
231, 2xywA, 0.9378, 1.06, 0.652, 263, 253, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
232, 1k7lE, 0.9377, 1.39, 0.643, 267, 255, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
233, 2gwxA, 0.9375, 1.06, 0.639, 265, 252, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
234, 3cwdA, 0.9371, 0.92, 0.992, 257, 251, MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA
235, 2xyjB, 0.9371, 1.36, 0.646, 259, 254, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
236, 5u3vA, 0.9370, 1.03, 0.643, 262, 252, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 6
237, 2rewA, 0.9369, 0.93, 0.641, 255, 251, CRYSTAL STRUCTURE OF PPARALPHA LIGAND BINDING DOMAIN WITH BMS-631707
238, 3k8sA, 0.9368, 1.27, 0.953, 262, 253, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384
239, 5u3rB, 0.9365, 1.19, 0.640, 261, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 2
240, 2q61B, 0.9365, 1.26, 0.964, 259, 253, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145
241, 1knuB, 0.9365, 1.25, 0.968, 258, 252, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
242, 2b50A, 0.9364, 1.17, 0.644, 261, 253, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2
243, 2i4jB, 0.9362, 1.27, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE)
244, 4pwlA, 0.9359, 0.86, 0.996, 255, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE S ENANTIOMER OF MBX-102 (METAGLIDASEN)
245, 5u44B, 0.9358, 1.36, 0.640, 260, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 13
246, 2q6rB, 0.9358, 1.30, 0.953, 258, 253, CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147
247, 3et1A, 0.9356, 1.66, 0.645, 263, 256, STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
248, 2q5sB, 0.9353, 1.29, 0.960, 258, 253, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA
249, 5y7xA, 0.9352, 1.49, 0.642, 258, 254, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DELTA IN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST 
250, 5u3wB, 0.9352, 0.97, 0.645, 261, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 7
251, 3dy6A, 0.9351, 1.14, 0.639, 257, 252, PPARDELTA COMPLEXED WITH AN ANTHRANILIC ACID PARTIAL AGONIST
252, 4o8fA, 0.9350, 1.00, 0.992, 252, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA MUTANT R357A AND ROSIGLITAZONE
253, 5f9bA, 0.9349, 0.79, 0.988, 254, 249, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN THE COMPLEX WITH CAULOPHYLLOGENIN
254, 2q8sA, 0.9347, 0.69, 0.996, 253, 248, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
255, 1k7lA, 0.9347, 1.56, 0.643, 267, 255, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
256, 2zk0B, 0.9346, 1.23, 0.956, 259, 252, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN
257, 1y0sB, 0.9346, 1.26, 0.636, 258, 253, CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331
258, 5u5lB, 0.9344, 1.33, 0.956, 254, 252, X-RAY CRYSTAL STRUCTURE OF THE PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH RIVOGLITAZONE
259, 1k7lG, 0.9344, 1.58, 0.643, 267, 255, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
260, 3ho0B, 0.9342, 1.30, 0.953, 270, 253, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
261, 3sp9A, 0.9341, 1.39, 0.641, 269, 256, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
262, 2q6sA, 0.9341, 0.81, 0.996, 254, 249, 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES
263, 4yt1B, 0.9340, 1.13, 0.976, 257, 251, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT76
264, 2q8sB, 0.9340, 1.15, 0.948, 254, 251, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
265, 5xmxA, 0.9339, 1.17, 0.643, 257, 252, CO-CRYSTAL STRUCTURE OF INHIBITOR COMPOUND IN COMPLEX WITH HUMAN PPARDELTA LBD 
266, 3an4B, 0.9339, 1.09, 0.972, 257, 251, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R
267, 2i4zB, 0.9336, 1.35, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS.
268, 1rdtD, 0.9332, 0.81, 0.996, 253, 248, CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER
269, 5u41B, 0.9330, 1.00, 0.645, 261, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 16
270, 5u3zB, 0.9330, 1.01, 0.645, 261, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 10
271, 4e4qB, 0.9329, 1.15, 0.956, 268, 251, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214
272, 1k7lC, 0.9329, 1.60, 0.643, 267, 255, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
273, 3g8iA, 0.9327, 1.19, 0.635, 254, 252, ALEGLITAZAR A NEW POTENT AND BALANCED PPAR ALPHA/GAMMA AGONIST FOR THE TREATMENT OF TYPE II DIABETES
274, 3sp9B, 0.9326, 1.43, 0.641, 267, 256, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
275, 3ia6B, 0.9326, 1.10, 0.968, 255, 250, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
276, 2i4pB, 0.9325, 1.33, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS.
277, 5hykA, 0.9324, 1.15, 0.645, 255, 251, CRYSTAL STRUCTURE OF THE COMPLEX PPARALPHA/AL26-29
278, 3peqB, 0.9324, 1.40, 0.636, 257, 253, PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST
279, 4r06A, 0.9320, 0.93, 0.984, 252, 249, CRYSTAL STRUCTURE OF SR2067 BOUND TO PPARGAMMA
280, 4heeX, 0.9319, 0.90, 0.988, 251, 249, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH COMPOUND 13
281, 1nyxB, 0.9317, 1.36, 0.948, 258, 252, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST
282, 5ttoB, 0.9316, 1.24, 0.964, 258, 251, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1643
283, 2q59A, 0.9316, 0.91, 0.996, 254, 249, CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20
284, 2zk2B, 0.9315, 1.14, 0.976, 263, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
285, 2vv2B, 0.9313, 1.23, 0.968, 257, 251, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA
286, 4r6sB, 0.9312, 1.29, 0.964, 254, 251, CRYSTAL STRUCTURE OF PPARGAMMMA IN COMPLEX WITH SR1663
287, 3wmhB, 0.9310, 1.11, 0.980, 256, 250, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT75
288, 3vsoB, 0.9310, 1.08, 0.976, 260, 250, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21
289, 3vi8A, 0.9310, 1.25, 0.641, 258, 251, HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST APHM13
290, 2znnA, 0.9309, 1.25, 0.641, 258, 251, HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
291, 2xyxA, 0.9308, 1.05, 0.653, 261, 251, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
292, 4xumB, 0.9306, 1.36, 0.960, 260, 252, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
293, 3vspB, 0.9306, 1.08, 0.972, 259, 250, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28
294, 1i7iB, 0.9306, 1.15, 0.960, 258, 250, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
295, 4r2uD, 0.9305, 1.26, 0.968, 257, 251, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1664
296, 2zk1B, 0.9305, 1.12, 0.968, 263, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214- PROSTAGLANDIN J2
297, 3an3B, 0.9303, 1.10, 0.980, 256, 250, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S
298, 4bcrA, 0.9301, 1.30, 0.637, 263, 251, STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643
299, 6an1B, 0.9293, 1.26, 0.960, 253, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND AM-879
300, 5u3uA, 0.9291, 1.33, 0.641, 255, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 5
301, 2zk3B, 0.9291, 1.20, 0.968, 263, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO- EICOSATETRAENOIC ACID
302, 3peqA, 0.9290, 1.31, 0.645, 255, 251, PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST
303, 6c5tA, 0.9288, 1.49, 0.964, 269, 251, PPARG LBD BOUND TO SR11023 
304, 4prgD, 0.9287, 1.39, 0.949, 270, 253, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
305, 4e4kB, 0.9287, 1.22, 0.956, 268, 251, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21
306, 5lsgB, 0.9286, 1.22, 0.960, 260, 250, PPARGAMMA COMPLEX WITH THE BETULINIC ACID
307, 2zk4B, 0.9286, 1.19, 0.968, 263, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO- EICOSATETRAENOIC ACID
308, 2zk5B, 0.9285, 1.22, 0.968, 263, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233
309, 4jl4B, 0.9284, 1.18, 0.960, 267, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID]
310, 5u40B, 0.9283, 1.37, 0.635, 259, 252, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 15
311, 3adwB, 0.9283, 1.22, 0.972, 260, 250, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID
312, 2xkwB, 0.9283, 1.41, 0.968, 256, 251, LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
313, 2vsrB, 0.9283, 1.39, 0.968, 255, 250, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE
314, 2zvtB, 0.9282, 1.21, 0.972, 263, 250, CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
315, 4r06B, 0.9281, 1.25, 0.964, 252, 250, CRYSTAL STRUCTURE OF SR2067 BOUND TO PPARGAMMA
316, 2zk6B, 0.9280, 1.23, 0.960, 262, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY
317, 3dy6B, 0.9277, 1.14, 0.640, 255, 250, PPARDELTA COMPLEXED WITH AN ANTHRANILIC ACID PARTIAL AGONIST
318, 3d5fB, 0.9276, 1.25, 0.644, 254, 250, CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX
319, 4ci5B, 0.9275, 1.42, 0.960, 260, 252, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR GAMMA AGONIST
320, 6f2lB, 0.9272, 1.31, 0.968, 255, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570: STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 15 DAYS.
321, 4prgB, 0.9271, 1.40, 0.945, 270, 253, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
322, 6c5qA, 0.9270, 1.48, 0.956, 277, 251, PPARG LBD BOUND TO SR10171 
323, 4jazB, 0.9269, 1.21, 0.964, 267, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS- RESVERATROL
324, 3advB, 0.9269, 1.31, 0.960, 257, 250, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN
325, 5aztA, 0.9266, 1.44, 0.627, 261, 252, TERNARY COMPLEX OF HPPARALPHA LIGAND BINDING DOMAIN 17-OXODHA AND A SRC1 PEPTIDE
326, 2znpA, 0.9266, 1.27, 0.641, 259, 251, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP204
327, 2awhA, 0.9258, 1.34, 0.651, 254, 252, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
328, 5u41A, 0.9257, 1.08, 0.644, 260, 250, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 16
329, 3r8aA, 0.9254, 1.21, 0.960, 251, 249, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY
330, 3adxB, 0.9251, 1.22, 0.968, 251, 249, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233
331, 5hzcA, 0.9249, 0.76, 0.988, 251, 246, CRYSTAL STRUCTURE OF THE COMPLEX PPARGAMMA/AL26-29
332, 3x1hB, 0.9249, 1.36, 0.968, 254, 249, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-OXO- TRICOSAHEXAENOIC ACID
333, 2q6sB, 0.9248, 1.43, 0.948, 253, 249, 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES
334, 5u3yB, 0.9243, 1.37, 0.641, 255, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 9
335, 3adsB, 0.9242, 1.23, 0.968, 251, 249, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
336, 4ci4A, 0.9233, 0.80, 0.638, 248, 246, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR ALPHA AGONIST
337, 2q59B, 0.9233, 1.27, 0.968, 253, 248, CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20
338, 5u44A, 0.9225, 1.39, 0.640, 257, 250, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 13
339, 2vv0B, 0.9225, 1.29, 0.956, 252, 249, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA
340, 5aztB, 0.9224, 0.91, 0.640, 251, 247, TERNARY COMPLEX OF HPPARALPHA LIGAND BINDING DOMAIN 17-OXODHA AND A SRC1 PEPTIDE
341, 3et0B, 0.9223, 1.15, 0.940, 258, 248, STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)- PROPIONIC ACID
342, 2bawA, 0.9222, 1.09, 0.649, 250, 248, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
343, 4o8fB, 0.9220, 0.85, 0.996, 249, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA MUTANT R357A AND ROSIGLITAZONE
344, 3d5fA, 0.9219, 1.39, 0.648, 254, 250, CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX
345, 3aduB, 0.9211, 1.31, 0.964, 261, 249, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE
346, 3adtB, 0.9210, 1.32, 0.956, 257, 249, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE
347, 3pbaB, 0.9208, 1.32, 0.968, 249, 248, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA)
348, 3t03B, 0.9202, 0.88, 0.996, 249, 246, CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A NOVEL PARTIAL AGONIST GQ-16
349, 2znoB, 0.9200, 1.26, 0.968, 251, 248, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
350, 2hwrB, 0.9192, 1.27, 0.960, 253, 247, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
351, 2hwqB, 0.9192, 1.26, 0.968, 253, 247, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
352, 4oj4A, 0.9183, 1.29, 0.964, 260, 247, CRYSTAL STRUCTURE OF V290M PPARGAMMA MUTANT IN COMPLEX WITH DICLOFENAC
353, 2awhB, 0.9183, 1.10, 0.649, 250, 248, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
354, 5u40A, 0.9182, 1.21, 0.635, 257, 249, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 15
355, 2bawB, 0.9179, 0.93, 0.659, 248, 246, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
356, 3oswB, 0.9162, 1.23, 0.959, 248, 246, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA)
357, 5u3xB, 0.9148, 0.99, 0.654, 252, 246, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 8
358, 4xtaA, 0.9146, 0.95, 0.984, 248, 245, MECHANISMS OF PPARGAMMA ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
359, 3po9B, 0.9144, 1.52, 0.960, 249, 248, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN
360, 5u3uB, 0.9130, 1.10, 0.645, 250, 245, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 5
361, 2j14A, 0.9115, 1.34, 0.649, 253, 248, 345-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2
362, 5wr1B, 0.9114, 1.31, 0.967, 246, 245, COVALENT BOND FORMATION OF BIFUNCTIONAL LIGAND WITH HPPARG-LBD
363, 4l98B, 0.9114, 1.79, 0.940, 258, 250, CRYSTAL STRUCTURE OF THE COMPLEX OF F360L PPARGAMMA MUTANT WITH THE LIGAND LT175
364, 5wqxB, 0.9110, 1.33, 0.967, 246, 245, COVALENT BOND FORMATION OF SYNTHETIC LIGAND WITH HPPARG-LBD
365, 5wr0B, 0.9107, 1.33, 0.967, 246, 245, HUISGEN CYCLOADDITION FOR PPARG-LBD LABELING BY SOAKING METHOD
366, 1zeoB, 0.9106, 1.27, 0.963, 247, 245, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST
367, 2vv4B, 0.9105, 1.36, 0.963, 247, 245, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE
368, 5azvB, 0.9102, 1.35, 0.967, 246, 245, CRYSTAL STRUCTURE OF HPPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 17-OXODHA
369, 2vv3B, 0.9094, 1.37, 0.967, 246, 245, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA
370, 2vstB, 0.9094, 1.64, 0.955, 248, 247, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)- HODE
371, 3oz0A, 0.9090, 1.65, 0.633, 260, 248, PPAR DELTA IN COMPLEX WITH AZPPARD02
372, 4l96A, 0.9088, 1.73, 0.948, 260, 251, STRUCTURE OF THE COMPLEX BETWEEN THE F360L PPARGAMMA MUTANT AND THE LIGAND LT175 (SPACE GROUP I222)
373, 3feiA, 0.9088, 1.03, 0.648, 246, 244, DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL PPARA/G AGONISTS
374, 3osiB, 0.9086, 1.25, 0.967, 245, 244, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA)
375, 3vjhB, 0.9084, 1.39, 0.959, 246, 245, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35
376, 2prgB, 0.9080, 0.93, 0.992, 246, 242, LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
377, 2j14B, 0.9071, 1.28, 0.650, 251, 246, 345-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2
378, 2p4yA, 0.9044, 0.93, 0.996, 244, 242, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR
379, 4pvuB, 0.9034, 1.16, 0.967, 252, 243, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE R ENANTIOMER OF MBX-102 (METAGLIDASEN)
380, 3vjiB, 0.9031, 1.50, 0.963, 245, 244, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53
381, 2pobB, 0.9031, 1.11, 0.971, 247, 242, PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709
382, 4pwlB, 0.9022, 1.17, 0.959, 252, 243, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE S ENANTIOMER OF MBX-102 (METAGLIDASEN)
383, 3b0qB, 0.9016, 1.50, 0.967, 245, 244, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555
384, 2q5pB, 0.9011, 1.43, 0.947, 245, 243, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24
385, 3b0rB, 0.8992, 1.58, 0.967, 245, 244, HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM
386, 4em9B, 0.8988, 1.41, 0.959, 243, 242, HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS
387, 5f9bB, 0.8980, 1.11, 0.954, 250, 241, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN THE COMPLEX WITH CAULOPHYLLOGENIN
388, 6enqB, 0.8972, 1.14, 0.967, 247, 241, STRUCTURE OF HUMAN PPAR GAMMA LBD IN COMPLEX WITH LANIFIBRANOR (IVA337)
389, 1kkqB, 0.8962, 1.86, 0.609, 269, 248, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
390, 5xmxB, 0.8960, 1.29, 0.647, 245, 241, CO-CRYSTAL STRUCTURE OF INHIBITOR COMPOUND IN COMPLEX WITH HUMAN PPARDELTA LBD 
391, 1kkqD, 0.8953, 1.75, 0.607, 269, 247, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
392, 5hzcB, 0.8944, 1.22, 0.954, 250, 241, CRYSTAL STRUCTURE OF THE COMPLEX PPARGAMMA/AL26-29
393, 1kkqA, 0.8940, 1.88, 0.617, 269, 248, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
394, 1kkqC, 0.8939, 1.78, 0.611, 269, 247, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
395, 4emaB, 0.8920, 1.27, 0.942, 244, 241, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE
396, 4xtaB, 0.8893, 1.12, 0.962, 243, 239, MECHANISMS OF PPARGAMMA ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
397, 3r8aB, 0.8858, 1.47, 0.950, 239, 239, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY
398, 2vv1B, 0.8848, 1.36, 0.971, 239, 238, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA
399, 3x1iB, 0.8778, 1.33, 0.970, 237, 236, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXO- TETRACOSAHEXAENOIC ACID
400, 2q6rA, 0.8756, 0.65, 0.987, 235, 232, CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147
401, 2q5gA, 0.8728, 1.61, 0.633, 244, 237, LIGAND BINDING DOMAIN OF PPAR DELTA RECEPTOR IN COMPLEX WITH A PARTIAL AGONIST
402, 4l98A, 0.8637, 1.47, 0.949, 244, 234, CRYSTAL STRUCTURE OF THE COMPLEX OF F360L PPARGAMMA MUTANT WITH THE LIGAND LT175
403, 2q5gB, 0.8624, 1.04, 0.651, 235, 232, LIGAND BINDING DOMAIN OF PPAR DELTA RECEPTOR IN COMPLEX WITH A PARTIAL AGONIST
404, 2p4yB, 0.8349, 1.35, 0.964, 227, 225, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR
405, 2qmvA, 0.8316, 2.80, 0.914, 270, 255, HIGH RESOLUTION STRUCTURE OF PEROXISONE PROLIFERATION-ACTIVATED RECEPTOR GAMMA AND CHARACTERISATION OF ITS INTERACTION WITH THE CO- ACTIVATOR TRANSCRIPTIONAL INTERMEDIARY FACTOR 2
406, 1n83A, 0.8201, 2.28, 0.256, 251, 238, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE ORPHAN NUCLEAR HORMONE RECEPTOR ROR(ALPHA)-LBD AND CHOLESTEROL
407, 1s0xA, 0.8195, 2.30, 0.252, 251, 238, CRYSTAL STRUCTURE OF THE HUMAN RORALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH CHOLESTEROL SULFATE AT 2.2A
408, 4s15B, 0.8172, 2.43, 0.243, 250, 239, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
409, 5iz0G, 0.8116, 2.40, 0.223, 246, 238, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
410, 5iz0B, 0.8104, 2.36, 0.224, 245, 237, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
411, 4wpfA, 0.8082, 2.54, 0.223, 246, 238, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST
412, 1k4wA, 0.8082, 2.31, 0.237, 244, 236, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR BETA LIGAND-BINDING DOMAIN IN THE ACTIVE CONFORMATION
413, 4wpfD, 0.8080, 2.55, 0.223, 246, 238, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST
414, 4s15A, 0.8078, 2.35, 0.246, 244, 236, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
415, 5vb3A, 0.8076, 2.58, 0.223, 259, 238, X-RAY STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN + SRC2 PEPTIDE
416, 5vb5A, 0.8057, 2.62, 0.223, 259, 238, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN INVERSE AGONIST AND SRC2 PEPTIDE
417, 5g46A, 0.8057, 2.52, 0.224, 246, 237, LIGAND COMPLEX OF RORG LBD
418, 5vqlA, 0.8051, 2.62, 0.223, 259, 238, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH A INVERSE AGONIST AND SRC2 PEPTIDE 
419, 5vb6A, 0.8041, 2.64, 0.223, 259, 238, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN INVERSE AGONIST AND SRC2 PEPTIDE
420, 5g43A, 0.8041, 2.53, 0.232, 252, 237, LIGAND COMPLEX OF RORG LBD
421, 5aphA, 0.8041, 2.53, 0.224, 252, 237, LIGAND COMPLEX OF RORG LBD
422, 4ymqA, 0.8036, 2.43, 0.225, 254, 236, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT + SRC2 PEPTIDE WITH A BENZOTHIADIAZOLE DIOXIDE INVERSE AGONIST
423, 1nq7A, 0.8036, 2.40, 0.237, 244, 236, CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR RORBETA
424, 5g45A, 0.8035, 2.43, 0.225, 244, 236, LIGAND COMPLEX OF RORG LBD
425, 5g42A, 0.8029, 2.55, 0.224, 252, 237, LIGAND COMPLEX OF RORG LBD
426, 5yp5A, 0.8028, 2.38, 0.226, 243, 235, CRYSTAL STRUCTURE OF RORGAMMA COMPLEXED WITH SRC2 AND COMPOUND 5D
427, 4xt9A, 0.8028, 2.38, 0.226, 243, 235, RORGAMMA (263-509) COMPLEXED WITH GSK2435341A AND SRC2
428, 1n4hA, 0.8028, 2.39, 0.237, 244, 236, CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR RORBETA
429, 5x8wA, 0.8022, 2.51, 0.220, 244, 236, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN.
430, 5vqkA, 0.8022, 2.56, 0.224, 256, 237, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH A INVERSE AGONIST AND SRC2 PEPTIDE 
431, 5nu1A, 0.8022, 2.46, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
432, 5yp6A, 0.8021, 2.38, 0.226, 243, 235, RORGAMMA (263-509) COMPLEXED WITH SRC2 AND COMPOUND 6
433, 5x8uA, 0.8021, 2.51, 0.225, 244, 236, CRYSTAL STRUCTURE OF THE WILD HUMAN ROR GAMMA LIGAND BINDING DOMAIN.
434, 5vb7A, 0.8021, 2.65, 0.223, 259, 238, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN AGONIST AND SRC2 PEPTIDE
435, 5g44A, 0.8018, 2.46, 0.225, 245, 236, LIGAND COMPLEX OF RORG LBD
436, 5ejvB, 0.8018, 2.45, 0.225, 245, 236, RORY IN COMPLEX WITH T090131718 AND COACTIVATOR PEPTIDE EBI96
437, 6fzuA, 0.8015, 2.46, 0.225, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ( CPD-1 ) AND RIP140 PEPTIDE AT 1.80A 
438, 6fx0A, 0.8013, 2.49, 0.245, 238, 233, STRUCTURE-BASED DESIGN OF TRIFAROTENE (CD5789); A POTENT AND SELECTIVE RAR GAMMA AGONIST FOR THE TREATMENT OF ACNE 
439, 5ntwD, 0.8012, 2.47, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
440, 5apjA, 0.8009, 2.41, 0.226, 250, 235, LIGAND COMPLEX OF RORG LBD
441, 4nieB, 0.8004, 2.47, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND
442, 6g07D, 0.8000, 2.49, 0.225, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
443, 4wlbB, 0.7999, 2.43, 0.230, 248, 235, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST COMPOUND
444, 4dm8B, 0.7998, 2.44, 0.249, 239, 233, CRYSTAL STRUCTURE OF RARB LBD IN COMPLEX WITH 9CIS RETINOIC ACID
445, 5ntnC, 0.7996, 2.50, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
446, 4dm6B, 0.7992, 2.48, 0.245, 239, 233, CRYSTAL STRUCTURE OF RARB LBD HOMODIMER IN COMPLEX WITH TTNPB
447, 3l0lB, 0.7991, 2.43, 0.226, 248, 235, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
448, 6g07A, 0.7987, 2.50, 0.225, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
449, 6g05B, 0.7987, 2.50, 0.225, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-2  AND RIP140 PEPTIDE AT 1.90A 
450, 3lbdA, 0.7985, 2.47, 0.246, 237, 232, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO 9-CIS RETINOIC ACID
451, 5ntwC, 0.7982, 2.50, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
452, 4jyhA, 0.7982, 2.46, 0.245, 239, 233, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE AGONIST BMS948 [4-{[(8-PHENYLNAPHTHALEN-2-YL)CARBONYL]AMINO}BENZOIC ACID]
453, 5ejvA, 0.7981, 2.44, 0.226, 245, 235, RORY IN COMPLEX WITH T090131718 AND COACTIVATOR PEPTIDE EBI96
454, 4s14A, 0.7981, 2.54, 0.224, 245, 237, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORGAMMA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
455, 5iz0A, 0.7980, 2.51, 0.225, 244, 236, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
456, 4lbdA, 0.7977, 2.48, 0.246, 237, 232, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO THE SYNTHETIC AGONIST BMS961
457, 5ntnA, 0.7976, 2.51, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
458, 3l0jA, 0.7976, 2.47, 0.226, 243, 235, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
459, 5nu1B, 0.7975, 2.53, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
460, 5iz0D, 0.7975, 2.46, 0.226, 243, 235, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
461, 5ntwA, 0.7973, 2.51, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
462, 5ntnB, 0.7973, 2.46, 0.226, 244, 235, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
463, 1exxA, 0.7971, 2.45, 0.251, 236, 231, ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE INACTIVE S-ENANTIOMER BMS270395.
464, 6fzuB, 0.7970, 2.51, 0.225, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ( CPD-1 ) AND RIP140 PEPTIDE AT 1.80A 
465, 5ntiC, 0.7970, 2.55, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
466, 2lbdA, 0.7965, 2.50, 0.246, 237, 232, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO ALL-TRANS RETINOIC ACID
467, 4jygA, 0.7963, 2.48, 0.245, 239, 233, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH AGONIST BMS411 [4- {[(55-DIMETHYL-8-PHENYL-56-DIHYDRONAPHTHALEN-2-YL) CARBONYL]AMINO}BENZOIC ACID]
468, 4jyiA, 0.7961, 2.49, 0.245, 239, 233, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE PARTIAL AGONIST BMS641 [3-CHLORO-4-[(E)-2-(55-DIMETHYL-8-PHENYL-56- DIHYDRONAPHTHALEN-2-YL)ETHENYL]BENZOIC ACID]
469, 4dm6A, 0.7960, 2.45, 0.250, 240, 232, CRYSTAL STRUCTURE OF RARB LBD HOMODIMER IN COMPLEX WITH TTNPB
470, 6g07C, 0.7957, 2.59, 0.224, 246, 237, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
471, 1fcyA, 0.7956, 2.49, 0.247, 236, 231, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA- SELECTIVE RETINOID CD564
472, 4nieA, 0.7955, 2.54, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND
473, 4jyhB, 0.7955, 2.56, 0.249, 239, 233, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE AGONIST BMS948 [4-{[(8-PHENYLNAPHTHALEN-2-YL)CARBONYL]AMINO}BENZOIC ACID]
474, 3kytA, 0.7955, 2.47, 0.226, 243, 235, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
475, 5ntiA, 0.7948, 2.56, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
476, 4wlbA, 0.7943, 2.50, 0.226, 248, 235, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST COMPOUND
477, 5ntiB, 0.7941, 2.52, 0.226, 244, 235, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
478, 4jygB, 0.7941, 2.59, 0.249, 240, 233, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH AGONIST BMS411 [4- {[(55-DIMETHYL-8-PHENYL-56-DIHYDRONAPHTHALEN-2-YL) CARBONYL]AMINO}BENZOIC ACID]
479, 1exaA, 0.7941, 2.48, 0.251, 236, 231, ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE ACTIVE R-ENANTIOMER BMS270394.
480, 1fcxA, 0.7935, 2.47, 0.248, 235, 230, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID BMS184394
481, 5ntwB, 0.7934, 2.55, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
482, 5m24A, 0.7933, 2.39, 0.248, 236, 230, RARG MUTANT-S371E
483, 4jyiB, 0.7924, 2.61, 0.249, 239, 233, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE PARTIAL AGONIST BMS641 [3-CHLORO-4-[(E)-2-(55-DIMETHYL-8-PHENYL-56- DIHYDRONAPHTHALEN-2-YL)ETHENYL]BENZOIC ACID]
484, 3l0lA, 0.7922, 2.52, 0.226, 247, 235, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
485, 1fd0A, 0.7917, 2.37, 0.249, 235, 229, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID SR11254
486, 1fczA, 0.7909, 2.38, 0.249, 235, 229, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE PANAGONIST RETINOID BMS181156
487, 6g07B, 0.7898, 2.60, 0.225, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
488, 6g05A, 0.7893, 2.59, 0.229, 245, 236, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-2  AND RIP140 PEPTIDE AT 1.90A 
489, 4nqaI, 0.7889, 2.58, 0.248, 385, 230, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
490, 5ntnD, 0.7879, 2.56, 0.226, 244, 235, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
491, 3a9eB, 0.7876, 2.66, 0.245, 239, 233, CRYSTAL STRUCTURE OF A MIXED AGONIST-BOUND RAR-ALPHA AND ANTAGONIST- BOUND RXR-ALPHA HETERODIMER LIGAND BINDING DOMAINS
492, 5hjpB, 0.7874, 2.61, 0.249, 259, 229, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
493, 4dm8A, 0.7869, 2.47, 0.252, 238, 230, CRYSTAL STRUCTURE OF RARB LBD IN COMPLEX WITH 9CIS RETINOIC ACID
494, 3falD, 0.7857, 2.36, 0.261, 242, 226, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
495, 5i4vE, 0.7854, 2.41, 0.247, 245, 227, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
496, 2aclB, 0.7853, 2.35, 0.261, 242, 226, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
497, 5kyjE, 0.7852, 2.42, 0.247, 245, 227, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
498, 5ntiD, 0.7851, 2.62, 0.226, 244, 235, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
499, 3uvvA, 0.7850, 2.84, 0.258, 250, 236, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE THYROID RECEPTOR:RETINOID X RECEPTOR COMPLEXED WITH 33 5 TRIIODO-L- THYRONINE AND 9-CIS RETINOIC ACID
500, 5i4vA, 0.7849, 2.79, 0.243, 260, 230, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
501, 1xdkF, 0.7849, 2.54, 0.251, 245, 231, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
502, 1xdkB, 0.7849, 2.54, 0.251, 245, 231, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
503, 2aclH, 0.7848, 2.70, 0.258, 244, 229, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
504, 1nq1A, 0.7847, 2.85, 0.254, 253, 236, TR RECEPTOR MUTATIONS CONFERRING HORMONE RESISTANCE AND REDUCED COREPRESSOR RELEASE EXHIBIT DECREASED STABILITY IN THE NTERMINAL LBD
505, 2aclF, 0.7845, 2.48, 0.256, 242, 227, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
506, 5hjpD, 0.7843, 2.52, 0.256, 251, 227, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
507, 5kyaE, 0.7842, 2.62, 0.246, 251, 228, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
508, 5kyaA, 0.7842, 2.36, 0.248, 244, 226, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
509, 4nqaB, 0.7842, 2.60, 0.245, 369, 229, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
510, 3fc6D, 0.7839, 2.52, 0.269, 241, 227, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
511, 4zo1X, 0.7836, 2.86, 0.250, 242, 236, CRYSTAL STRUCTURE OF THE T3-BOUND TR-BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH RXR-ALPHA
512, 3fc6B, 0.7836, 2.41, 0.270, 241, 226, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
513, 3falB, 0.7833, 2.39, 0.256, 238, 227, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
514, 5kyjA, 0.7828, 2.64, 0.246, 251, 228, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
515, 4dqmC, 0.7828, 2.49, 0.250, 234, 228, REVEALING A MARINE NATURAL PRODUCT AS A NOVEL AGONIST FOR RETINOIC ACID RECEPTORS WITH A UNIQUE BINDING MODE AND ANTITUMOR ACTIVITY
516, 2aclD, 0.7823, 2.44, 0.257, 242, 226, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
517, 3kmrA, 0.7822, 2.47, 0.250, 234, 228, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH AN AGONIST LIGAND (AM580) AND A COACTIVATOR FRAGMENT
518, 1nq0A, 0.7822, 2.88, 0.254, 253, 236, TR RECEPTOR MUTATIONS CONFERRING HORMONE RESISTANCE AND REDUCED COREPRESSOR RELEASE EXHIBIT DECREASED STABILITY IN THE NTERMINAL LBD
519, 4dqmA, 0.7821, 2.48, 0.254, 234, 228, REVEALING A MARINE NATURAL PRODUCT AS A NOVEL AGONIST FOR RETINOIC ACID RECEPTORS WITH A UNIQUE BINDING MODE AND ANTITUMOR ACTIVITY
520, 5uanB, 0.7819, 2.47, 0.253, 308, 229, CRYSTAL STRUCTURE OF MULTI-DOMAIN RAR-BETA-RXR-ALPHA HETERODIMER ON DNA
521, 1nq2A, 0.7816, 2.92, 0.250, 255, 236, TWO RTH MUTANTS WITH IMPAIRED HORMONE BINDING
522, 1xzxX, 0.7812, 2.84, 0.251, 249, 235, THYROXINE-THYROID HORMONE RECEPTOR INTERACTIONS
523, 1p8dA, 0.7809, 2.47, 0.251, 240, 227, X-RAY CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN WITH 24(S)25- EPOXYCHOLESTEROL
524, 4oztE, 0.7808, 2.16, 0.259, 238, 224, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (PONA CRYSTAL)
525, 3l0eA, 0.7808, 2.64, 0.263, 243, 228, X-RAY CRYSTAL STRUCTURE OF A POTENT LIVER X RECEPTOR MODULATOR
526, 1y0xX, 0.7802, 2.83, 0.247, 250, 235, THYROXINE-THYROID HORMONE RECEPTOR INTERACTIONS
527, 4rakB, 0.7795, 2.35, 0.258, 232, 225, CRYSTAL STRUCTURE OF NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2 (LXRB) COMPLEXED WITH PARTIAL AGONIST
528, 4dk8C, 0.7789, 2.26, 0.259, 229, 224, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST 5
529, 5k13A, 0.7788, 2.67, 0.249, 235, 229, CRYSTAL STRUCTURE OF THE RAR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST
530, 1xapA, 0.7787, 2.40, 0.257, 232, 226, STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOIC ACID RECEPTOR BETA
531, 3ipuA, 0.7785, 2.45, 0.257, 238, 226, X-RAY STRUCTURE OF BENZISOXAZOLE UREA SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
532, 3ipuB, 0.7784, 2.39, 0.267, 235, 225, X-RAY STRUCTURE OF BENZISOXAZOLE UREA SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
533, 1p8dB, 0.7775, 2.37, 0.249, 239, 225, X-RAY CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN WITH 24(S)25- EPOXYCHOLESTEROL
534, 2nxxE, 0.7773, 2.15, 0.251, 234, 223, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
535, 1pq6B, 0.7773, 2.67, 0.250, 241, 228, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
536, 1pq6A, 0.7773, 2.37, 0.253, 232, 225, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
537, 5lwpA, 0.7769, 3.06, 0.229, 244, 236, DISCOVERY OF PHENOXYINDAZOLES AND PHENYLTHIOINDAZOLES AS RORG INVERSE AGONISTS
538, 3kfcA, 0.7767, 2.42, 0.253, 233, 225, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
539, 2nxxH, 0.7767, 2.18, 0.251, 234, 223, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
540, 4ypqA, 0.7761, 2.87, 0.222, 243, 234, CRYSTAL STRUCTURE OF THE ROR(GAMMA)T LIGAND BINDING DOMAIN IN COMPLEX WITH 4-(1-(2-CHLORO-6-(TRIFLUOROMETHYL)BENZOYL)-1H-INDAZOL-3-YL) BENZOIC ACID
541, 1bsxB, 0.7761, 2.86, 0.251, 243, 235, STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
542, 1bsxA, 0.7761, 2.86, 0.251, 243, 235, STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
543, 3kfcD, 0.7759, 2.44, 0.253, 233, 225, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
544, 2nxxG, 0.7757, 2.09, 0.252, 233, 222, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
545, 2nxxF, 0.7757, 2.09, 0.252, 233, 222, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
546, 2pinB, 0.7753, 2.91, 0.247, 250, 235, THYROID RECEPTOR BETA IN COMPLEX WITH INHIBITOR
547, 3d57B, 0.7752, 2.92, 0.247, 248, 235, TR VARIANT D355R
548, 1pqcA, 0.7752, 2.55, 0.257, 232, 226, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
549, 1pq9A, 0.7752, 2.55, 0.257, 232, 226, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
550, 3kfcB, 0.7744, 2.34, 0.250, 232, 224, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
551, 4dk8A, 0.7743, 2.34, 0.250, 233, 224, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST 5
552, 3d57A, 0.7743, 2.95, 0.247, 245, 235, TR VARIANT D355R
553, 1pqcC, 0.7741, 2.17, 0.257, 231, 222, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
554, 1pq9C, 0.7741, 2.17, 0.257, 231, 222, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
555, 5jy3B, 0.7737, 2.20, 0.260, 230, 223, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
556, 1pqcB, 0.7737, 2.47, 0.258, 238, 225, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
557, 1pq9B, 0.7732, 2.49, 0.258, 238, 225, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
558, 2pinA, 0.7731, 2.96, 0.247, 245, 235, THYROID RECEPTOR BETA IN COMPLEX WITH INHIBITOR
559, 3imyA, 0.7730, 2.86, 0.253, 248, 233, STRUCTURE OF TR-BETA BOUND TO SELECTIVE THYROMIMETIC GC-1
560, 3m7rA, 0.7722, 2.84, 0.252, 253, 230, CRYSTAL STRUCTURE OF VDR H305Q MUTANT
561, 1z5xE, 0.7722, 2.21, 0.242, 237, 223, HEMIPTERAN ECDYSONE RECEPTOR LIGAND-BINDING DOMAIN COMPLEXED WITH PONASTERONE A
562, 1s19A, 0.7719, 2.62, 0.259, 253, 228, CRYSTAL STRUCTURE OF VDR LIGAND BINDING DOMAIN COMPLEXED TO CALCIPOTRIOL.
563, 5jy3D, 0.7716, 2.20, 0.261, 227, 222, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
564, 1naxA, 0.7713, 2.94, 0.247, 250, 235, THYROID RECEPTOR BETA1 IN COMPLEX WITH A BETA-SELECTIVE LIGAND
565, 5k6eB, 0.7710, 2.78, 0.224, 234, 232, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0654919
566, 2hb8A, 0.7710, 2.64, 0.263, 254, 228, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-METHYL CALCITRIOL
567, 3tkcA, 0.7709, 2.79, 0.258, 254, 229, DESIGN SYNTHESIS EVALUATION AND STRUCTURE OF VITAMIN D ANALOGUES WITH FURAN SIDE CHAINS
568, 3ogtA, 0.7709, 2.79, 0.258, 254, 229, DESIGN CHEMICAL SYNTHESIS FUNCTIONAL CHARACTERIZATION AND CRYSTAL STRUCTURE OF THE SIDECHAIN ANALOGUE OF 125-DIHYDROXYVITAMIN D3.
569, 1txiA, 0.7708, 2.64, 0.263, 253, 228, CRYSTAL STRUCTURE OF THE VDR LIGAND BINDING DOMAIN COMPLEXED TO TX522
570, 1s0zA, 0.7708, 2.63, 0.263, 253, 228, CRYSTAL STRUCTURE OF THE VDR LBD COMPLEXED TO SEOCALCITOL.
571, 3x36A, 0.7707, 2.64, 0.268, 254, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 78-CIS-1A25-DIHYDROXY-19-NORVITAMIN D3
572, 1nuoA, 0.7707, 2.92, 0.252, 247, 234, TWO RTH MUTANTS WITH IMPAIRED HORMONE BINDING
573, 3kpzA, 0.7703, 2.80, 0.253, 253, 229, CRYSTAL STRUCTURE OF A NOVEL VITAMIN D3 ANALOGUE ZK203278 SHOWING DISSOCIATED PROFILE
574, 5gt4A, 0.7698, 2.65, 0.268, 255, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R2S3R5Z7E14BETA17ALPHA)-2-CYANOPROPOXY- 910-SECOCHOLESTA-5710-TRIENE-1325-TRIOL
575, 4g2iA, 0.7698, 2.81, 0.253, 253, 229, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
576, 3wwrA, 0.7697, 2.65, 0.268, 254, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1-((((1S2R6RZ)-26-DIHYDROXY-4-((E)-2-((1R 3AS7AR)-1-((R)-6-HYDROXY-6-METHYLHEPTAN-2-YL)-7A-METHYLHEXAHYDRO-1H- INDEN-4(2H)-YLIDENE)ETHYLIDENE)-3-METHYLENECYCLOHEXYL)OXY)METHYL) CYCLOPROPANECARBONITRILE
577, 2j4aA, 0.7697, 2.97, 0.251, 250, 235, HUMAN THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH KB131084
578, 2hb7A, 0.7697, 2.65, 0.268, 254, 228, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA(3- HYDROXY-1-PROPYL) CALCITRIOL
579, 6bn6A, 0.7696, 2.37, 0.227, 228, 225, IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
580, 5ysyA, 0.7696, 2.79, 0.258, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R;2R;3R)-5-[(E)-2-{(1R;3AS;7AR)-1-[(R)-6- HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-2;3;3A;6;7;7A-HEXAHYDRO-1H- INDEN-4-YL}VINYL]-2-(3-HYDROXYPROPYL)CYCLOHEX-4-ENE-1;3-DIOL 
581, 3b0tA, 0.7694, 2.66, 0.268, 254, 228, HUMAN VDR LIGAND BINDING DOMAIN IN COMPLEX WITH MAXACALCITOL
582, 3aurA, 0.7694, 2.66, 0.268, 253, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2BETA- METHYL-19-NORVITAMIN D3
583, 3a3zX, 0.7693, 2.80, 0.253, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277A(C23S)
584, 3cs4A, 0.7692, 2.81, 0.258, 254, 229, STRUCTURE-BASED DESIGN OF A SUPERAGONIST LIGAND FOR THE VITAMIN D NUCLEAR RECEPTOR
585, 5yt2A, 0.7691, 2.66, 0.268, 255, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R;2S;3R)-5-[(E)-2-{(1R;3AS;7AR)-1-[(R)-6- HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-2;3;3A;6;7;7A-HEXAHYDRO-1H- INDEN-4-YL}VINYL]-2-(3-HYDROXYPROPYL)CYCLOHEX-4-ENE-1;3-DIOL 
586, 4itfA, 0.7691, 2.74, 0.266, 253, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA25-DIHYDROXY-2ALPHA-[2-(1H-TETRAZOLE-1- YL)ETHYL]VITAMIN D3
587, 3cs6A, 0.7690, 2.82, 0.258, 254, 229, STRUCTURE-BASED DESIGN OF A SUPERAGONIST LIGAND FOR THE VITAMIN D NUCLEAR RECEPTOR
588, 3x31A, 0.7689, 2.81, 0.258, 254, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 78-CIS-14-EPI-1A25-DIHYDROXY-19-NORVITAMIN D3
589, 3a78A, 0.7689, 2.67, 0.263, 255, 228, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE NATURAL METABOLITE 1ALPHA25-DIHYDROXY-3-EPI-VITAMIN D3
590, 1upvA, 0.7689, 2.34, 0.261, 232, 222, CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST
591, 3a40X, 0.7688, 2.81, 0.258, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277B(C23R)
592, 3a2iA, 0.7688, 2.66, 0.272, 253, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR (H305F) LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647
593, 1ie9A, 0.7688, 2.81, 0.253, 255, 229, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D LIGAND BINDING DOMAIN BOUND TO MC1288
594, 4g21A, 0.7687, 2.96, 0.242, 239, 231, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
595, 4g1zA, 0.7687, 2.86, 0.248, 239, 230, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
596, 3auqA, 0.7687, 2.72, 0.266, 253, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2ALPHA- METHYL-19-NORVITAMIN D3
597, 5v39A, 0.7686, 2.62, 0.269, 251, 227, CRYSTAL STRUCTURE OF HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A VDRM
598, 5ow7A, 0.7686, 2.78, 0.253, 240, 229, VDR COMPLEX
599, 3ax8A, 0.7686, 2.81, 0.258, 253, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 15ALPHA-METHOXY-1ALPHA25-DIHYDROXYVITAMIN D3
600, 5c4tA, 0.7685, 3.02, 0.222, 241, 234, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
601, 4g1dA, 0.7685, 2.88, 0.248, 239, 230, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
602, 3o1eA, 0.7685, 2.90, 0.257, 239, 230, STRUCTURE-FUNCTION OF GEMINI DERIVATIVES WITH TWO DIFFERENT SIDE CHAINS AT C-20 GEMINI-0072 AND GEMINI-0097.
603, 1n46A, 0.7683, 2.87, 0.253, 248, 233, CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
604, 3p8xA, 0.7682, 2.83, 0.258, 255, 229, SYNTHESIS STRUCTURE AND BIOLOGICAL ACTIVITY OF DES-SIDE CHAIN ANALOGUES OF 1ALPHA25-DIHYDROXYVITAMIN D3 WITH SUBSTITUENTS AT C-18
605, 1pq6D, 0.7682, 2.19, 0.259, 227, 220, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
606, 6fo7A, 0.7681, 2.83, 0.253, 239, 229, VITAMIN D NUCLEAR RECEPTOR COMPLEX 3 
607, 5c4oA, 0.7681, 2.97, 0.223, 241, 233, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
608, 1upwA, 0.7681, 2.36, 0.261, 232, 222, CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST
609, 1q4xA, 0.7681, 2.96, 0.252, 239, 234, CRYSTAL STRUCTURE OF HUMAN THYROID HORMONE RECEPTOR BETA LBD IN COMPLEX WITH SPECIFIC AGONIST GC-24
610, 3vhwA, 0.7679, 2.68, 0.268, 254, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 4-MP
611, 5ntqA, 0.7677, 2.53, 0.220, 234, 227, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
612, 4iteA, 0.7675, 2.68, 0.263, 253, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA25-DIHYDROXY-2ALPHA-[2-(2H-TETRAZOL-2- YL)ETHYL]VITAMIN D3
613, 3jzcA, 0.7673, 2.95, 0.250, 244, 232, CRYSTAL STRUCTURE OF TR-BETA BOUND TO THE SELECTIVE THYROMIMETIC TRIAC
614, 5lgaA, 0.7672, 2.91, 0.257, 238, 230, STRUCTURAL ANALYSIS AND BIOLOGICAL ACTIVITIES OF BXL0124 A GEMINI ANALOG OF VITAMIN D
615, 3a2jA, 0.7672, 2.83, 0.258, 253, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR (H305F/H397F) LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647
616, 5ow9A, 0.7671, 2.94, 0.251, 239, 231, VITAMIN D RECEPTOR COMPLEX
617, 4wqpA, 0.7671, 2.69, 0.225, 234, 227, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A BENZYL SULFONAMIDE INVERSE AGONIST
618, 3v3qB, 0.7671, 2.88, 0.210, 239, 229, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH ETHYL 2-[234 TRIMETHOXY-6(1-OCTANOYL)PHENYL]ACETATE
619, 3ilzA, 0.7671, 3.05, 0.263, 263, 236, STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN P212121 SPACE GROUP
620, 5nmaA, 0.7666, 2.80, 0.253, 239, 229, STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF VITAMIN D ANALOGS WITH OXOLANE GROUP IN THEIR SIDE CHAIN
621, 1n46B, 0.7666, 2.80, 0.254, 239, 232, CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
622, 3ipsB, 0.7665, 2.23, 0.273, 226, 220, X-RAY STRUCTURE OF BENZISOXAZOLE SYNTHETIC AGONIST BOUND TO THE LXR- ALPHA
623, 5nmbA, 0.7664, 2.97, 0.255, 238, 231, 
624, 1db1A, 0.7664, 2.65, 0.264, 250, 227, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D COMPLEXED TO VITAMIN D
625, 5mx7A, 0.7661, 2.76, 0.259, 238, 228, struct.pdbx_descriptor               Vitamin D3 receptor A; Nuclear receptor coactivator 1 (E.C.2.3.1.48)  
626, 3gwsX, 0.7660, 2.85, 0.251, 243, 231, CRYSTAL STRUCTURE OF T3-BOUND THYROID HORMONE RECEPTOR
627, 2hasA, 0.7660, 2.72, 0.268, 253, 228, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-(1- PROPOXY) CALCITRIOL
628, 1navA, 0.7660, 2.92, 0.272, 253, 232, THYROID RECEPTOR ALPHA IN COMPLEX WITH AN AGONIST SELECTIVE FOR THYROID RECEPTOR BETA1
629, 4qm0A, 0.7659, 2.61, 0.221, 234, 226, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A TERTIARY SULFONAMIDE INVERSE AGONIST
630, 5aviC, 0.7658, 2.22, 0.264, 226, 220, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 4
631, 5apkB, 0.7658, 2.68, 0.225, 236, 227, LIGAND COMPLEX OF RORG LBD
632, 4q0aC, 0.7657, 2.81, 0.249, 239, 229, VITAMIN D RECEPTOR COMPLEX WITH LITHOCHOLIC ACID
633, 2hamA, 0.7656, 2.73, 0.268, 253, 228, CRYSTAL STRUCTURE OF VDR LBD COMPLEXED TO 2ALPHA-PROPYL- CALCITRIOL
634, 5e7vA, 0.7655, 2.91, 0.257, 239, 230, POTENT VITAMIN D RECEPTOR AGONIST
635, 5c4uA, 0.7653, 2.93, 0.224, 241, 232, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
636, 5c4sA, 0.7653, 2.91, 0.224, 241, 232, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
637, 4lnwA, 0.7652, 3.00, 0.265, 259, 234, CRYSTAL STRUCTURE OF TR-ALPHA BOUND TO T3 IN A SECOND SITE
638, 5hjsB, 0.7651, 2.24, 0.273, 226, 220, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
639, 3wgpA, 0.7651, 2.67, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
640, 2harA, 0.7651, 2.72, 0.268, 252, 228, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2 ALPHA-(3- HYDROXY-1-PROPOXY) CALCITRIOL
641, 5hjsA, 0.7649, 2.23, 0.273, 226, 220, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
642, 3w0cA, 0.7649, 2.68, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
643, 5b5bA, 0.7648, 2.95, 0.260, 249, 231, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-2627- DIPHENYL-19-NOR-125-DIHYDROXYVITAMIN D3
644, 6b31A, 0.7647, 2.46, 0.222, 228, 225, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 2 
645, 1ie8A, 0.7647, 2.82, 0.254, 250, 228, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D LIGAND BINDING DOMAIN BOUND TO KH1060
646, 3az3A, 0.7646, 2.69, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
647, 5nkyA, 0.7645, 2.87, 0.258, 238, 229, STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF VITAMIN D ANALOGS WITH OXOLANE GROUP IN THEIR SIDE CHAIN
648, 5avlA, 0.7645, 2.50, 0.261, 224, 222, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 32B
649, 3w0aA, 0.7645, 2.68, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
650, 3v3eB, 0.7645, 2.79, 0.203, 237, 227, CRYSTAL STRUCTURE OF THE HUMAN NUR77 LIGAND-BINDING DOMAIN
651, 3jzbA, 0.7645, 3.01, 0.265, 260, 234, CRYSTAL STRUCTURE OF TR-ALFA BOUND TO THE SELECTIVE THYROMIMETIC TRIAC
652, 5b5bD, 0.7644, 2.56, 0.270, 240, 226, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-2627- DIPHENYL-19-NOR-125-DIHYDROXYVITAMIN D3
653, 6cvhA, 0.7643, 2.52, 0.222, 227, 225, IDENTIFICATION AND BIOLOGICAL EVALUATION OF THIAZOLE-BASED INVERSE AGONISTS OF RORGT 
654, 3az2A, 0.7643, 2.69, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
655, 5zweA, 0.7641, 2.78, 0.269, 240, 227, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING A VINYL KETONE GROUP VIA CONJUGATE ADDITION REACTION 
656, 6fo9A, 0.7640, 2.83, 0.253, 239, 229, VITAMIN D NUCLEAR RECEPTOR COMPLEX 2 
657, 4kziB, 0.7639, 2.82, 0.211, 234, 227, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH DPDO
658, 3w0iA, 0.7639, 2.77, 0.266, 242, 229, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
659, 2zxnA, 0.7639, 2.79, 0.268, 240, 228, A NEW CLASS OF VITAMIN D RECEPTOR LIGANDS THAT INDUCE STRUCTURAL REARRANGEMENT OF THE LIGAND-BINDING POCKET
660, 4lnxA, 0.7638, 3.02, 0.265, 259, 234, CRYSTAL STRUCTURE OF TR-ALPHA BOUND TO T4 IN A SECOND SITE
661, 3wt7A, 0.7638, 2.74, 0.273, 240, 227, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22R-BUTYL-2-METHYLIDENE- 2627-DIMETHYL-1924-DINOR-1 25-DIHYDROXYVITAMIN D3
662, 3vt5A, 0.7637, 2.69, 0.269, 240, 227, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
663, 3o1dA, 0.7637, 2.89, 0.252, 240, 230, STRUCTURE-FUNCTION STUDY OF GEMINI DERIVATIVES WITH TWO DIFFERENT SIDE CHAINS AT C-20 GEMINI-0072 AND GEMINI-0097.
664, 4fhhA, 0.7635, 2.91, 0.257, 239, 230, DEVELOPMENT OF SYNTHETICALLY ACCESSIBLE NON-SECOSTEROIDAL HYBRID MOLECULES COMBINING VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITION
665, 3w0jA, 0.7635, 2.83, 0.266, 242, 229, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
666, 5xzhA, 0.7633, 2.80, 0.268, 239, 228, VITAMIN D RECEPTOR WITH A SYNTHETIC LIGAND ADRO2 
667, 3ipsA, 0.7632, 2.23, 0.274, 224, 219, X-RAY STRUCTURE OF BENZISOXAZOLE SYNTHETIC AGONIST BOUND TO THE LXR- ALPHA
668, 4rzgB, 0.7631, 2.63, 0.204, 235, 225, CRYSTAL STRUCTURE ANALYSIS OF THE DNPA-BOUNDED NUR77 LIGAND BINDING DOMAIN
669, 3vt3A, 0.7631, 2.74, 0.263, 250, 228, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
670, 1rkgA, 0.7631, 2.79, 0.263, 241, 228, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2MBISP AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
671, 3vt6A, 0.7630, 2.73, 0.269, 240, 227, CRYSTAL STRUCTURE OF RAT VDR-LBD WITH 2-SUBSTITUTED-16-ENE-22-THIA- 1ALPHA25-DIHYDROXY-2627-DIMETHYL-19-NORVITAMIN D3
672, 5aviA, 0.7629, 2.31, 0.264, 228, 220, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 4
673, 2hc4A, 0.7628, 3.02, 0.251, 239, 231, CRYSTAL STRUCTURE OF THE LBD OF VDR OF DANIO RERIO IN COMPLEX WITH CALCITRIOL
674, 4ia1A, 0.7627, 3.12, 0.246, 239, 232, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
675, 4g2hA, 0.7627, 3.08, 0.247, 239, 231, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
676, 2h79A, 0.7627, 3.14, 0.260, 262, 235, CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN ORTHORHOMBIC SPACE GROUP
677, 1xv9D, 0.7627, 2.92, 0.226, 246, 230, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
678, 1dkfB, 0.7627, 2.67, 0.241, 232, 224, CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
679, 4whgB, 0.7626, 2.65, 0.204, 232, 225, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 3
680, 3wtqA, 0.7626, 2.75, 0.264, 240, 227, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-2-METHYLIDENE- 19-NOR-1A25-DIHYDROXYVITAMIN D3
681, 3w0yA, 0.7626, 2.72, 0.260, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
682, 3az1A, 0.7626, 2.85, 0.254, 250, 228, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
683, 5zwfA, 0.7625, 2.71, 0.274, 237, 226, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING A ENONE WITH A BETA METHYL GROUP VIA CONJUGATE ADDITION REACTION 
684, 5owdA, 0.7625, 2.84, 0.263, 238, 228, VITAMIN D RECEPTOR COMPLEX
685, 4rujA, 0.7625, 3.00, 0.243, 240, 230, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-VD COMPLEX
686, 3afrA, 0.7625, 2.76, 0.269, 240, 227, CRYSTAL STRUCTURE OF VDR-LBD/22S-BUTYL-1A24R-DIHYDROXYVITAMIN D3 COMPLEX
687, 5gicA, 0.7624, 2.63, 0.278, 237, 227, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-2P
688, 3w5pA, 0.7624, 2.77, 0.264, 240, 227, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
689, 4g20A, 0.7623, 2.87, 0.263, 237, 228, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
690, 5k74A, 0.7622, 2.54, 0.228, 227, 224, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0655870
691, 3w5qA, 0.7622, 2.71, 0.274, 240, 226, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
692, 3vt4A, 0.7622, 2.80, 0.269, 240, 227, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
693, 5xpoA, 0.7621, 2.66, 0.274, 239, 226, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25-(HYDROXYPHENYL)-2- METHYLIDENE-19;26;27-TRINOR-25-OXO-1-HYDROXYVITAMIN D3 
694, 4ummG, 0.7621, 2.49, 0.241, 236, 224, THE CRYO-EM STRUCTURE OF THE PALINDROMIC DNA-BOUND USP-ECR NUCLEAR RECEPTOR REVEALS AN ASYMMETRIC ORGANIZATION WITH ALLOSTERIC DOMAIN POSITIONING
695, 1r1kD, 0.7621, 2.49, 0.241, 236, 224, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO PONASTERONE A
696, 5k38A, 0.7620, 2.56, 0.228, 227, 224, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN
697, 5gieA, 0.7619, 2.79, 0.268, 251, 228, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4P (P21 FORM)
698, 6b31B, 0.7618, 2.44, 0.223, 227, 224, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 2 
699, 5zwiA, 0.7618, 2.76, 0.273, 240, 227, INTERACTION BETWEEN VITAMIN D RECEPTOR (VDR) AND A LIGAND HAVING A DIENONE GROUP 
700, 5b41A, 0.7617, 2.78, 0.269, 239, 227, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-19-NOR-1A 25-DIHYDROXYVITAMIN D3
701, 4ruoX, 0.7617, 3.07, 0.242, 239, 231, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-GEMINI COMPLEX
702, 4fhiA, 0.7617, 2.88, 0.262, 238, 229, DEVELOPMENT OF SYNTHETICALLY ACCESSIBLE NON-SECOSTEROIDAL HYBRID MOLECULES COMBINING VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITION
703, 3dr1A, 0.7617, 3.12, 0.241, 240, 232, SIDE-CHAIN FLUORINE ATOMS OF NON-STEROIDAL VITAMIN D3 ANALOGS STABILIZE HELIX 12 OF VITAMIN D RECEPTOR
704, 2zlaA, 0.7617, 2.80, 0.269, 238, 227, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
705, 6fodA, 0.7616, 2.86, 0.253, 239, 229, VITAMIN D NUCLEAR RECEPTOR COMPLEX 1 
706, 3vruA, 0.7616, 2.67, 0.270, 238, 226, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-METHYLIDENE-1924-DINOR- 1ALPHA25-DIHYDROXY VITAMIND3
707, 2hcdA, 0.7616, 3.01, 0.248, 239, 230, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE VITAMIN D NUCLEAR RECEPTOR IN COMPLEX WITH GEMINI AND A COACTIVATOR PEPTIDE
708, 4ia3A, 0.7614, 3.00, 0.248, 239, 230, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
709, 2hbhA, 0.7614, 2.87, 0.253, 239, 229, CRYSTAL STRUCTURE OF VITAMIN D NUCLEAR RECEPTOR LIGAND BINDING DOMAIN BOUND TO A LOCKED SIDE-CHAIN ANALOG OF CALCITRIOL AND SRC-1 PEPTIDE
710, 2h77A, 0.7614, 3.11, 0.261, 251, 234, CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN MONOCLINIC SPACE GROUP
711, 3w5rA, 0.7613, 2.89, 0.271, 242, 229, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
712, 1uhlB, 0.7613, 2.19, 0.258, 219, 217, CRYSTAL STRUCTURE OF THE LXRALFA-RXRBETA LBD HETERODIMER
713, 5k74B, 0.7612, 2.56, 0.228, 227, 224, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0655870
714, 5k3nD, 0.7612, 2.49, 0.231, 228, 225, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
715, 5awkA, 0.7612, 2.85, 0.268, 240, 228, CRYSTAL STRUCTURE OF VDR-LBD/PARTIAL AGONIST COMPLEX: 22S-ETHYL ANALOGUE
716, 4ia2A, 0.7612, 3.14, 0.241, 239, 232, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
717, 5zwhA, 0.7611, 2.72, 0.279, 237, 226, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING AN ENE-YNONE GROUP VIA CONJUGATE ADDITION REACTION 
718, 4rupA, 0.7611, 3.06, 0.242, 239, 231, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-GEMINI72 COMPLEX
719, 4reeB, 0.7611, 2.79, 0.208, 233, 226, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 6
720, 3w5tA, 0.7611, 2.83, 0.272, 242, 228, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
721, 3vrwA, 0.7611, 2.70, 0.274, 238, 226, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 22S-BUTYL-2-METHYLIDENE-26 27-DIMETHYL-1924-DINOR-1ALPHA25-DIHYDROXYVITAMIN D3
722, 3ipqA, 0.7611, 2.05, 0.272, 220, 217, X-RAY STRUCTURE OF GW3965 SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
723, 2zxmA, 0.7611, 2.91, 0.266, 240, 229, A NEW CLASS OF VITAMIN D RECEPTOR LIGANDS THAT INDUCE STRUCTURAL REARRANGEMENT OF THE LIGAND-BINDING POCKET
724, 3w0hA, 0.7610, 2.80, 0.263, 247, 228, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
725, 3w0gA, 0.7610, 2.83, 0.266, 242, 229, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
726, 1xvpD, 0.7610, 2.91, 0.222, 246, 230, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
727, 3a2hA, 0.7609, 2.77, 0.268, 239, 228, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
728, 4dk7C, 0.7608, 2.27, 0.256, 224, 219, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH FULL AGONIST 1
729, 4dk7A, 0.7608, 2.40, 0.255, 229, 220, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH FULL AGONIST 1
730, 1xvpB, 0.7608, 2.95, 0.226, 246, 230, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
731, 3wt5A, 0.7607, 2.83, 0.276, 240, 228, A MIXED POPULATION OF ANTAGONIST AND AGONIST BINDING CONFORMERS IN A SINGLE CRYSTAL EXPLAINS PARTIAL AGONISM AGAINST VITAMIN D RECEPTOR: ACTIVE VITAMIN D ANALOGUES WITH 22R-ALKYL GROUP
732, 4g1yA, 0.7606, 3.03, 0.248, 239, 230, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
733, 2o4rA, 0.7606, 2.76, 0.264, 240, 227, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH VITIII 17-20E AND THE NR2 BOX OF DRIP 205
734, 3vrvA, 0.7605, 2.72, 0.270, 237, 226, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-METHYLIDENE-2627- DIMETHYL-1924-DINOR-1ALPHA25-DIHYDROXYVITAMIN D3
735, 2zlcA, 0.7605, 2.77, 0.269, 240, 227, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
736, 5gidA, 0.7604, 2.60, 0.279, 237, 226, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4 (C2 FORM)
737, 5xpnA, 0.7603, 2.69, 0.274, 239, 226, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25RS-(HYDROXYPHENYL)-25- METHOXY-2-METHYLIDENE-19;26;27-TRINOR-1-HYDROXYVITAMIN D3 
738, 5xpmA, 0.7603, 2.71, 0.273, 239, 227, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-25RS- (HYDROXYPHENYL)-25-METHOXY-2-METHYLIDENE-19;26;27-TRINOR-1- HYDROXYVITAMIN D3 
739, 2zmjA, 0.7603, 2.81, 0.269, 240, 227, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
740, 1rk3A, 0.7603, 2.78, 0.269, 239, 227, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 125-DIHYDROXYVITAMIN D3 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
741, 5awjA, 0.7602, 2.77, 0.276, 240, 228, CRYSTAL STRUCTURE OF VDR-LBD/PARTIAL AGONIST COMPLEX: 22S-HEXYL ANALOGUE
742, 2zfxA, 0.7601, 2.75, 0.269, 241, 227, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YR301 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
743, 1rkhA, 0.7601, 2.90, 0.268, 242, 228, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2AM20R AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
744, 3vjsA, 0.7600, 2.87, 0.268, 239, 228, VITAMIN D RECEPTOR COMPLEX WITH A CARBORANE COMPOUND
745, 5k3lD, 0.7599, 2.40, 0.224, 226, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
746, 2zl9A, 0.7598, 2.71, 0.270, 238, 226, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
747, 5k38B, 0.7594, 2.49, 0.224, 226, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN
748, 3vjtA, 0.7593, 2.84, 0.269, 238, 227, VITAMIN D RECEPTOR COMPLEX WITH A CARBORANE COMPOUND
749, 5k6eA, 0.7592, 2.52, 0.223, 226, 224, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0654919
750, 4kzmB, 0.7592, 2.54, 0.215, 230, 223, CRYSTAL STRUCTURE OF TR3 LBD S553A MUTANT
751, 2zmiA, 0.7592, 2.84, 0.266, 242, 229, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
752, 6fobA, 0.7591, 2.98, 0.249, 238, 229, VITAMIN D RECEPTOR COMPLEX 5 
753, 5k3lB, 0.7591, 2.41, 0.229, 226, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
754, 4ynkA, 0.7591, 2.90, 0.263, 240, 228, CRYSTAL STRUCTURE OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH A 19-NORVITAMIN D COMPOUND
755, 6fo81, 0.7590, 2.81, 0.260, 236, 227, VITAMIN D NUCLEAR RECEPTOR COMPLEX 4 
756, 3vtbA, 0.7590, 2.80, 0.264, 240, 227, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 25-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK1
757, 4ia7A, 0.7589, 3.00, 0.245, 238, 229, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
758, 2o4jA, 0.7589, 2.79, 0.269, 240, 227, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH VITIII 17-20Z AND THE NR2 BOX OF DRIP 205
759, 3vtdA, 0.7588, 2.68, 0.274, 240, 226, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 26-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK4
760, 3vtcA, 0.7588, 2.81, 0.272, 240, 228, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 26-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK3
761, 5xppA, 0.7587, 2.72, 0.274, 239, 226, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25RS-(HYDROXYPHENYL)-2- METHYLIDENE-19;26;27-TRINOR-1;25-DIHYDROXYVITAMIN D3 
762, 2zmhA, 0.7587, 2.78, 0.273, 240, 227, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
763, 4refB, 0.7585, 2.87, 0.211, 235, 227, CRYSTAL STRUCTURE OF TR3 LBD_L449W IN COMPLEX WITH MOLECULE 2
764, 1rjkA, 0.7585, 2.82, 0.269, 239, 227, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2MD AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
765, 5h1eA, 0.7584, 2.72, 0.279, 239, 226, INTERACTION BETWEEN VITAMIN D RECEPTOR AND COACTIVATOR PEPTIDE SRC2-3
766, 1xlsF, 0.7583, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
767, 1xlsG, 0.7582, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
768, 1xlsH, 0.7581, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
769, 1xlsE, 0.7581, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
770, 1xv9B, 0.7576, 3.02, 0.225, 246, 231, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
771, 5x8sA, 0.7575, 2.78, 0.216, 235, 227, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH URSOLIC ACID.
772, 3vrtA, 0.7575, 2.69, 0.276, 238, 225, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-MEHYLIDENE-19252627- TETRANOR-1ALPHA24-DIHYDROXYVITAMIND3
773, 5x8sB, 0.7574, 2.79, 0.216, 232, 227, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH URSOLIC ACID.
774, 4rzeB, 0.7574, 2.59, 0.206, 229, 223, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN L437W D594E MUTANT
775, 5k3nA, 0.7572, 2.56, 0.231, 228, 225, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
776, 4rzfB, 0.7572, 2.70, 0.201, 232, 224, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN S441W MUTANT
777, 1r6gA, 0.7571, 2.70, 0.257, 239, 226, CRYSTAL STRUCTURE OF THE THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BETA SELECTIVE COMPOUND
778, 4whfB, 0.7569, 2.60, 0.202, 229, 223, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH 1-(345- TRIHYDROXYPHENYL)DECAN-1-ONE
779, 5ufoA, 0.7568, 2.60, 0.224, 225, 223, STRUCTURE OF RORGT BOUND TO
780, 5ntpA, 0.7566, 2.78, 0.221, 230, 226, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
781, 5k3lC, 0.7566, 2.44, 0.229, 226, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
782, 5xzfA, 0.7564, 2.71, 0.271, 237, 225, VITAMIN D RECEPTOR WITH A SYNTHETIC LIGAND ADRO1 
783, 5k3nC, 0.7562, 2.57, 0.231, 228, 225, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
784, 5k3nB, 0.7559, 2.47, 0.224, 226, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
785, 4qm0C, 0.7559, 2.76, 0.214, 236, 224, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A TERTIARY SULFONAMIDE INVERSE AGONIST
786, 2r40D, 0.7558, 2.53, 0.243, 233, 222, CRYSTAL STRUCTURE OF 20E BOUND ECR/USP
787, 2o9iB, 0.7545, 3.18, 0.247, 279, 227, CRYSTAL STRUCTURE OF THE HUMAN PREGNANE X RECEPTOR LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND T0901317
788, 1xvpA, 0.7543, 2.77, 0.220, 232, 227, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
789, 4nqaA, 0.7540, 2.71, 0.211, 317, 228, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
790, 4kzjB, 0.7540, 2.58, 0.212, 229, 222, CRYSTAL STRUCTURE OF TR3 LBD L449W MUTANT
791, 5gieD, 0.7539, 2.44, 0.277, 230, 220, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4P (P21 FORM)
792, 5k3lA, 0.7538, 2.43, 0.234, 225, 222, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
793, 3aunA, 0.7538, 2.71, 0.276, 238, 225, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YR335 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
794, 3wt6A, 0.7537, 2.84, 0.269, 239, 227, A MIXED POPULATION OF ANTAGONIST AND AGONIST BINDING CONFORMERS IN A SINGLE CRYSTAL EXPLAINS PARTIAL AGONISM AGAINST VITAMIN D RECEPTOR: ACTIVE VITAMIN D ANALOGUES WITH 22R-ALKYL GROUP
795, 3hzfA, 0.7534, 3.26, 0.266, 259, 233, STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN C2 SPACE GROUP
796, 6eu9A, 0.7532, 2.66, 0.272, 227, 224, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
797, 6eu9D, 0.7524, 2.79, 0.265, 227, 223, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
798, 4j5wB, 0.7524, 3.13, 0.248, 293, 226, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
799, 1xv9A, 0.7524, 2.77, 0.225, 232, 227, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
800, 4zomB, 0.7521, 2.46, 0.227, 222, 220, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
801, 4nb6B, 0.7520, 2.31, 0.228, 222, 219, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF RORC WITH T0901317
802, 4iqrE, 0.7520, 2.91, 0.215, 303, 228, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
803, 5ntqB, 0.7514, 2.40, 0.227, 223, 220, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
804, 4re8B, 0.7513, 2.56, 0.217, 227, 221, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 5
805, 4j5wA, 0.7513, 3.32, 0.246, 294, 228, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
806, 6bn6B, 0.7505, 2.35, 0.228, 223, 219, IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
807, 4zomA, 0.7504, 2.58, 0.217, 223, 221, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
808, 2o9iA, 0.7500, 3.20, 0.242, 279, 227, CRYSTAL STRUCTURE OF THE HUMAN PREGNANE X RECEPTOR LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND T0901317
809, 5m96B, 0.7494, 2.44, 0.227, 223, 220, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW TRIAZOLO AND IMIDAZOLOPYRIDINE RORGT INVERSE AGONISTS
810, 3hc6A, 0.7491, 3.05, 0.296, 230, 226, FXR WITH SRC1 AND GSK088
811, 1xv9C, 0.7491, 2.89, 0.220, 232, 227, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
812, 3hvlB, 0.7489, 3.23, 0.248, 289, 226, TETHERED PXR-LBD/SRC-1P COMPLEXED WITH SR-12813
813, 4wqpB, 0.7488, 2.32, 0.229, 221, 218, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A BENZYL SULFONAMIDE INVERSE AGONIST
814, 5m96A, 0.7487, 2.66, 0.224, 225, 223, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW TRIAZOLO AND IMIDAZOLOPYRIDINE RORGT INVERSE AGONISTS
815, 1fm6A, 0.7486, 2.75, 0.217, 232, 226, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
816, 4j5xA, 0.7485, 3.23, 0.251, 293, 227, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
817, 1xvpC, 0.7485, 3.05, 0.223, 236, 229, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
818, 4nb6A, 0.7484, 2.32, 0.229, 221, 218, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF RORC WITH T0901317
819, 6bnsB, 0.7483, 3.13, 0.249, 283, 225, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND 25A AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
820, 1nrlB, 0.7483, 3.08, 0.253, 275, 225, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND SR12813
821, 5ickB, 0.7482, 3.02, 0.281, 229, 224, A UNIQUE BINDING MODEL OF FXR LBD WITH FEROLINE
822, 1ovlD, 0.7481, 2.48, 0.214, 228, 220, CRYSTAL STRUCTURE OF NURR1 LBD
823, 5apkA, 0.7480, 2.53, 0.227, 229, 220, LIGAND COMPLEX OF RORG LBD
824, 5a86B, 0.7480, 2.94, 0.256, 274, 223, STRUCTURE OF PREGNANE X RECEPTOR IN COMPLEX WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 ANTAGONIST
825, 1fm6U, 0.7478, 2.76, 0.217, 232, 226, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
826, 1k74A, 0.7477, 2.77, 0.221, 232, 226, THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES.
827, 3hlvB, 0.7474, 2.85, 0.191, 240, 225, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S9R13S14R 16R)-316-DIHYDROXY-13-METHYL-78911121415 16-OCTAHYDRO-6H- CYCLOPENTA[A]PHENANTHREN-17-ONE
828, 1ilhA, 0.7473, 3.33, 0.250, 270, 228, CRYSTAL STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TO SR12813
829, 1pqcD, 0.7468, 2.31, 0.265, 219, 215, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
830, 1fm9A, 0.7467, 2.77, 0.221, 232, 226, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
831, 1pq9D, 0.7464, 2.32, 0.265, 219, 215, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
832, 1ilgA, 0.7461, 3.24, 0.251, 270, 227, CRYSTAL STRUCTURE OF APO HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN
833, 4jgvB, 0.7458, 2.64, 0.205, 226, 220, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH THPN
834, 3ctbB, 0.7457, 3.09, 0.246, 287, 224, TETHERED PXR-LBD/SRC-1P APOPROTEIN
835, 5di7B, 0.7456, 2.87, 0.191, 245, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN METHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(4-HYDROXY-2-METHYLPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
836, 3gd2A, 0.7456, 2.99, 0.290, 227, 224, ISOXAZOLE LIGAND BOUND TO FARNESOID X RECEPTOR (FXR)
837, 5x0rB, 0.7454, 3.16, 0.237, 257, 224, CRYSTAL STRUCTURE OF PXR LBD COMPLEXED WITH SJB7
838, 5didB, 0.7454, 2.88, 0.182, 245, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(23-DIFLUORO-4-HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1- OL
839, 4p6wA, 0.7454, 2.60, 0.176, 252, 222, CRYSTAL STRUCTURE OF MOMETASONE FUROATE-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
840, 5iawA, 0.7453, 2.96, 0.278, 228, 223, NOVEL NATURAL FXR MODULATOR WITH A UNIQUE BINDING MODE
841, 1ovlB, 0.7452, 2.89, 0.196, 233, 224, CRYSTAL STRUCTURE OF NURR1 LBD
842, 4zjrB, 0.7451, 2.47, 0.220, 220, 218, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
843, 1r20D, 0.7451, 2.74, 0.239, 228, 222, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO THE SYNTHETIC AGONIST BYI06830
844, 5dziB, 0.7450, 2.89, 0.196, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
845, 4iqrF, 0.7450, 2.71, 0.223, 314, 224, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
846, 5k3mB, 0.7449, 2.45, 0.233, 222, 219, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH UUA
847, 4s0tB, 0.7449, 3.07, 0.253, 283, 225, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
848, 5xuqA, 0.7448, 2.61, 0.277, 231, 220, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH AN ANTAGONIST; 2- METHYLIDENE-19;26;27-TRINOR-22-(S)-BUTYL-1-HYDROXY-25-OXO-25-(1H- PYRROL-2-YL)- VITAMIN D3 
849, 3vt9A, 0.7448, 2.75, 0.270, 233, 222, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
850, 1ovlE, 0.7448, 2.92, 0.218, 247, 225, CRYSTAL STRUCTURE OF NURR1 LBD
851, 2qabB, 0.7447, 2.89, 0.191, 245, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH AN ETHYL INDAZOLE COMPOUND
852, 5ufrB, 0.7446, 2.76, 0.213, 223, 221, STRUCTURE OF RORGT BOUND TO
853, 6eu9B, 0.7445, 2.87, 0.265, 227, 223, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
854, 5tlvB, 0.7441, 2.89, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(THIOPHENE-23-DIYL)BIS(3-FLUOROPHENOL)
855, 5didA, 0.7441, 2.94, 0.187, 244, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(23-DIFLUORO-4-HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1- OL
856, 4j5xB, 0.7441, 3.02, 0.237, 293, 224, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
857, 5di7A, 0.7440, 2.92, 0.187, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN METHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(4-HYDROXY-2-METHYLPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
858, 4x1gA, 0.7440, 2.92, 0.256, 279, 223, CRYSTAL STRUCTURE OF THE HPXR-LBD IN COMPLEX WITH THE SYNTHETIC ESTROGEN 17ALPHA-ETHINYLESTRADIOL AND THE PESTICIDE TRANS-NONACHLOR
859, 5dl4B, 0.7439, 2.90, 0.191, 240, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(PHENYLAMINO)PHENYL]PROP-1-ENE-11-DIYL}DIPHENOL
860, 5aygB, 0.7439, 2.39, 0.222, 219, 216, CRYSTAL STRUCTURE OF THE HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH 3G
861, 4xaoA, 0.7439, 3.03, 0.254, 275, 224, CRYSTAL STRUCTURE OF THE HPXR-LBD OBTAINED IN PRESENCE OF THE PESTICIDE TRANS-NONACHLOR
862, 3vt8A, 0.7438, 2.76, 0.266, 233, 222, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
863, 4j5xC, 0.7437, 2.50, 0.222, 238, 221, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
864, 1m13A, 0.7437, 3.07, 0.253, 273, 225, CRYSTAL STRUCTURE OF THE HUMAN PREGANE X RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH HYPERFORIN A CONSTITUENT OF ST. JOHN S WORT
865, 5xplA, 0.7436, 2.93, 0.276, 237, 225, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-25- HYDROXYPHENYL-2-METHYLIDENE-19;26;27-TRINOR-25-OXO-1-HYDROXYVITAMIN D3 
866, 5q1iA, 0.7436, 2.90, 0.269, 227, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
867, 4zomC, 0.7436, 2.42, 0.230, 219, 217, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
868, 4x1fA, 0.7436, 3.04, 0.250, 271, 224, CRYSTAL STRUCTURE OF THE HPXR-LBD IN COMPLEX WITH THE SYNTHETIC ESTROGEN 17ALPHA-ETHINYLESTRADIOL
869, 2qa6B, 0.7435, 2.92, 0.182, 242, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA MUTANT 537S COMPLEXED WITH 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-13-DIOL
870, 1nrlA, 0.7434, 2.93, 0.256, 278, 223, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND SR12813
871, 3ctbA, 0.7432, 3.03, 0.247, 287, 223, TETHERED PXR-LBD/SRC-1P APOPROTEIN
872, 2qr9B, 0.7432, 2.95, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DERIVATIVE COMPOUND
873, 2p15B, 0.7432, 2.96, 0.182, 242, 225, CRYSTAL STRUCTURE OF THE ER ALPHA LIGAND BINDING DOMAIN WITH THE AGONIST ORTHO-TRIFLUOROMETHYLPHENYLVINYL ESTRADIOL
874, 1xiuB, 0.7431, 2.37, 0.223, 224, 220, CRYSTAL STRUCTURE OF THE AGONIST-BOUND LIGAND-BINDING DOMAIN OF BIOMPHALARIA GLABRATA RXR
875, 5a86A, 0.7430, 2.98, 0.251, 271, 223, STRUCTURE OF PREGNANE X RECEPTOR IN COMPLEX WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 ANTAGONIST
876, 5tn1B, 0.7427, 2.97, 0.187, 245, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14SE)-17-((4- ISOPROPYLPHENYL)IMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
877, 3q95A, 0.7427, 2.84, 0.183, 243, 224, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL
878, 1qkuB, 0.7427, 2.87, 0.182, 247, 225, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
879, 1qkuA, 0.7427, 2.87, 0.182, 250, 225, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
880, 5t1zA, 0.7425, 2.98, 0.187, 240, 225, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ETHOXYTRIPHENYLETHYLENE AND GRIP PEPTIDE
881, 3hvlA, 0.7425, 3.02, 0.256, 287, 223, TETHERED PXR-LBD/SRC-1P COMPLEXED WITH SR-12813
882, 3p88A, 0.7424, 3.09, 0.289, 229, 225, FXR BOUND TO ISOQUINOLINECARBOXYLIC ACID
883, 2qseB, 0.7424, 2.98, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH BURNED MEAT COMPOUND 4-OH-PHIP
884, 5k3mA, 0.7423, 2.48, 0.233, 222, 219, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH UUA
885, 4j5xD, 0.7423, 2.53, 0.217, 239, 221, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
886, 5tn3B, 0.7422, 2.92, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S)-17-((4- ISOPROPYLPHENYL)AMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
887, 1g50A, 0.7422, 2.86, 0.182, 247, 225, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
888, 3dcuA, 0.7421, 3.11, 0.302, 229, 225, FXR WITH SRC1 AND GSK8062
889, 5ickA, 0.7420, 3.06, 0.295, 229, 224, A UNIQUE BINDING MODEL OF FXR LBD WITH FEROLINE
890, 5krlA, 0.7419, 2.98, 0.182, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(2-CHLORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
891, 4qe6A, 0.7419, 3.24, 0.276, 228, 225, FXR WITH CDCA AND NCOA-2 PEPTIDE
892, 2yjaB, 0.7418, 2.98, 0.173, 245, 225, STAPLED PEPTIDES BINDING TO ESTROGEN RECEPTOR ALPHA.
893, 2qabA, 0.7418, 2.97, 0.178, 236, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH AN ETHYL INDAZOLE COMPOUND
894, 5krmB, 0.7416, 2.90, 0.187, 240, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(25-DIFLUORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
895, 5digA, 0.7416, 2.98, 0.191, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUOROMETHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S 3AR5S7AS)-5-[4-HYDROXY-2-(TRIFLUOROMETHYL)PHENYL]-7A- METHYLOCTAHYDRO-1H-INDEN-1-OL
896, 2qxmB, 0.7416, 2.98, 0.182, 242, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO BURNED MEAT COMPOUND PHIP
897, 5krmA, 0.7415, 2.96, 0.182, 237, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(25-DIFLUORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
898, 5drjB, 0.7415, 2.93, 0.182, 242, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 3-METHYL 25-DIARYLTHIOPHENE-CORE LIGAND 44 -(3-METHYLTHIENE-25-DIYL)BIS(3-CHLOROPHENOL)
899, 4ny9A, 0.7415, 2.96, 0.257, 260, 222, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH N-{(2R)-1- [(4S)-4-(4-CHLOROPHENYL)-4-HYDROXY-33-DIMETHYLPIPERIDIN-1-YL]-3- METHYL-1-OXOBUTAN-2-YL}-3-HYDROXY-3-METHYLBUTANAMIDE
900, 3dctA, 0.7415, 3.11, 0.302, 229, 225, FXR WITH SRC1 AND GW4064
901, 5ufrA, 0.7414, 2.85, 0.213, 223, 221, STRUCTURE OF RORGT BOUND TO
902, 5tmrA, 0.7414, 2.92, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (CYCLOHEXYLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
903, 5tm6B, 0.7414, 2.81, 0.187, 243, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEXANOIC ACID
904, 4iqrB, 0.7414, 2.56, 0.222, 308, 221, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
905, 5tm5A, 0.7413, 2.95, 0.191, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 5-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)PENTANOIC ACID
906, 5tm3B, 0.7413, 2.92, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 23-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
907, 4iqrA, 0.7413, 3.06, 0.220, 302, 227, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
908, 5tltB, 0.7412, 2.97, 0.191, 240, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OCTANE-18-DIYL BIS(23-BIS(4-HYDROXYPHENYL)PENTANOATE)
909, 3ruuA, 0.7412, 3.11, 0.289, 229, 225, FXR WITH SRC1 AND GSK237
910, 1qkuC, 0.7412, 2.82, 0.183, 247, 224, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
911, 4mg9A, 0.7411, 2.97, 0.187, 241, 225, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BUTYLPARABEN
912, 2qnvA, 0.7411, 2.90, 0.258, 249, 221, CRYSTAL STRUCTURE OF THE PREGNANE X RECEPTOR BOUND TO COLUPULONE
913, 2qgwB, 0.7411, 2.98, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH A CHLORO-INDAZOLE COMPOUND
914, 5e19B, 0.7409, 2.95, 0.191, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE METHYL {4-[BIS(4-HYDROXYPHENYL) METHYLIDENE]CYCLOHEXYL}ACETATE
915, 5uhiA, 0.7408, 2.73, 0.214, 223, 220, STRUCTURE OF RORGT BOUND TO
916, 5digB, 0.7408, 2.90, 0.187, 242, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUOROMETHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S 3AR5S7AS)-5-[4-HYDROXY-2-(TRIFLUOROMETHYL)PHENYL]-7A- METHYLOCTAHYDRO-1H-INDEN-1-OL
917, 6bnsA, 0.7407, 2.87, 0.253, 286, 221, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND 25A AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
918, 4zjrC, 0.7407, 2.48, 0.226, 220, 217, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
919, 2qgwA, 0.7407, 2.98, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH A CHLORO-INDAZOLE COMPOUND
920, 1xlsC, 0.7407, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
921, 1xlsB, 0.7407, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
922, 5tmqB, 0.7406, 2.93, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE 4-BROMOPHENYL 44  - DIHYDROXY-[11 :2 1  -TERPHENYL]-4 -SULFONATE
923, 5dieA, 0.7406, 2.98, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR 5S7AS)-7A-METHYL-5-(235-TRIFLUORO-4-HYDROXYPHENYL)OCTAHYDRO-1H- INDEN-1-OL
924, 4iwfA, 0.7406, 3.01, 0.182, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC OXIME-DERIVATIVE
925, 1xlsD, 0.7406, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
926, 1xlsA, 0.7406, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
927, 5e1cB, 0.7405, 2.97, 0.187, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE DIMETHYL {(1S)-3-[BIS(4- HYDROXYPHENYL)METHYLIDENE]CYCLOHEXYL}PROPANEDIOATE
928, 2qgtB, 0.7405, 2.95, 0.182, 239, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO AN ETHER ESTRADIOL COMPOUND
929, 5tmuA, 0.7404, 2.85, 0.187, 241, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(CYCLOHEPTYLIDENEMETHYLENE)DIPHENOL
930, 5tlvA, 0.7404, 2.99, 0.187, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(THIOPHENE-23-DIYL)BIS(3-FLUOROPHENOL)
931, 2qgtA, 0.7404, 2.99, 0.191, 237, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO AN ETHER ESTRADIOL COMPOUND
932, 5tlxB, 0.7403, 2.94, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
933, 5dmfA, 0.7403, 2.91, 0.179, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}PROP-1-ENE-11- DIYL)DIPHENOL
934, 4xhdA, 0.7403, 2.87, 0.258, 268, 221, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH COMPOUND-1
935, 3hlvA, 0.7403, 2.88, 0.192, 240, 224, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S9R13S14R 16R)-316-DIHYDROXY-13-METHYL-78911121415 16-OCTAHYDRO-6H- CYCLOPENTA[A]PHENANTHREN-17-ONE
936, 5tn6A, 0.7402, 2.96, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE SPIRO BC-ESTRADIOL (1S1 S3A S7A S)-7A -METHYL- 1 22 33 3A 4 6 7 7A -DECAHYDRO-15 -SPIROBI[INDENE]-1 5- DIOL
937, 5tn3A, 0.7402, 3.02, 0.182, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S)-17-((4- ISOPROPYLPHENYL)AMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
938, 5tmoB, 0.7401, 2.95, 0.191, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE PHENYL 44  -DIHYDROXY- [11 :2 1  -TERPHENYL]-4 -SULFONATE
939, 5dueB, 0.7401, 3.00, 0.196, 242, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PARA-HYDROXYL-SUBSTITUTED SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG 4-HYDROXYPHENYL (1S2S4S5S6R 7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7-THIABICYCLO[2.2.1]HEPTANE-2- SULFONATE 7-OXIDE
940, 4ppsB, 0.7401, 2.99, 0.182, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN A-CD RING ESTROGEN DERIVATIVE
941, 3rvfA, 0.7401, 3.07, 0.290, 228, 224, FXR WITH SRC1 AND GSK2034
942, 3bejA, 0.7401, 2.82, 0.286, 224, 220, STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO- ACTIVATOR PEPTIDE
943, 3rutA, 0.7400, 3.10, 0.289, 229, 225, FXR WITH SRC1 AND GSK359
944, 2qa6A, 0.7400, 2.92, 0.183, 243, 224, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA MUTANT 537S COMPLEXED WITH 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-13-DIOL
945, 5u2bC, 0.7399, 2.93, 0.188, 244, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
946, 5q0zC, 0.7399, 3.30, 0.265, 230, 226, LIGAND BINDING TO FARNESOID-X-RECEPTOR
947, 5krcB, 0.7399, 2.98, 0.182, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH ZEARALENONE
948, 3l03B, 0.7399, 3.00, 0.187, 242, 225, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-135(10)-TRIENE-315 ALPHA 16ALPHA17BETA-TETROL)
949, 3kmzA, 0.7399, 2.61, 0.236, 221, 216, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH THE INVERSE AGONIST BMS493 AND A COREPRESSOR FRAGMENT
950, 5q1gA, 0.7398, 3.12, 0.274, 224, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
951, 5ntkA, 0.7398, 2.68, 0.209, 225, 220, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
952, 5uhiB, 0.7397, 2.85, 0.213, 223, 221, STRUCTURE OF RORGT BOUND TO
953, 5tn4B, 0.7397, 2.96, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ACD-RING ESTROGEN (S)-5-(4-HYDROXY-35- DIMETHYLPHENYL)-23-DIHYDRO-1H-INDEN-1-OL
954, 5tlgB, 0.7397, 2.84, 0.183, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-44  -DIHYDROXY-3 -((HYDROXYIMINIO)METHYL)-[11 :2  1  -TERPHENYL]-4 -OLATE
955, 4znhA, 0.7397, 3.00, 0.191, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-FLUORO-SUBSTITUTED OBHS DERIVATIVE
956, 3bejB, 0.7397, 3.14, 0.278, 228, 223, STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO- ACTIVATOR PEPTIDE
957, 2zkcA, 0.7397, 2.64, 0.214, 226, 220, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL Z
958, 5tn8B, 0.7396, 2.73, 0.188, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-4-OLATE
959, 3uuaA, 0.7396, 2.87, 0.187, 241, 224, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-AF
960, 1ovlA, 0.7396, 2.55, 0.220, 226, 218, CRYSTAL STRUCTURE OF NURR1 LBD
961, 5tlpA, 0.7395, 2.87, 0.179, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-BSC ANALOG 3-FLUOROPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE AND 3-METHYL-6-PHENYL-3H- IMIDAZO[45-B]PYRIDIN-2-AMINE
962, 5duhA, 0.7395, 2.94, 0.183, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-3 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-3-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
963, 4zn7B, 0.7395, 2.98, 0.182, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DIETHYLSTILBESTROL
964, 5tmzB, 0.7393, 2.85, 0.187, 243, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S17S)-16-(3- METHOXYBENZYL)-13-METHYL-78911121314151617-DECAHYDRO-6H- CYCLOPENTA[A]PHENANTHRENE-317-DIOL
965, 5q14C, 0.7392, 3.30, 0.265, 230, 226, LIGAND BINDING TO FARNESOID-X-RECEPTOR
966, 5dxkB, 0.7392, 2.89, 0.192, 239, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(9S)-BICYCLO[3.3.1]NON-9- YLMETHANEDIYL]DIPHENOL
967, 4s0tA, 0.7391, 3.11, 0.256, 279, 223, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
968, 4pppB, 0.7391, 2.77, 0.188, 235, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH FLUORO-RESVERATROL
969, 3kmzB, 0.7391, 2.64, 0.236, 221, 216, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH THE INVERSE AGONIST BMS493 AND A COREPRESSOR FRAGMENT
970, 5q13A, 0.7390, 3.44, 0.274, 232, 230, LIGAND BINDING TO FARNESOID-X-RECEPTOR
971, 5dkgB, 0.7390, 2.93, 0.187, 240, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A T-BUTYL-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 - [2-(4-TERT-BUTYLPHENYL)PROP-1-ENE-11-DIYL]DIPHENOL
972, 5egvB, 0.7389, 2.78, 0.185, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX THE 34-DIARYL-FURAN DERIVATIVE 3-CHLORANYL-4-[4-(2- CHLORANYL-4-OXIDANYL-PHENYL)FURAN-3-YL]PHENOL
973, 5x0rA, 0.7387, 2.93, 0.243, 237, 218, CRYSTAL STRUCTURE OF PXR LBD COMPLEXED WITH SJB7
974, 5tn7A, 0.7387, 2.96, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-3 -FLUORO-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[1 1 -BIPHENYL]-4-OLATE
975, 4reeA, 0.7387, 2.89, 0.200, 234, 225, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 6
976, 2zasA, 0.7387, 2.67, 0.213, 227, 221, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 4-ALPHA-CUMYLPHENOL A BISPHENOL A DERIVATIVE
977, 1g50B, 0.7387, 2.92, 0.187, 246, 225, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
978, 5q10A, 0.7386, 2.88, 0.281, 227, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
979, 6br3A, 0.7385, 2.35, 0.224, 216, 214, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST TAK-828.
980, 4mg8A, 0.7385, 2.87, 0.188, 240, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALANOL
981, 3vt7A, 0.7385, 2.70, 0.274, 230, 219, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
982, 5dxrB, 0.7384, 2.94, 0.173, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- METHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
983, 3hc5A, 0.7384, 3.13, 0.289, 229, 225, FXR WITH SRC1 AND GSK826
984, 3erdA, 0.7384, 2.91, 0.179, 245, 224, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
985, 5tn1A, 0.7383, 2.83, 0.193, 245, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14SE)-17-((4- ISOPROPYLPHENYL)IMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
986, 5q12A, 0.7383, 3.11, 0.281, 228, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
987, 5tmvB, 0.7382, 2.82, 0.189, 239, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS ANALOG 4-IODOPHENYL (1S2R4S)-56-BIS(4- HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
988, 5q0pC, 0.7382, 3.32, 0.265, 230, 226, LIGAND BINDING TO FARNESOID-X-RECEPTOR
989, 5dl4A, 0.7382, 2.88, 0.184, 237, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(PHENYLAMINO)PHENYL]PROP-1-ENE-11-DIYL}DIPHENOL
990, 4iwcA, 0.7382, 3.01, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC THIOPHENE-DERIVATIVE
991, 2gp7B, 0.7382, 2.53, 0.215, 225, 219, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
992, 5q0wA, 0.7380, 3.14, 0.277, 228, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
993, 5dz1B, 0.7380, 2.94, 0.182, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-ETHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
994, 3uudA, 0.7380, 2.95, 0.192, 240, 224, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ESTRADIOL
995, 5kccA, 0.7379, 2.93, 0.192, 237, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE (OBHS-N)
996, 4dmaA, 0.7379, 2.98, 0.182, 238, 225, CRYSTAL STRUCTURE OF ERA LBD IN COMPLEX WITH RU100132
997, 3erdB, 0.7379, 2.85, 0.184, 237, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
998, 3r8dA, 0.7378, 2.82, 0.255, 264, 220, ACTIVATION OF THE HUMAN NUCLEAR XENOBIOTIC RECEPTOR PXR BY THE REVERSE TRANSCRIPTASE-TARGETED ANTI-HIV DRUG PNU-142721
999, 1zh7A, 0.7378, 2.88, 0.179, 243, 223, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
1000, 5q0rA, 0.7377, 2.90, 0.279, 224, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1001, 5du5B, 0.7377, 2.99, 0.192, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1002, 4p6xK, 0.7377, 2.90, 0.180, 255, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1003, 5dtvB, 0.7376, 2.92, 0.192, 238, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIMETHYL-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1004, 3b0wB, 0.7376, 2.41, 0.223, 217, 215, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH DIGOXIN
1005, 5tmsB, 0.7375, 2.84, 0.188, 243, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (BICYCLO[3.3.1]NONAN-9-YLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
1006, 5drmA, 0.7375, 3.11, 0.182, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 25-DIARYLTHIOPHENE-CORE LIGAND 44 - THIENE-25-DIYLBIS(3-CHLOROPHENOL)
1007, 4iwcB, 0.7375, 2.91, 0.193, 240, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC THIOPHENE-DERIVATIVE
1008, 5dxmB, 0.7374, 2.95, 0.192, 237, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 3-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(4-HYDROXYPHENYL)METHYL]PHENOL
1009, 4ppsA, 0.7374, 2.89, 0.188, 238, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN A-CD RING ESTROGEN DERIVATIVE
1010, 4s0sA, 0.7373, 2.95, 0.258, 273, 221, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH ADNECTIN-1
1011, 4p6xC, 0.7373, 2.91, 0.180, 255, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1012, 3fxvA, 0.7373, 2.82, 0.271, 222, 218, IDENTIFICATION OF AN N-OXIDE PYRIDINE GW4064 ANALOGUE AS A POTENT FXR AGONIST
1013, 2gp7C, 0.7373, 2.48, 0.220, 224, 218, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
1014, 4zjrD, 0.7372, 2.42, 0.223, 219, 215, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
1015, 4s0sB, 0.7372, 2.96, 0.258, 273, 221, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH ADNECTIN-1
1016, 2gp7A, 0.7372, 2.48, 0.220, 224, 218, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
1017, 5dugA, 0.7371, 2.88, 0.184, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
1018, 2gp7D, 0.7371, 2.48, 0.220, 224, 218, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
1019, 2zbsA, 0.7370, 2.64, 0.218, 227, 220, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN APO FORM
1020, 1skxA, 0.7370, 2.97, 0.249, 242, 221, STRUCTURAL DISORDER IN THE COMPLEX OF HUMAN PXR AND THE MACROLIDE ANTIBIOTIC RIFAMPICIN
1021, 5aygA, 0.7369, 2.37, 0.224, 217, 214, CRYSTAL STRUCTURE OF THE HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH 3G
1022, 5q1hE, 0.7368, 3.26, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1023, 1pcgB, 0.7368, 2.95, 0.187, 243, 224, HELIX-STABILIZED CYCLIC PEPTIDES AS SELECTIVE INHIBITORS OF STEROID RECEPTOR-COACTIVATOR INTERACTIONS
1024, 5tn7B, 0.7367, 2.98, 0.183, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-3 -FLUORO-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[1 1 -BIPHENYL]-4-OLATE
1025, 5q1hA, 0.7367, 3.25, 0.267, 229, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1026, 5ethB, 0.7367, 2.61, 0.211, 221, 218, RORY IN COMPLEX WITH INVERSE AGONIST 3.
1027, 5tllA, 0.7366, 2.95, 0.183, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-2-CHLORO-4 -HYDROXY-4-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-3-OLATE
1028, 4tuzA, 0.7366, 3.05, 0.187, 235, 224, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALENOL
1029, 1lv2A, 0.7366, 2.71, 0.196, 225, 219, HEPATOCYTE NUCLEAR FACTOR 4 IS A TRANSCRIPTION FACTOR THAT CONSTITUTIVELY BINDS FATTY ACIDS
1030, 5u2dA, 0.7365, 3.04, 0.187, 246, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1031, 5tluB, 0.7365, 2.95, 0.192, 238, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PEG-LINKED DIMERIC ESTROGEN EE2-(EG)6-EE2-AMINE
1032, 5q1bA, 0.7365, 3.28, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1033, 3uu7A, 0.7365, 2.92, 0.184, 237, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-A
1034, 2qr9A, 0.7365, 2.86, 0.179, 242, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DERIVATIVE COMPOUND
1035, 5tn5B, 0.7364, 2.95, 0.183, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE AC-RING ESTROGEN (1S3AS5S7AS)-5-(4- HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
1036, 5t1zB, 0.7364, 2.93, 0.188, 238, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ETHOXYTRIPHENYLETHYLENE AND GRIP PEPTIDE
1037, 4zjrA, 0.7364, 2.43, 0.223, 217, 215, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
1038, 2p15A, 0.7364, 2.86, 0.179, 242, 223, CRYSTAL STRUCTURE OF THE ER ALPHA LIGAND BINDING DOMAIN WITH THE AGONIST ORTHO-TRIFLUOROMETHYLPHENYLVINYL ESTRADIOL
1039, 1zkyB, 0.7364, 2.91, 0.197, 242, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-3M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1040, 1gwqA, 0.7364, 2.74, 0.180, 243, 222, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
1041, 4znvB, 0.7363, 3.03, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHOXY-SUBSTITUTED OBHS DERIVATIVE
1042, 2qw4A, 0.7363, 2.85, 0.226, 230, 221, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1043, 5tlfA, 0.7362, 3.07, 0.182, 237, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CONSTRAINED WAY DERIVATIVE 4-(2-(3-METHYLBUT-2-EN- 1-YL)-7-(TRIFLUOROMETHYL)-2H-INDAZOL-3-YL)BENZENE-13-DIOL
1044, 5q0oA, 0.7362, 3.34, 0.265, 230, 226, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1045, 4p6xI, 0.7362, 2.86, 0.176, 255, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1046, 3q95B, 0.7362, 2.98, 0.193, 251, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL
1047, 3okiC, 0.7362, 3.29, 0.262, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N2-DICYCLOHEXYLETHANAMIDE
1048, 1ot7A, 0.7362, 3.23, 0.281, 229, 224, STRUCTURAL BASIS FOR 3-DEOXY-CDCA BINDING AND ACTIVATION OF FXR
1049, 1gwrB, 0.7362, 2.98, 0.179, 239, 224, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
1050, 5q16C, 0.7361, 3.25, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1051, 5q0xA, 0.7361, 2.81, 0.271, 222, 218, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1052, 4mgdA, 0.7361, 2.87, 0.185, 240, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH HPTE
1053, 2qzoB, 0.7361, 2.94, 0.197, 235, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH WAY-169916
1054, 2gpoA, 0.7361, 2.49, 0.211, 224, 218, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A SYNTHETIC PEPTIDE FROM RIP140
1055, 1osvA, 0.7361, 3.25, 0.277, 229, 224, STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
1056, 5w4rB, 0.7360, 2.33, 0.215, 217, 214, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1057, 5dxbA, 0.7360, 2.95, 0.188, 231, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P1 AND ESTRADIOL
1058, 4zn7A, 0.7360, 2.88, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DIETHYLSTILBESTROL
1059, 4p6xG, 0.7360, 3.02, 0.175, 254, 223, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1060, 5q0mA, 0.7359, 3.01, 0.279, 223, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1061, 5q0jC, 0.7359, 3.28, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1062, 5iawB, 0.7359, 3.13, 0.281, 227, 224, NOVEL NATURAL FXR MODULATOR WITH A UNIQUE BINDING MODE
1063, 2e2rA, 0.7359, 2.77, 0.208, 227, 221, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL A
1064, 1m2zD, 0.7359, 2.66, 0.183, 253, 219, CRYSTAL STRUCTURE OF A DIMER COMPLEX OF THE HUMAN GLUCOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEXAMETHASONE AND A TIF2 COACTIVATOR MOTIF
1065, 1gwqB, 0.7359, 2.65, 0.186, 242, 221, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
1066, 3fs1A, 0.7358, 2.81, 0.225, 230, 222, CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR PGC-1A FRAGMENT
1067, 2a3iA, 0.7358, 2.98, 0.148, 253, 223, STRUCTURAL AND BIOCHEMICAL MECHANISMS FOR THE SPECIFICITY OF HORMONE BINDING AND COACTIVATOR ASSEMBLY BY MINERALOCORTICOID RECEPTOR
1068, 5tmrB, 0.7357, 2.99, 0.183, 237, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (CYCLOHEXYLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
1069, 5q0vC, 0.7357, 3.25, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1070, 5ei1A, 0.7357, 2.86, 0.185, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- IODANYL-IMIDAZO[12-A]PYRIDIN-6-OL
1071, 5dziA, 0.7357, 2.87, 0.185, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1072, 1x7eB, 0.7357, 2.85, 0.188, 238, 223, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
1073, 5dlrB, 0.7356, 2.84, 0.185, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-ETHYLENE COMPOUND 44 -(2-PHENYLETHENE-11-DIYL) DIPHENOL
1074, 5q0jA, 0.7355, 3.35, 0.261, 230, 226, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1075, 5q0iA, 0.7355, 3.03, 0.284, 227, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1076, 5kceB, 0.7355, 2.97, 0.185, 239, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL 2-CHLOROBENZYL OBHS-N DERIVATIVE
1077, 5dmfB, 0.7355, 2.81, 0.180, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}PROP-1-ENE-11- DIYL)DIPHENOL
1078, 5q18A, 0.7354, 3.36, 0.265, 230, 226, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1079, 1gwrA, 0.7354, 2.79, 0.189, 238, 222, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
1080, 1e3kA, 0.7354, 2.76, 0.155, 251, 220, HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
1081, 5tmlB, 0.7353, 2.90, 0.184, 241, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND (E)-6-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1082, 5dieB, 0.7353, 2.95, 0.184, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR 5S7AS)-7A-METHYL-5-(235-TRIFLUORO-4-HYDROXYPHENYL)OCTAHYDRO-1H- INDEN-1-OL
1083, 4zjwB, 0.7353, 2.76, 0.209, 222, 220, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 16
1084, 4a2jA, 0.7353, 2.77, 0.155, 250, 220, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA- SUBSTITUTED STEROIDS
1085, 5q1dA, 0.7352, 3.28, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1086, 5q0zA, 0.7352, 3.42, 0.264, 230, 227, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1087, 4mgbA, 0.7352, 2.86, 0.185, 239, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH TCBPA
1088, 5tlyB, 0.7351, 2.97, 0.193, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
1089, 5q19C, 0.7351, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1090, 5eitB, 0.7351, 2.80, 0.185, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- (TRIFLUOROMETHYL)IMIDAZO[12-A]PYRIDIN-6-OL
1091, 4tuzB, 0.7351, 2.93, 0.197, 241, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALENOL
1092, 4mg5A, 0.7351, 2.92, 0.193, 239, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH CHLORDECONE
1093, 3okhA, 0.7351, 3.05, 0.286, 227, 220, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 2-(4-CHLOROPHENYL)-1- [(1S)-1-CYCLOHEXYL-2-(CYCLOHEXYLAMINO)-2-OXOETHYL]-1H-BENZIMIDAZOLE- 6-CARBOXYLIC ACID
1094, 4p6xE, 0.7350, 2.93, 0.176, 255, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1095, 4ivwB, 0.7350, 2.84, 0.189, 238, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 6B
1096, 3l03A, 0.7350, 2.98, 0.192, 235, 224, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-135(10)-TRIENE-315 ALPHA 16ALPHA17BETA-TETROL)
1097, 5q1dC, 0.7349, 3.28, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1098, 5dueA, 0.7349, 2.83, 0.189, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PARA-HYDROXYL-SUBSTITUTED SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG 4-HYDROXYPHENYL (1S2S4S5S6R 7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7-THIABICYCLO[2.2.1]HEPTANE-2- SULFONATE 7-OXIDE
1099, 4p6xA, 0.7349, 2.88, 0.176, 252, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1100, 3omkC, 0.7349, 3.27, 0.262, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2- METHYLPHENYL)ETHANAMIDE
1101, 1pk5A, 0.7349, 3.01, 0.183, 242, 224, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR LRH-1
1102, 5tmzA, 0.7348, 2.83, 0.185, 236, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S17S)-16-(3- METHOXYBENZYL)-13-METHYL-78911121314151617-DECAHYDRO-6H- CYCLOPENTA[A]PHENANTHRENE-317-DIOL
1103, 5q0kA, 0.7348, 2.93, 0.279, 224, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1104, 3v3eA, 0.7348, 2.97, 0.204, 234, 225, CRYSTAL STRUCTURE OF THE HUMAN NUR77 LIGAND-BINDING DOMAIN
1105, 2b1vB, 0.7348, 2.92, 0.197, 241, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1106, 1x7eA, 0.7348, 2.81, 0.194, 238, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
1107, 1pduA, 0.7348, 3.03, 0.227, 230, 225, LIGAND-BINDING DOMAIN OF DROSOPHILA ORPHAN NUCLEAR RECEPTOR DHR38
1108, 5tmwB, 0.7347, 2.82, 0.185, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS DERIVATIVE 4-ACETAMIDOPHENYL (1S2R4S)-56- BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
1109, 5tllB, 0.7347, 2.87, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-2-CHLORO-4 -HYDROXY-4-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-3-OLATE
1110, 4zomD, 0.7347, 2.33, 0.225, 215, 213, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
1111, 4apuB, 0.7347, 2.75, 0.150, 250, 220, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID
1112, 5q0yA, 0.7346, 3.26, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1113, 5dugB, 0.7346, 2.84, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
1114, 4pp6A, 0.7346, 2.85, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RESVERATROL
1115, 1e3kB, 0.7346, 2.73, 0.150, 249, 220, HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
1116, 5q0sC, 0.7345, 3.27, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1117, 3ookA, 0.7345, 3.17, 0.262, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-35-DIFLUOROBENZOIC ACID
1118, 1zdtB, 0.7345, 2.74, 0.176, 239, 221, THE CRYSTAL STRUCTURE OF HUMAN STEROIDOGENIC FACTOR-1
1119, 3q97A, 0.7344, 3.01, 0.193, 243, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE
1120, 3f5cA, 0.7344, 2.87, 0.185, 243, 222, STRUCTURE OF DAX-1:LRH-1 COMPLEX
1121, 1m2zA, 0.7344, 2.82, 0.177, 255, 220, CRYSTAL STRUCTURE OF A DIMER COMPLEX OF THE HUMAN GLUCOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEXAMETHASONE AND A TIF2 COACTIVATOR MOTIF
1122, 1g50C, 0.7344, 2.83, 0.188, 244, 223, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
1123, 5tn5A, 0.7343, 2.89, 0.185, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE AC-RING ESTROGEN (1S3AS5S7AS)-5-(4- HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
1124, 5tlxA, 0.7343, 3.02, 0.184, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
1125, 5tldB, 0.7343, 2.95, 0.193, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1126, 5q1aC, 0.7343, 3.19, 0.268, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1127, 4iw6B, 0.7343, 2.89, 0.189, 235, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 7B
1128, 1zh7B, 0.7343, 2.92, 0.179, 243, 223, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
1129, 1a28B, 0.7343, 2.78, 0.150, 249, 220, HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
1130, 5q16A, 0.7342, 3.27, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1131, 5q15C, 0.7342, 3.31, 0.271, 229, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1132, 4whgA, 0.7342, 2.89, 0.201, 234, 224, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 3
1133, 5q1bC, 0.7341, 3.31, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1134, 5kriA, 0.7341, 2.84, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16B-BENZYL 17B-ESTRADIOL
1135, 4kzmA, 0.7341, 2.94, 0.201, 233, 224, CRYSTAL STRUCTURE OF TR3 LBD S553A MUTANT
1136, 3k22A, 0.7341, 2.86, 0.181, 250, 221, GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE
1137, 3v3qA, 0.7340, 3.14, 0.212, 237, 226, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH ETHYL 2-[234 TRIMETHOXY-6(1-OCTANOYL)PHENYL]ACETATE
1138, 5x8xE, 0.7338, 2.68, 0.211, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1139, 5q1aA, 0.7338, 3.29, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1140, 3q97B, 0.7338, 2.98, 0.188, 240, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE
1141, 3ommC, 0.7338, 3.30, 0.262, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID
1142, 2faiA, 0.7338, 2.95, 0.184, 233, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-2M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1143, 5x8qE, 0.7337, 2.71, 0.206, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1144, 5q19A, 0.7337, 3.29, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1145, 5q0sA, 0.7337, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1146, 1ereA, 0.7337, 2.71, 0.186, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1147, 5q18C, 0.7336, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1148, 4re8A, 0.7336, 2.91, 0.201, 233, 224, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 5
1149, 3oofA, 0.7336, 3.27, 0.267, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)BENZOIC ACID
1150, 1zucB, 0.7336, 2.80, 0.150, 251, 220, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE NONSTEROIDAL AGONIST TANAPROGET
1151, 1ereB, 0.7336, 2.71, 0.181, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1152, 5u2bA, 0.7335, 2.85, 0.195, 242, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1153, 5q15A, 0.7335, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1154, 5drjA, 0.7335, 2.91, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 3-METHYL 25-DIARYLTHIOPHENE-CORE LIGAND 44 -(3-METHYLTHIENE-25-DIYL)BIS(3-CHLOROPHENOL)
1155, 1ereD, 0.7335, 2.71, 0.181, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1156, 5x8xA, 0.7334, 2.68, 0.211, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1157, 5x8qA, 0.7334, 2.72, 0.206, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1158, 5q0yC, 0.7334, 3.29, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1159, 5dk9B, 0.7334, 2.88, 0.194, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 4 4 -{2-[3-(PHENYLAMINO)PHENYL]BUT-1-ENE-11-DIYL}DIPHENOL
1160, 3g8oB, 0.7334, 2.76, 0.155, 250, 220, PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1
1161, 1ereF, 0.7334, 2.71, 0.181, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1162, 6br2A, 0.7333, 2.37, 0.221, 215, 213, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE AGONIST.
1163, 5tn4A, 0.7333, 2.94, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ACD-RING ESTROGEN (S)-5-(4-HYDROXY-35- DIMETHYLPHENYL)-23-DIHYDRO-1H-INDEN-1-OL
1164, 5tlfB, 0.7333, 2.86, 0.190, 235, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CONSTRAINED WAY DERIVATIVE 4-(2-(3-METHYLBUT-2-EN- 1-YL)-7-(TRIFLUOROMETHYL)-2H-INDAZOL-3-YL)BENZENE-13-DIOL
1165, 5kriB, 0.7333, 2.89, 0.194, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16B-BENZYL 17B-ESTRADIOL
1166, 5dxkA, 0.7333, 2.90, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(9S)-BICYCLO[3.3.1]NON-9- YLMETHANEDIYL]DIPHENOL
1167, 5du5A, 0.7333, 2.70, 0.191, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1168, 1ereC, 0.7333, 2.72, 0.181, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1169, 5tmwA, 0.7332, 2.99, 0.187, 240, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS DERIVATIVE 4-ACETAMIDOPHENYL (1S2R4S)-56- BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
1170, 2q6jA, 0.7332, 2.99, 0.183, 242, 224, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED TO A B-N SUBSTITUTED LIGAND
1171, 1ereE, 0.7332, 2.72, 0.186, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1172, 5ntkB, 0.7331, 2.80, 0.214, 225, 220, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1173, 5dx3A, 0.7331, 2.95, 0.185, 231, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P3 AND ESTRADIOL
1174, 4rzgA, 0.7331, 2.97, 0.201, 233, 224, CRYSTAL STRUCTURE ANALYSIS OF THE DNPA-BOUNDED NUR77 LIGAND BINDING DOMAIN
1175, 3plzB, 0.7331, 2.78, 0.189, 240, 222, HUMAN LRH1 LBD BOUND TO GR470
1176, 3e7cA, 0.7331, 2.85, 0.186, 248, 221, GLUCOCORTICOID RECEPTOR LBD BOUND TO GSK866
1177, 2w8yA, 0.7331, 2.80, 0.155, 250, 220, RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION
1178, 5tmtA, 0.7330, 2.97, 0.185, 237, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((13-DIHYDRO-2H-INDEN-2-YLIDENE)METHYLENE)DIPHENOL
1179, 5q1eA, 0.7330, 3.01, 0.268, 224, 220, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1180, 5dz3B, 0.7330, 3.00, 0.179, 238, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(FLUOROMETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1181, 2b1vA, 0.7330, 3.00, 0.188, 233, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1182, 1xj7A, 0.7330, 3.14, 0.142, 256, 226, COMPLEX ANDROGEN RECEPTOR LBD AND RAC3 PEPTIDE
1183, 5q0uC, 0.7329, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1184, 5krhB, 0.7329, 2.85, 0.189, 237, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16-BENZYLIDENE ESTRONE
1185, 4rzfA, 0.7329, 2.93, 0.201, 233, 224, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN S441W MUTANT
1186, 3zr7A, 0.7329, 2.79, 0.155, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1187, 3d90B, 0.7329, 2.81, 0.159, 249, 220, CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND- BINDING DOMAIN BOUND TO LEVONORGESTREL
1188, 5x8xC, 0.7328, 2.69, 0.211, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1189, 5q0qC, 0.7328, 2.87, 0.289, 223, 218, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1190, 5z12A, 0.7327, 3.13, 0.282, 223, 220, A STRUCTURE OF FXR/RXR 
1191, 3olfC, 0.7327, 3.31, 0.262, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID
1192, 2qa8A, 0.7327, 2.74, 0.190, 229, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH GENISTEIN
1193, 1sr7B, 0.7327, 2.75, 0.150, 249, 220, PROGESTERONE RECEPTOR HORMONE BINDING DOMAIN WITH BOUND MOMETASONE FUROATE
1194, 4mgaA, 0.7326, 3.01, 0.188, 239, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH 4-TERT- OCTYLPHENOL
1195, 2faiB, 0.7326, 2.94, 0.189, 242, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-2M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1196, 1pzlA, 0.7326, 2.77, 0.226, 227, 221, CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR SRC-1 PEPTIDE
1197, 5kr9B, 0.7325, 2.80, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH COUMESTROL
1198, 5ei1B, 0.7325, 2.84, 0.190, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- IODANYL-IMIDAZO[12-A]PYRIDIN-6-OL
1199, 4qe8A, 0.7325, 2.92, 0.288, 224, 219, FXR WITH DM175 AND NCOA-2 PEPTIDE
1200, 2g44A, 0.7325, 2.92, 0.194, 234, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M-G AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1201, 1x78B, 0.7325, 2.61, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
1202, 1tfcA, 0.7325, 2.74, 0.218, 226, 220, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
1203, 1pk5B, 0.7325, 2.84, 0.186, 236, 221, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR LRH-1
1204, 5e14B, 0.7324, 3.04, 0.184, 237, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- PHENYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1205, 3zrbB, 0.7324, 2.80, 0.155, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1206, 3oofC, 0.7324, 3.39, 0.265, 230, 226, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)BENZOIC ACID
1207, 3k22B, 0.7324, 2.91, 0.186, 250, 221, GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE
1208, 2j7yA, 0.7324, 2.65, 0.174, 226, 219, STRUCTURE OF 17-EPIESTRIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
1209, 2j7xA, 0.7324, 2.76, 0.173, 228, 220, STRUCTURE OF ESTRADIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
1210, 2g5oA, 0.7324, 2.92, 0.198, 235, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 2- (BUT-1-ENYL)-17BETA-ESTRADIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1211, 5x8qG, 0.7323, 2.73, 0.206, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1212, 5q13C, 0.7323, 3.48, 0.264, 230, 227, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1213, 5kr9A, 0.7323, 2.84, 0.186, 236, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH COUMESTROL
1214, 4tv1B, 0.7323, 2.83, 0.186, 231, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH PROPYLPARABEN
1215, 4qe8B, 0.7323, 2.88, 0.289, 223, 218, FXR WITH DM175 AND NCOA-2 PEPTIDE
1216, 3zraA, 0.7323, 2.81, 0.155, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1217, 3olfA, 0.7323, 3.28, 0.267, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID
1218, 5tm7B, 0.7322, 2.92, 0.185, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)HEPTANOIC ACID
1219, 5q0uA, 0.7322, 3.31, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1220, 5dkbB, 0.7322, 2.97, 0.184, 232, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-METHYLPHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(3-METHYLPHENYL)AMINO]PHENYL}BUT-1-ENE-11- DIYL)DIPHENOL
1221, 4kziA, 0.7322, 2.81, 0.216, 232, 222, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH DPDO
1222, 5q0oC, 0.7321, 3.29, 0.267, 232, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1223, 5e1cA, 0.7321, 2.85, 0.180, 237, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE DIMETHYL {(1S)-3-[BIS(4- HYDROXYPHENYL)METHYLIDENE]CYCLOHEXYL}PROPANEDIOATE
1224, 3hm1A, 0.7321, 2.98, 0.184, 232, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R9S13S14S)-3-HYDROXY-13-METHYL- 7891112141516-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE)
1225, 5tmsA, 0.7320, 2.95, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (BICYCLO[3.3.1]NONAN-9-YLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
1226, 5krcA, 0.7320, 2.87, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH ZEARALENONE
1227, 5kd9A, 0.7320, 2.79, 0.186, 235, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1228, 5eitA, 0.7320, 2.85, 0.186, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- (TRIFLUOROMETHYL)IMIDAZO[12-A]PYRIDIN-6-OL
1229, 5dwiA, 0.7320, 2.91, 0.189, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 2-CHLORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(2-CHLOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1230, 5dweA, 0.7320, 2.83, 0.190, 236, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-CHLORO-SUBSTITUTED TRIARYL-IMINE ANALOG 44 -[(2- CHLOROPHENYL)CARBONIMIDOYL]DIPHENOL
1231, 5tn6B, 0.7319, 2.83, 0.181, 230, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE SPIRO BC-ESTRADIOL (1S1 S3A S7A S)-7A -METHYL- 1 22 33 3A 4 6 7 7A -DECAHYDRO-15 -SPIROBI[INDENE]-1 5- DIOL
1232, 5tmvA, 0.7319, 3.07, 0.183, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS ANALOG 4-IODOPHENYL (1S2R4S)-56-BIS(4- HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
1233, 5tm6A, 0.7319, 2.89, 0.194, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEXANOIC ACID
1234, 5q0pA, 0.7319, 3.29, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1235, 4iw8A, 0.7319, 2.85, 0.185, 239, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 9A
1236, 2qw4C, 0.7319, 2.76, 0.210, 227, 219, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1237, 5tm8A, 0.7318, 2.99, 0.189, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEPTANOIC ACID
1238, 5kctA, 0.7318, 3.02, 0.184, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1239, 5ixkB, 0.7318, 2.64, 0.212, 220, 217, RORGAMMA IN COMPLEX WITH INVERSE AGONIST BIO399.
1240, 5dxrA, 0.7318, 2.99, 0.179, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- METHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1241, 4rzeA, 0.7318, 2.83, 0.198, 232, 222, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN L437W D594E MUTANT
1242, 3omkA, 0.7318, 3.32, 0.262, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2- METHYLPHENYL)ETHANAMIDE
1243, 3hq5B, 0.7318, 2.79, 0.150, 251, 220, PROGESTERONE RECEPTOR BOUND TO AN ALKYLPYRROLIDINE LIGAND.
1244, 1zkyA, 0.7318, 2.99, 0.188, 236, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-3M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1245, 5q0vA, 0.7317, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1246, 5duhB, 0.7317, 2.85, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-3 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-3-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
1247, 4znsB, 0.7317, 3.06, 0.188, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-FLUORO-SUBSTITUTED OBHS DERIVATIVE
1248, 3mnpA, 0.7317, 2.88, 0.155, 257, 220, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY (A611V V708A E711G) MUTATIONS AT 1.50A
1249, 3bqdA, 0.7317, 2.66, 0.178, 253, 219, DOUBLING THE SIZE OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING POCKET BY DEACYLCORTIVAZOL
1250, 2g5oB, 0.7317, 3.01, 0.193, 236, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 2- (BUT-1-ENYL)-17BETA-ESTRADIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1251, 1a28A, 0.7317, 2.78, 0.150, 251, 220, HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
1252, 6el7A, 0.7316, 2.63, 0.179, 247, 218, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH COMPOUND 31
1253, 5tmqA, 0.7316, 2.90, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE 4-BROMOPHENYL 44  - DIHYDROXY-[11 :2 1  -TERPHENYL]-4 -SULFONATE
1254, 5tm3A, 0.7316, 2.84, 0.186, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 23-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1255, 4tv1A, 0.7316, 3.03, 0.188, 233, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH PROPYLPARABEN
1256, 3okiA, 0.7316, 3.29, 0.267, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N2-DICYCLOHEXYLETHANAMIDE
1257, 5tmoA, 0.7315, 2.90, 0.185, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE PHENYL 44  -DIHYDROXY- [11 :2 1  -TERPHENYL]-4 -SULFONATE
1258, 5kraF, 0.7315, 3.06, 0.188, 237, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1259, 5dz0A, 0.7315, 3.06, 0.179, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-METHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
1260, 5dwiB, 0.7315, 2.89, 0.186, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 2-CHLORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(2-CHLOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1261, 3gn8A, 0.7315, 2.76, 0.174, 249, 219, X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE
1262, 5x8qC, 0.7314, 2.73, 0.206, 228, 218, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1263, 5tmuB, 0.7314, 2.91, 0.176, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(CYCLOHEPTYLIDENEMETHYLENE)DIPHENOL
1264, 5q14A, 0.7314, 3.29, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1265, 1yucB, 0.7314, 2.71, 0.187, 240, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP
1266, 6b30A, 0.7313, 2.28, 0.217, 215, 212, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 1
1267, 5tlyA, 0.7313, 2.88, 0.181, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
1268, 5q0nA, 0.7313, 3.20, 0.268, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1269, 4oniA, 0.7313, 3.03, 0.184, 241, 223, STRUCTURE OF HUMAN ORPHAN RECEPTOR LRH1 BOUND TO TWO BACTERIAL PHOSPHOLIPIDS
1270, 4apuA, 0.7313, 2.83, 0.150, 250, 220, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID
1271, 3ookC, 0.7313, 3.38, 0.265, 230, 226, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-35-DIFLUOROBENZOIC ACID
1272, 5tlgA, 0.7312, 2.74, 0.186, 229, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-44  -DIHYDROXY-3 -((HYDROXYIMINIO)METHYL)-[11 :2  1  -TERPHENYL]-4 -OLATE
1273, 5q1cA, 0.7312, 3.26, 0.268, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1274, 5q0nC, 0.7312, 3.17, 0.265, 228, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1275, 3gn8B, 0.7311, 2.74, 0.183, 249, 219, X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE
1276, 2w8yB, 0.7311, 2.83, 0.155, 250, 220, RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION
1277, 2b1zA, 0.7311, 2.85, 0.190, 232, 221, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17METHYL-17ALPHA-DIHYDROEQUILENIN AND A GLUCOC INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1278, 1mznE, 0.7311, 2.76, 0.227, 224, 220, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1279, 1mznA, 0.7311, 2.78, 0.227, 224, 220, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1280, 5nftA, 0.7310, 2.76, 0.174, 248, 219, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH AZD5423
1281, 4a2jB, 0.7310, 2.83, 0.150, 250, 220, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA- SUBSTITUTED STEROIDS
1282, 3kbaB, 0.7310, 2.79, 0.150, 250, 220, PROGESTERONE RECEPTOR BOUND TO SULFONAMIDE PYRROLIDINE PARTIAL AGONIST
1283, 3b0wA, 0.7310, 2.42, 0.221, 215, 213, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH DIGOXIN
1284, 1ovlC, 0.7310, 2.62, 0.221, 223, 217, CRYSTAL STRUCTURE OF NURR1 LBD
1285, 5g5wA, 0.7309, 2.70, 0.174, 247, 218, DISCOVERY OF A NOVEL HIGHLY POTENT NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATOR SERIES MODULATORS
1286, 4kzjA, 0.7309, 2.88, 0.203, 231, 222, CRYSTAL STRUCTURE OF TR3 LBD L449W MUTANT
1287, 1u3qB, 0.7309, 2.72, 0.165, 227, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1288, 1p93A, 0.7309, 2.91, 0.172, 247, 221, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1289, 5q1cC, 0.7308, 3.16, 0.274, 228, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1290, 5hyrA, 0.7308, 3.00, 0.185, 231, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-SP2 AND ESTRADIOL
1291, 4zjwA, 0.7308, 2.57, 0.227, 219, 216, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 16
1292, 4oniB, 0.7308, 2.79, 0.186, 242, 220, STRUCTURE OF HUMAN ORPHAN RECEPTOR LRH1 BOUND TO TWO BACTERIAL PHOSPHOLIPIDS
1293, 5dvsA, 0.7307, 2.88, 0.186, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-METHYL-SUBSTITUTED TRIARYL-IMINE 44 -[(2-METHYLPHENYL) CARBONIMIDOYL]DIPHENOL
1294, 3p89A, 0.7307, 2.93, 0.288, 223, 219, FXR BOUND TO A QUINOLINECARBOXYLIC ACID
1295, 5kraE, 0.7306, 2.74, 0.186, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1296, 4j24B, 0.7306, 2.88, 0.164, 228, 220, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1297, 2b1zB, 0.7306, 2.95, 0.203, 235, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17METHYL-17ALPHA-DIHYDROEQUILENIN AND A GLUCOC INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1298, 5kraB, 0.7305, 2.92, 0.180, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1299, 5g3jA, 0.7305, 2.69, 0.178, 248, 219, DISCOVERY OF NEW SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST LEADS
1300, 1x7rA, 0.7305, 2.61, 0.187, 235, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH GENISTEIN
1301, 1sqnB, 0.7305, 2.83, 0.150, 250, 220, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN WITH BOUND NORETHINDRONE
1302, 5q1fA, 0.7304, 3.23, 0.268, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1303, 4mg5B, 0.7304, 2.99, 0.189, 234, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH CHLORDECONE
1304, 1zucA, 0.7304, 2.81, 0.155, 251, 220, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE NONSTEROIDAL AGONIST TANAPROGET
1305, 1u3qA, 0.7303, 2.72, 0.165, 226, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1306, 5z12D, 0.7302, 3.06, 0.283, 223, 219, A STRUCTURE OF FXR/RXR 
1307, 4ltwA, 0.7302, 2.85, 0.140, 251, 221, ANCESTRAL KETOSTEROID RECEPTOR-PROGESTERONE-MIFEPRISTONE COMPLEX
1308, 5q17A, 0.7301, 3.10, 0.268, 224, 220, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1309, 2qh6A, 0.7301, 2.91, 0.186, 232, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DIARYLETHYLENE COMPOUND
1310, 2p7aA, 0.7301, 2.61, 0.217, 223, 217, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR G IN COMPLEX WITH 3-METHYL PHENOL
1311, 5q1hC, 0.7300, 3.19, 0.269, 228, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1312, 5drmB, 0.7300, 2.73, 0.195, 235, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 25-DIARYLTHIOPHENE-CORE LIGAND 44 - THIENE-25-DIYLBIS(3-CHLOROPHENOL)
1313, 4qjrA, 0.7300, 2.86, 0.176, 244, 222, CRYSTAL STRUCTURE OF HUMAN NUCLEAR RECEPTOR SF-1 (NR5A1) BOUND TO ITS HORMONE PIP3 AT 2.4 A RESOLUTION
1314, 4iu7A, 0.7300, 3.04, 0.179, 235, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 2B
1315, 3zraB, 0.7300, 2.83, 0.150, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1316, 2qa8B, 0.7300, 3.01, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH GENISTEIN
1317, 6el6A, 0.7299, 2.71, 0.174, 247, 218, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH COMPOUND 4
1318, 5dxmA, 0.7299, 2.92, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 3-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(4-HYDROXYPHENYL)METHYL]PHENOL
1319, 4jgvA, 0.7299, 2.91, 0.202, 233, 223, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH THPN
1320, 3zrbA, 0.7299, 2.83, 0.150, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1321, 5q1fC, 0.7298, 3.20, 0.274, 229, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1322, 4mgcB, 0.7298, 2.95, 0.189, 234, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZOPHENONE-2
1323, 4mgcA, 0.7298, 2.92, 0.189, 235, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZOPHENONE-2
1324, 4iu7B, 0.7298, 2.96, 0.180, 237, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 2B
1325, 3ommA, 0.7298, 3.31, 0.267, 230, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID
1326, 5egvA, 0.7297, 2.71, 0.187, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX THE 34-DIARYL-FURAN DERIVATIVE 3-CHLORANYL-4-[4-(2- CHLORANYL-4-OXIDANYL-PHENYL)FURAN-3-YL]PHENOL
1327, 4dorB, 0.7297, 2.73, 0.187, 240, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN SHP BOX1
1328, 4qk4A, 0.7296, 2.86, 0.176, 244, 222, CRYSTAL STRUCTURE OF HUMAN NUCLEAR RECEPTOR SF-1 (NR5A1) BOUND TO PIP2 AT 2.8 A RESOLUTION
1329, 4znuA, 0.7295, 3.12, 0.184, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHYL-SUBSTITUTED OBHS DERIVATIVE
1330, 3g8oA, 0.7295, 2.73, 0.160, 250, 219, PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1
1331, 1u3qD, 0.7295, 2.71, 0.165, 226, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1332, 5wgqB, 0.7293, 2.89, 0.186, 229, 221, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-BCP1 
1333, 5ufsA, 0.7293, 2.79, 0.183, 248, 219, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH TRIAMCINOLONE ACETONIDE AND SHP COREGULATOR FRAGMENT
1334, 5gs4A, 0.7293, 2.64, 0.178, 236, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH A STABILIZED PEPTIDE ANTAGONIST
1335, 5dydB, 0.7293, 2.71, 0.186, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(METHYLSULFANYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1336, 5ufsB, 0.7292, 2.79, 0.183, 248, 219, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH TRIAMCINOLONE ACETONIDE AND SHP COREGULATOR FRAGMENT
1337, 4mg6B, 0.7292, 3.13, 0.184, 234, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZYLBUTYLPHTALATE
1338, 2gppA, 0.7292, 2.71, 0.216, 225, 218, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A RIP140 PEPTIDE AND SYNTHETIC LIGAND GSK4716
1339, 5tltA, 0.7291, 3.04, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OCTANE-18-DIYL BIS(23-BIS(4-HYDROXYPHENYL)PENTANOATE)
1340, 3k23B, 0.7291, 2.93, 0.182, 247, 220, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
1341, 4whfA, 0.7290, 2.92, 0.203, 231, 222, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH 1-(345- TRIHYDROXYPHENYL)DECAN-1-ONE
1342, 3hm1B, 0.7290, 3.04, 0.189, 236, 222, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R9S13S14S)-3-HYDROXY-13-METHYL- 7891112141516-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE)
1343, 1ovlF, 0.7290, 2.44, 0.224, 220, 214, CRYSTAL STRUCTURE OF NURR1 LBD
1344, 4pp6B, 0.7289, 2.90, 0.181, 230, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RESVERATROL
1345, 1yp0A, 0.7289, 2.96, 0.180, 239, 222, STRUCTURE OF THE STEROIDOGENIC FACTOR-1 LIGAND BINDING DOMAIN BOUND TO PHOSPHOLIPID AND A SHP PEPTIDE MOTIF
1346, 5krlB, 0.7288, 2.79, 0.186, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(2-CHLORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
1347, 2gppB, 0.7288, 2.66, 0.217, 224, 217, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A RIP140 PEPTIDE AND SYNTHETIC LIGAND GSK4716
1348, 1p93D, 0.7288, 2.83, 0.174, 247, 219, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1349, 1p93C, 0.7288, 2.84, 0.174, 247, 219, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1350, 4fn9B, 0.7287, 2.81, 0.141, 249, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - PROGESTERONE COMPLEX
1351, 4iv2B, 0.7286, 2.92, 0.180, 238, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 5A
1352, 2g44B, 0.7286, 2.82, 0.186, 234, 220, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M-G AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1353, 1sr7A, 0.7286, 2.86, 0.150, 249, 220, PROGESTERONE RECEPTOR HORMONE BINDING DOMAIN WITH BOUND MOMETASONE FUROATE
1354, 5q0tA, 0.7285, 3.03, 0.280, 222, 218, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1355, 4udcA, 0.7285, 2.76, 0.183, 248, 219, GR IN COMPLEX WITH DEXAMETHASONE
1356, 4pppA, 0.7285, 2.71, 0.187, 228, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH FLUORO-RESVERATROL
1357, 1u9eB, 0.7285, 2.59, 0.167, 228, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
1358, 6el9A, 0.7284, 2.70, 0.170, 247, 218, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH AZD9567
1359, 5krfA, 0.7284, 3.03, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE DYNAMIC WAY DERIVATIVE 1A
1360, 5dybB, 0.7284, 2.97, 0.190, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -(34-DIHYDRONAPHTHALEN-2(1H)- YLIDENEMETHANEDIYL)DIPHENOL
1361, 1kv6B, 0.7284, 2.50, 0.213, 222, 216, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ERR3 LIGAND- BINDING DOMAIN IN THE CONSTITUTIVELY ACTIVE CONFORMATION
1362, 5tm2B, 0.7283, 2.93, 0.186, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1363, 4j26B, 0.7282, 2.98, 0.163, 229, 221, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1364, 5q1hG, 0.7281, 3.19, 0.265, 229, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1365, 5x8xG, 0.7280, 2.73, 0.212, 224, 217, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1366, 5tldA, 0.7280, 2.75, 0.187, 230, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1367, 4mgdB, 0.7280, 3.00, 0.189, 234, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH HPTE
1368, 4iv4A, 0.7280, 2.74, 0.187, 229, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 5B
1369, 4dmaB, 0.7280, 2.92, 0.181, 235, 221, CRYSTAL STRUCTURE OF ERA LBD IN COMPLEX WITH RU100132
1370, 1zafB, 0.7279, 2.69, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 3-BROMO-6-HYDROXY-2-(4-HYDROXY-PHENYL)-INDEN-1-ONE
1371, 1s9pD, 0.7279, 2.61, 0.212, 225, 217, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1372, 5q11A, 0.7278, 2.94, 0.290, 221, 217, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1373, 5dxqA, 0.7278, 2.81, 0.186, 227, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENEMETHANEDIYL]DIPHENOL
1374, 5dtvA, 0.7278, 2.86, 0.186, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIMETHYL-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1375, 3ollB, 0.7278, 2.96, 0.167, 233, 222, CRYSTAL STRUCTURE OF PHOSPHORYLATED ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1376, 3ollA, 0.7278, 2.96, 0.167, 234, 222, CRYSTAL STRUCTURE OF PHOSPHORYLATED ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1377, 1u3qC, 0.7278, 2.74, 0.165, 226, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1378, 5dwjA, 0.7277, 2.87, 0.186, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 4-FLUORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(4-FLUOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1379, 5nfpA, 0.7276, 2.70, 0.179, 247, 218, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH BUDESONIDE
1380, 4mg7A, 0.7276, 2.87, 0.186, 238, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH FERUTININE
1381, 1p93B, 0.7276, 2.83, 0.170, 245, 218, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1382, 5ixkA, 0.7274, 2.63, 0.213, 219, 216, RORGAMMA IN COMPLEX WITH INVERSE AGONIST BIO399.
1383, 5ethA, 0.7274, 2.58, 0.219, 218, 215, RORY IN COMPLEX WITH INVERSE AGONIST 3.
1384, 4refA, 0.7274, 2.96, 0.203, 231, 222, CRYSTAL STRUCTURE OF TR3 LBD_L449W IN COMPLEX WITH MOLECULE 2
1385, 6br3B, 0.7273, 2.37, 0.218, 213, 211, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST TAK-828.
1386, 5kcfA, 0.7273, 3.03, 0.185, 236, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-METHOXYBENZYL OBHS-N DERIVATIVE
1387, 2p7gA, 0.7273, 2.59, 0.213, 222, 216, X-RAY STRUCTURE OF ESTROGEN RELATED RECEPTOR G IN COMPLEX WITH BISPHENOL A.
1388, 1zduA, 0.7273, 2.82, 0.192, 233, 219, THE CRYSTAL STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOGUE-1
1389, 2q6jB, 0.7272, 3.06, 0.180, 233, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED TO A B-N SUBSTITUTED LIGAND
1390, 1x76B, 0.7272, 2.60, 0.167, 225, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
1391, 5kcwA, 0.7270, 2.72, 0.187, 233, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL OBHS-N DERIVATIVE
1392, 5dkbA, 0.7270, 2.92, 0.186, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-METHYLPHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(3-METHYLPHENYL)AMINO]PHENYL}BUT-1-ENE-11- DIYL)DIPHENOL
1393, 3olsA, 0.7270, 2.74, 0.169, 229, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1394, 5gtrA, 0.7269, 2.68, 0.187, 236, 219, ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH A STABILIZED PEPTIDE ANTAGONIST 6
1395, 5e0xB, 0.7269, 2.85, 0.186, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-METHOXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1396, 1e3gA, 0.7269, 2.81, 0.145, 250, 220, HUMAN ANDROGEN RECEPTOR LIGAND BINDING IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
1397, 5kroA, 0.7268, 2.76, 0.187, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE METHYL(PHENYL)AMINO-SUBSTITUTED ESTROGEN (8R9S 13S14S17S)-13-METHYL-17-(METHYL(PHENYL)AMINO)-7891112131415 1617-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1398, 5e0xA, 0.7268, 2.80, 0.183, 230, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-METHOXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1399, 4q13B, 0.7268, 2.75, 0.183, 226, 219, APO ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT WITH A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1400, 4e2jA, 0.7268, 2.72, 0.179, 246, 218, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH MOMETASONE FUROATE AND TIF-2 COACTIVATOR FRAGMENT
1401, 3k23C, 0.7268, 2.65, 0.188, 246, 218, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
1402, 1yy4B, 0.7268, 2.61, 0.167, 225, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 1-CHLORO-6-(4-HYDROXY-PHENYL)-NAPHTHALEN-2-OL
1403, 1x7jB, 0.7268, 2.74, 0.166, 225, 217, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
1404, 5dzhA, 0.7267, 3.05, 0.189, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1405, 1pduB, 0.7267, 3.01, 0.215, 228, 223, LIGAND-BINDING DOMAIN OF DROSOPHILA ORPHAN NUCLEAR RECEPTOR DHR38
1406, 5tmtB, 0.7266, 3.00, 0.189, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((13-DIHYDRO-2H-INDEN-2-YLIDENE)METHYLENE)DIPHENOL
1407, 5e14A, 0.7266, 3.05, 0.189, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- PHENYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1408, 4mg8B, 0.7266, 2.92, 0.191, 234, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALANOL
1409, 3uudB, 0.7266, 2.90, 0.186, 235, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ESTRADIOL
1410, 5krjB, 0.7265, 2.94, 0.177, 229, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN A-NAPHTHYL SUBSTITUTED OBHS DERIVATIVE
1411, 4iwfB, 0.7265, 2.87, 0.186, 228, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC OXIME-DERIVATIVE
1412, 4csjA, 0.7265, 2.75, 0.174, 247, 218, THE DISCOVERY OF POTENT SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS SUITABLE FOR INHALATION
1413, 1kv6A, 0.7265, 2.50, 0.219, 222, 215, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ERR3 LIGAND- BINDING DOMAIN IN THE CONSTITUTIVELY ACTIVE CONFORMATION
1414, 1fbyA, 0.7265, 2.27, 0.235, 217, 213, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
1415, 5w4rA, 0.7264, 2.32, 0.218, 214, 211, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1416, 5tn8A, 0.7264, 2.70, 0.188, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-4-OLATE
1417, 5krfB, 0.7264, 2.93, 0.186, 236, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE DYNAMIC WAY DERIVATIVE 1A
1418, 5tm5B, 0.7263, 2.94, 0.177, 233, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 5-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)PENTANOIC ACID
1419, 5tloB, 0.7263, 2.77, 0.183, 232, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A SQUARIC ACID-LINKED DIMERIC ESTROGEN
1420, 4zi1A, 0.7263, 2.88, 0.169, 230, 219, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH KB095285 AND CIA12 COACTIVATOR PEPTIDE
1421, 3omqA, 0.7263, 2.75, 0.169, 229, 219, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1422, 3ompA, 0.7263, 2.75, 0.169, 229, 219, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1423, 1u3rA, 0.7263, 2.73, 0.164, 231, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-338
1424, 1osvB, 0.7263, 3.31, 0.272, 229, 224, STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
1425, 5wgdA, 0.7262, 2.89, 0.183, 228, 219, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-LP1 
1426, 5kcdA, 0.7262, 2.94, 0.186, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL SUBSTITUTED OBHS-N DERIVATIVE
1427, 5dkgA, 0.7262, 2.86, 0.183, 231, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A T-BUTYL-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 - [2-(4-TERT-BUTYLPHENYL)PROP-1-ENE-11-DIYL]DIPHENOL
1428, 4fn9A, 0.7262, 2.85, 0.141, 250, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - PROGESTERONE COMPLEX
1429, 4e2jB, 0.7262, 2.73, 0.174, 247, 218, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH MOMETASONE FUROATE AND TIF-2 COACTIVATOR FRAGMENT
1430, 3d90A, 0.7262, 2.95, 0.150, 247, 220, CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND- BINDING DOMAIN BOUND TO LEVONORGESTREL
1431, 5e0wA, 0.7261, 2.93, 0.191, 234, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-HYDROXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1432, 3uuaB, 0.7261, 2.79, 0.192, 228, 219, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-AF
1433, 3mneA, 0.7261, 2.67, 0.157, 253, 217, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY F608S MUTATION AT 1.96A
1434, 2qseA, 0.7261, 2.79, 0.183, 238, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH BURNED MEAT COMPOUND 4-OH-PHIP
1435, 5tluA, 0.7260, 2.78, 0.187, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PEG-LINKED DIMERIC ESTROGEN EE2-(EG)6-EE2-AMINE
1436, 4fneA, 0.7260, 2.85, 0.136, 247, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - DOC COMPLEX
1437, 3mnoA, 0.7260, 2.74, 0.157, 255, 217, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY (A611V F608S) MUTATIONS AT 1.55A
1438, 1sqnA, 0.7260, 2.90, 0.155, 248, 220, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN WITH BOUND NORETHINDRONE
1439, 3cldA, 0.7259, 2.94, 0.183, 243, 219, LIGAND BINDING DOMAIN OF THE GLUCOCORTICOID RECEPTOR COMPLEXED WITH FLUTICAZONE FUROATE
1440, 1ymtA, 0.7259, 2.81, 0.187, 235, 219, MOUSE SF-1 LBD
1441, 1l2iA, 0.7259, 3.02, 0.181, 233, 221, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH (RR)-511-CIS-DIETHYL-561112- TETRAHYDROCHRYSENE-28-DIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1442, 4j26A, 0.7258, 2.97, 0.164, 228, 220, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1443, 3omoA, 0.7258, 2.76, 0.169, 229, 219, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1444, 1zdtA, 0.7258, 2.82, 0.177, 233, 220, THE CRYSTAL STRUCTURE OF HUMAN STEROIDOGENIC FACTOR-1
1445, 5dy8A, 0.7257, 3.01, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3- ETHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1446, 4pleA, 0.7257, 2.82, 0.187, 241, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1447, 4iw6A, 0.7257, 3.02, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 7B
1448, 1yucA, 0.7257, 2.81, 0.187, 240, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP
1449, 1tfcB, 0.7257, 2.70, 0.216, 225, 218, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
1450, 5krhA, 0.7256, 2.91, 0.191, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16-BENZYLIDENE ESTRONE
1451, 5e19A, 0.7256, 2.83, 0.182, 233, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE METHYL {4-[BIS(4-HYDROXYPHENYL) METHYLIDENE]CYCLOHEXYL}ACETATE
1452, 2b23B, 0.7256, 2.90, 0.191, 230, 220, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1453, 3e7cB, 0.7255, 2.92, 0.187, 245, 219, GLUCOCORTICOID RECEPTOR LBD BOUND TO GSK866
1454, 1ot7B, 0.7255, 3.31, 0.277, 229, 224, STRUCTURAL BASIS FOR 3-DEOXY-CDCA BINDING AND ACTIVATION OF FXR
1455, 5wgqA, 0.7254, 2.88, 0.182, 231, 220, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-BCP1 
1456, 4mgaB, 0.7253, 3.11, 0.185, 233, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH 4-TERT- OCTYLPHENOL
1457, 3cldB, 0.7253, 2.84, 0.179, 241, 218, LIGAND BINDING DOMAIN OF THE GLUCOCORTICOID RECEPTOR COMPLEXED WITH FLUTICAZONE FUROATE
1458, 5e15B, 0.7252, 3.01, 0.195, 233, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1459, 4mgbB, 0.7251, 3.04, 0.186, 232, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH TCBPA
1460, 2qw4B, 0.7251, 3.20, 0.238, 230, 223, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1461, 5dlrA, 0.7250, 3.00, 0.176, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-ETHYLENE COMPOUND 44 -(2-PHENYLETHENE-11-DIYL) DIPHENOL
1462, 2qw4D, 0.7250, 2.86, 0.228, 227, 219, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1463, 5dxpB, 0.7249, 2.83, 0.178, 230, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 4-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(PHENYL)METHYL]PHENOL
1464, 4iw8B, 0.7249, 3.04, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 9A
1465, 5kd9B, 0.7248, 2.73, 0.184, 228, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1466, 4zntA, 0.7248, 2.85, 0.186, 229, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-BROMO-SUBSTITUTED OBHS DERIVATIVE
1467, 4mg9B, 0.7247, 2.87, 0.191, 230, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BUTYLPARABEN
1468, 3uu7B, 0.7247, 2.92, 0.191, 232, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-A
1469, 2qh6B, 0.7247, 2.81, 0.183, 228, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DIARYLETHYLENE COMPOUND
1470, 2nv7B, 0.7247, 2.75, 0.166, 225, 217, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-555
1471, 4n1yB, 0.7246, 2.84, 0.164, 227, 220, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1472, 1l2iB, 0.7246, 2.78, 0.188, 231, 218, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH (RR)-511-CIS-DIETHYL-561112- TETRAHYDROCHRYSENE-28-DIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1473, 4znsA, 0.7245, 2.97, 0.190, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-FLUORO-SUBSTITUTED OBHS DERIVATIVE
1474, 4iv4B, 0.7245, 2.92, 0.187, 232, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 5B
1475, 1x7bB, 0.7245, 2.68, 0.166, 225, 217, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
1476, 5krjA, 0.7244, 2.94, 0.186, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN A-NAPHTHYL SUBSTITUTED OBHS DERIVATIVE
1477, 1zafA, 0.7244, 2.74, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 3-BROMO-6-HYDROXY-2-(4-HYDROXY-PHENYL)-INDEN-1-ONE
1478, 4pleG, 0.7243, 2.88, 0.186, 241, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1479, 5jmmB, 0.7242, 3.07, 0.185, 233, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BIOCHANIN A
1480, 5dx3B, 0.7242, 2.61, 0.184, 224, 217, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P3 AND ESTRADIOL
1481, 4znwA, 0.7242, 3.08, 0.186, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 4-BROMO-SUBSTITUTED OBHS DERIVATIVE
1482, 3ry9B, 0.7242, 2.95, 0.151, 247, 219, CRYSTAL STRUCTURE OF THE RESURRECTED ANCESTRAL GLUCOCORTICOID RECEPTOR 1 IN COMPLEX WITH DOC
1483, 5dy8B, 0.7241, 2.92, 0.187, 235, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3- ETHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1484, 4pxmA, 0.7241, 2.86, 0.187, 230, 219, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH ESTRADIOL AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1485, 5dxeA, 0.7240, 2.98, 0.191, 228, 220, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P4 AND ESTRADIOL
1486, 4j24A, 0.7240, 2.75, 0.166, 225, 217, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1487, 3ixpD, 0.7240, 2.63, 0.247, 220, 215, CRYSTAL STRUCTURE OF THE ECDYSONE RECEPTOR BOUND TO BYI08346
1488, 2nv7A, 0.7240, 2.72, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-555
1489, 4pxmB, 0.7239, 2.69, 0.184, 226, 217, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH ESTRADIOL AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1490, 1u3rB, 0.7239, 2.65, 0.167, 227, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-338
1491, 6br2B, 0.7238, 2.38, 0.219, 212, 210, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE AGONIST.
1492, 5tm8B, 0.7238, 2.77, 0.188, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEPTANOIC ACID
1493, 5kcuA, 0.7238, 2.77, 0.188, 226, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL ALPHA-NAPHTHYL OBHS-N DERIVATIVE
1494, 4ivwA, 0.7238, 3.04, 0.186, 234, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 6B
1495, 2pitA, 0.7238, 2.91, 0.145, 250, 220, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1496, 1m7wA, 0.7238, 2.36, 0.216, 223, 213, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1497, 5ehjB, 0.7237, 2.84, 0.187, 234, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4AR8AR)-OCTAHYDRONAPHTHALEN- 2(1H)-YLIDENEMETHANEDIYL]DIPHENOL
1498, 4j24C, 0.7237, 2.75, 0.166, 225, 217, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1499, 3zr7B, 0.7237, 2.66, 0.157, 246, 217, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1500, 1x7bA, 0.7235, 2.74, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
1501, 5krkA, 0.7234, 2.91, 0.182, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((5-BROMO-23-DIHYDRO-1H-INDEN-1-YLIDENE) METHYLENE)DIPHENOL
1502, 5dxgA, 0.7234, 2.85, 0.192, 228, 219, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P5
1503, 6cbzA, 0.7233, 2.77, 0.188, 227, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ESTRADIOL AND GRIP PEPTIDE
1504, 3plzA, 0.7233, 2.64, 0.189, 231, 217, HUMAN LRH1 LBD BOUND TO GR470
1505, 3l1bA, 0.7233, 2.70, 0.288, 216, 212, COMPLEX STRUCTURE OF FXR LIGAND-BINDING DOMAIN WITH A TETRAHYDROAZEPINOINDOLE COMPOUND
1506, 5dxqB, 0.7232, 2.85, 0.183, 232, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENEMETHANEDIYL]DIPHENOL
1507, 5l7hA, 0.7231, 2.70, 0.175, 249, 217, MCR IN COMPLEX WITH LIGAND
1508, 5dz0B, 0.7230, 2.89, 0.183, 234, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-METHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
1509, 4zntB, 0.7230, 2.86, 0.188, 233, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-BROMO-SUBSTITUTED OBHS DERIVATIVE
1510, 5dxbB, 0.7229, 2.77, 0.188, 224, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P1 AND ESTRADIOL
1511, 4mg7B, 0.7229, 3.01, 0.191, 232, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH FERUTININE
1512, 1u3sA, 0.7229, 2.78, 0.165, 227, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-797
1513, 3hq5A, 0.7227, 2.69, 0.157, 246, 216, PROGESTERONE RECEPTOR BOUND TO AN ALKYLPYRROLIDINE LIGAND.
1514, 5jjmA, 0.7226, 2.95, 0.145, 252, 221, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1515, 5dp0B, 0.7226, 2.92, 0.192, 232, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 4 4 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}ETHENE-11-DIYL)DIPHENOL
1516, 5dmcB, 0.7226, 2.96, 0.196, 231, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A NITRILE-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 33-BIS(4- HYDROXYPHENYL)-2-PHENYLPROP-2-ENENITRILE
1517, 4znhB, 0.7226, 2.92, 0.187, 227, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-FLUORO-SUBSTITUTED OBHS DERIVATIVE
1518, 4rwvA, 0.7226, 2.85, 0.187, 242, 219, CRYSTAL STRUCTURE OF PIP3 BOUND HUMAN NUCLEAR RECEPTOR LRH-1 (LIVER RECEPTOR HOMOLOG 1 NR5A2) IN COMPLEX WITH A CO-REGULATOR DAX-1 (NR0B1) PEPTIDE AT 1.86 A RESOLUTION
1519, 4dosA, 0.7226, 2.85, 0.187, 242, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO DLPC AND A FRAGMENT OF TIF-2
1520, 1yokA, 0.7226, 2.85, 0.183, 236, 219, CRYSTAL STRUCTURE OF HUMAN LRH-1 BOUND WITH TIF-2 PEPTIDE AND PHOSPHATIDYLGLYCEROL
1521, 5dk9A, 0.7225, 3.02, 0.182, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 4 4 -{2-[3-(PHENYLAMINO)PHENYL]BUT-1-ENE-11-DIYL}DIPHENOL
1522, 4uddA, 0.7225, 2.86, 0.178, 249, 219, GR IN COMPLEX WITH DESISOBUTYRYLCICLESONIDE
1523, 5dzhB, 0.7224, 2.89, 0.192, 235, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1524, 1x78A, 0.7224, 2.74, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
1525, 5tm7A, 0.7223, 2.98, 0.186, 234, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)HEPTANOIC ACID
1526, 5syzA, 0.7223, 3.05, 0.189, 237, 222, HUMAN LIVER RECEPTOR HOMOLOGUE-1 (LRH-1) BOUND TO A RJW100 STEREOISOMER AND A FRAGMENT OF TIF-2
1527, 5jjmC, 0.7223, 2.96, 0.145, 250, 221, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1528, 4znvA, 0.7223, 3.06, 0.181, 237, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHOXY-SUBSTITUTED OBHS DERIVATIVE
1529, 4ivyB, 0.7222, 2.90, 0.192, 232, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 7A
1530, 4iv2A, 0.7221, 2.99, 0.186, 231, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 5A
1531, 2ocfA, 0.7221, 2.88, 0.187, 231, 219, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND THE E2#23 FN3 MONOBODY
1532, 1yowA, 0.7220, 2.60, 0.176, 230, 216, HUMAN STEROIDOGENIC FACTOR 1 LBD WITH BOUND CO-FACTOR PEPTIDE
1533, 6eu9C, 0.7219, 2.52, 0.275, 217, 211, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1534, 4j5wD, 0.7219, 2.28, 0.231, 227, 212, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
1535, 3wffA, 0.7219, 2.91, 0.173, 258, 220, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2B
1536, 5tm1B, 0.7218, 2.80, 0.183, 226, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1537, 3fliA, 0.7217, 3.09, 0.280, 221, 218, DISCOVERY OF XL335 A HIGHLY POTENT SELECTIVE AND ORALLY- ACTIVE AGONIST OF THE FARNESOID X RECEPTOR (FXR)
1538, 1yyeA, 0.7217, 2.76, 0.165, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-202196
1539, 2pipL, 0.7214, 2.86, 0.146, 249, 219, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1540, 1yyeB, 0.7213, 2.76, 0.167, 224, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-202196
1541, 4zn9A, 0.7211, 3.07, 0.182, 237, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1542, 4pleE, 0.7211, 2.78, 0.188, 241, 218, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1543, 1u3sB, 0.7211, 2.55, 0.168, 223, 214, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-797
1544, 6b30B, 0.7210, 2.29, 0.220, 212, 209, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 1
1545, 5kctB, 0.7210, 2.77, 0.191, 226, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1546, 4znwB, 0.7210, 2.78, 0.184, 228, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 4-BROMO-SUBSTITUTED OBHS DERIVATIVE
1547, 4j5wC, 0.7210, 2.30, 0.231, 226, 212, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
1548, 3ozjA, 0.7210, 2.25, 0.237, 215, 211, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA COMPLEXED WITH BIGELOVIN AND COACTIVATOR SRC-1
1549, 3uvvB, 0.7209, 2.33, 0.235, 218, 213, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE THYROID RECEPTOR:RETINOID X RECEPTOR COMPLEXED WITH 33 5 TRIIODO-L- THYRONINE AND 9-CIS RETINOIC ACID
1550, 5dz1A, 0.7208, 3.02, 0.186, 232, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-ETHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
1551, 5kroB, 0.7205, 2.84, 0.183, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE METHYL(PHENYL)AMINO-SUBSTITUTED ESTROGEN (8R9S 13S14S17S)-13-METHYL-17-(METHYL(PHENYL)AMINO)-7891112131415 1617-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1552, 2pklA, 0.7205, 2.89, 0.146, 249, 219, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1553, 2pivA, 0.7205, 2.86, 0.146, 249, 219, ANDROGEN RECEPTOR WITH SMALL MOLECULE
1554, 1gs4A, 0.7205, 2.79, 0.147, 244, 218, STRUCTURAL BASIS FOR THE GLUCOCORTICOID RESPONSE IN A MUTANT HUMAN ANDROGEN RECEPTOR (ARCCR) DERIVED FROM AN ANDROGEN-INDEPENDENT PROSTATE CANCER
1555, 5l7gA, 0.7204, 2.66, 0.176, 247, 216, MCR IN COMPLEX WITH LIGAND
1556, 1t7fA, 0.7204, 2.99, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A LXXLL MOTIF
1557, 1pcgA, 0.7204, 2.82, 0.197, 232, 218, HELIX-STABILIZED CYCLIC PEPTIDES AS SELECTIVE INHIBITORS OF STEROID RECEPTOR-COACTIVATOR INTERACTIONS
1558, 1xnxA, 0.7203, 2.79, 0.207, 232, 217, CRYSTAL STRUCTURE OF CONSTITUTIVE ANDROSTANE RECEPTOR
1559, 1t73A, 0.7203, 2.96, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXFF MOTIF
1560, 5jjmD, 0.7202, 2.94, 0.145, 249, 220, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1561, 3r5mA, 0.7202, 2.27, 0.237, 215, 211, CRYSTAL STRUCTURE OF RXRALPHALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1562, 3kbaA, 0.7202, 2.74, 0.162, 243, 216, PROGESTERONE RECEPTOR BOUND TO SULFONAMIDE PYRROLIDINE PARTIAL AGONIST
1563, 1yjeA, 0.7202, 2.95, 0.218, 226, 220, CRYSTAL STRUCTURE OF THE RNGFI-B LIGAND-BINDING DOMAIN
1564, 5q0qA, 0.7201, 2.99, 0.292, 221, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1565, 5jjmB, 0.7201, 2.94, 0.145, 250, 220, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1566, 5z12B, 0.7200, 2.45, 0.230, 217, 213, A STRUCTURE OF FXR/RXR 
1567, 5tm4A, 0.7197, 2.96, 0.179, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG 5-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)PENTANOIC ACID
1568, 4rmeA, 0.7197, 2.20, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB111 AND COACTIVATOR PEPTIDE GRIP-1
1569, 4n1yD, 0.7197, 2.83, 0.164, 226, 219, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1570, 2zy0C, 0.7197, 2.28, 0.232, 215, 211, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1571, 5dz3A, 0.7196, 2.84, 0.183, 231, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(FLUOROMETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1572, 5u2dB, 0.7195, 3.15, 0.181, 239, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1573, 5dksB, 0.7195, 2.87, 0.194, 227, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-NAPHTHYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(NAPHTHALEN-1-YLAMINO)PHENYL]BUT-1-ENE-11- DIYL}DIPHENOL
1574, 4pf3A, 0.7195, 3.03, 0.159, 249, 220, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 37A
1575, 2qxmA, 0.7195, 2.90, 0.188, 233, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO BURNED MEAT COMPOUND PHIP
1576, 2piwA, 0.7195, 2.83, 0.147, 248, 218, ANDROGEN RECEPTOR WITH SMALL MOLECULE
1577, 1yy4A, 0.7195, 2.72, 0.167, 225, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 1-CHLORO-6-(4-HYDROXY-PHENYL)-NAPHTHALEN-2-OL
1578, 5e0wB, 0.7194, 2.94, 0.183, 230, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-HYDROXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1579, 5dwgA, 0.7193, 2.78, 0.189, 225, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE TRIARYL-SUBSTITUTED IMINE ANALOG 4-{(E)-(4-HYDROXYPHENYL) [(2-METHYLPHENYL)IMINO]METHYL}BENZENE-13-DIOL
1580, 4rmdA, 0.7192, 2.21, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB110 AND COACTIVATOR PEPTIDE GRIP-1
1581, 4q13A, 0.7192, 2.89, 0.184, 226, 217, APO ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT WITH A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1582, 3zqtA, 0.7192, 2.91, 0.146, 250, 219, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1583, 3oapA, 0.7192, 2.21, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9-CIS RETINOIC ACID AND THE COACTIVATOR PEPTIDE GRIP-1
1584, 2pioA, 0.7192, 2.83, 0.147, 248, 218, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1585, 1t76A, 0.7192, 2.91, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A WXXVW MOTIF
1586, 1t63A, 0.7192, 2.97, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN WITH DHT AND A PEPTIDE DERIVED FROM ITS PHYSIOLOGICAL COACTIVATOR GRIP1 NR BOX3
1587, 5dydA, 0.7191, 2.83, 0.183, 225, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(METHYLSULFANYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1588, 4mg6A, 0.7191, 2.99, 0.193, 233, 218, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZYLBUTYLPHTALATE
1589, 1x7jA, 0.7191, 2.71, 0.167, 225, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
1590, 1t74A, 0.7191, 2.89, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A WXXLF MOTIF
1591, 5dkeB, 0.7190, 2.90, 0.179, 235, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-NAPHTHYL-SUBSTITUTED METHYL CIS-DIARYL-ETHYLENE COMPOUND 44 -[2-(NAPHTHALEN-2-YL)PROP-1-ENE-11-DIYL]DIPHENOL
1592, 2qpyA, 0.7190, 2.86, 0.147, 248, 218, AR LBD WITH SMALL MOLECULE
1593, 4rmcA, 0.7189, 2.22, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB76 AND THE COACTIVATOR PEPTIDE GRIP-1
1594, 2b23A, 0.7189, 2.87, 0.188, 226, 218, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1595, 4pleC, 0.7188, 2.94, 0.187, 239, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1596, 4nqaH, 0.7188, 2.54, 0.220, 319, 214, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
1597, 4n1yA, 0.7188, 2.95, 0.164, 226, 220, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1598, 3ozjC, 0.7188, 2.30, 0.237, 215, 211, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA COMPLEXED WITH BIGELOVIN AND COACTIVATOR SRC-1
1599, 3f7dA, 0.7188, 2.98, 0.188, 237, 218, SF-1 LBD BOUND BY PHOSPHATIDYLCHOLINE
1600, 2zy0A, 0.7188, 2.28, 0.227, 215, 211, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1601, 1t5zA, 0.7188, 3.00, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN (LBD) WITH DHT AND A PEPTIDE DERIVED FROM ITS PHYSIOLOGICAL COACTIVATOR ARA70
1602, 5tmlA, 0.7187, 2.86, 0.188, 235, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND (E)-6-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1603, 2am9A, 0.7187, 2.93, 0.146, 250, 219, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH TESTOSTERONE
1604, 1t65A, 0.7187, 3.00, 0.145, 251, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN WITH DHT AND A PEPTIDE DERIVED FORM ITS PHYSIOLOGICAL COACTIVATOR GRIP1 NR BOX 2 BOUND IN A NON- HELICAL CONFORMATION
1605, 2yloA, 0.7185, 2.94, 0.146, 250, 219, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1606, 4zshA, 0.7184, 2.14, 0.244, 213, 209, RXR LBD IN COMPLEX WITH 9-CIS-1314-DIHYDRORETINOIC ACID
1607, 2ylqA, 0.7184, 2.88, 0.147, 249, 218, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1608, 6cbzB, 0.7183, 2.70, 0.190, 223, 216, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ESTRADIOL AND GRIP PEPTIDE
1609, 5tloA, 0.7183, 2.77, 0.190, 229, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A SQUARIC ACID-LINKED DIMERIC ESTROGEN
1610, 5dksA, 0.7183, 2.71, 0.185, 225, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-NAPHTHYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(NAPHTHALEN-1-YLAMINO)PHENYL]BUT-1-ENE-11- DIYL}DIPHENOL
1611, 2piqA, 0.7183, 2.90, 0.146, 249, 219, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1612, 1xdkE, 0.7183, 2.32, 0.231, 217, 212, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1613, 1xdkA, 0.7183, 2.32, 0.231, 217, 212, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1614, 1t79A, 0.7183, 3.01, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXLW MOTIF
1615, 1m7wD, 0.7183, 2.65, 0.219, 221, 215, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1616, 5kraA, 0.7182, 2.77, 0.184, 226, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1617, 5dybA, 0.7182, 2.71, 0.190, 229, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -(34-DIHYDRONAPHTHALEN-2(1H)- YLIDENEMETHANEDIYL)DIPHENOL
1618, 4m8hA, 0.7182, 2.23, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (R)4-METHYL 9CUAB30 AND COACTIVATOR PEPTIDE GRIP- 3 1
1619, 2ambA, 0.7182, 2.88, 0.147, 246, 218, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH TETRAHYDROGESTRINONE
1620, 2yjdB, 0.7181, 2.69, 0.172, 223, 215, STAPLED PEPTIDE BOUND TO ESTROGEN RECEPTOR BETA
1621, 3l3zA, 0.7180, 2.99, 0.146, 249, 219, CRYSTAL STRUCTURE OF DHT-BOUND ANDROGEN RECEPTOR IN COMPLEX WITH THE THIRD MOTIF OF STEROID RECEPTOR COACTIVATOR 3
1622, 4k6iA, 0.7179, 2.25, 0.243, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH TARGRETIN AND THE COACTIVATOR PEPTIDE GRIP-1
1623, 1t7rA, 0.7179, 3.01, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXLF MOTIF
1624, 5wgdB, 0.7178, 2.65, 0.191, 222, 215, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-LP1 
1625, 3g0wA, 0.7178, 2.92, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH AN N-ARYL-OXAZOLIDIN 2-IMINE INHIBITOR
1626, 1x76A, 0.7178, 2.73, 0.167, 225, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
1627, 1t7mA, 0.7178, 2.92, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXYF MOTIF
1628, 5kcdB, 0.7177, 2.81, 0.189, 226, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL SUBSTITUTED OBHS-N DERIVATIVE
1629, 2piuA, 0.7177, 2.85, 0.147, 248, 218, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1630, 2aa7A, 0.7177, 3.10, 0.173, 253, 220, MINERALOCORTICOID RECEPTOR WITH BOUND DEOXYCORTICOSTERONE
1631, 1i37A, 0.7177, 2.76, 0.147, 246, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH DIHYDROTESTOSTERONE
1632, 4oj9A, 0.7176, 2.91, 0.146, 249, 219, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1633, 3ry9A, 0.7176, 2.70, 0.167, 243, 215, CRYSTAL STRUCTURE OF THE RESURRECTED ANCESTRAL GLUCOCORTICOID RECEPTOR 1 IN COMPLEX WITH DOC
1634, 5kcfB, 0.7175, 2.74, 0.188, 227, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-METHOXYBENZYL OBHS-N DERIVATIVE
1635, 3l3xA, 0.7175, 3.08, 0.145, 250, 220, CRYSTAL STRUCTURE OF DHT-BOUND ANDROGEN RECEPTOR IN COMPLEX WITH THE FIRST MOTIF OF STEROID RECEPTOR COACTIVATOR 3
1636, 4rfwA, 0.7174, 2.23, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB70 AND THE COACTIVATOR PEPTIDE GRIP-1
1637, 3vhvA, 0.7174, 2.78, 0.176, 255, 216, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH NON-STEROIDAL ANTAGONIST
1638, 2z4jA, 0.7174, 2.87, 0.147, 248, 218, CRYSTAL STRUCTURE OF AR LBD WITH SHP PEPTIDE NR BOX 2
1639, 2hvcA, 0.7174, 2.98, 0.145, 250, 220, THE CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN (LBD) OF HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH A SELECTIVE MODULATOR LGD2226
1640, 4pojA, 0.7173, 2.24, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 7-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1641, 2pirA, 0.7173, 2.99, 0.145, 250, 220, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1642, 5dp0A, 0.7172, 2.86, 0.179, 229, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 4 4 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}ETHENE-11-DIYL)DIPHENOL
1643, 4pp5A, 0.7172, 2.23, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 5-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1644, 4j24D, 0.7172, 2.60, 0.169, 221, 213, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1645, 2ylpA, 0.7172, 2.90, 0.147, 249, 218, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1646, 5jmmA, 0.7171, 2.79, 0.190, 230, 216, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BIOCHANIN A
1647, 4m8eA, 0.7171, 2.24, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (S) 4-METHYL 9CUAB30 COACTIVATOR PEPTIDE GRIP-1
1648, 4k4jA, 0.7171, 2.24, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1649, 3v4aA, 0.7171, 2.80, 0.148, 244, 216, STRUCTURE OF AR LBD WITH ACTIVATOR PEPTIDE AND SARM INHIBITOR 2
1650, 1t7tA, 0.7171, 3.03, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH 5-ALPHA DIHYDROTESTOSTERONE
1651, 4zn9B, 0.7170, 3.00, 0.183, 235, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1652, 5hyrB, 0.7169, 2.76, 0.190, 223, 216, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-SP2 AND ESTRADIOL
1653, 5ehjA, 0.7169, 3.00, 0.183, 229, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4AR8AR)-OCTAHYDRONAPHTHALEN- 2(1H)-YLIDENEMETHANEDIYL]DIPHENOL
1654, 5dwjB, 0.7169, 2.79, 0.185, 229, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 4-FLUORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(4-FLUOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1655, 5toaB, 0.7168, 2.86, 0.157, 232, 216, CRYSTAL STRUCTURE OF ER BETA BOUND TO ESTRADIOL
1656, 5dxeB, 0.7168, 2.72, 0.190, 222, 216, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P4 AND ESTRADIOL
1657, 5kcwB, 0.7167, 2.78, 0.182, 224, 214, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL OBHS-N DERIVATIVE
1658, 4udbA, 0.7167, 2.78, 0.171, 244, 217, MR IN COMPLEX WITH DESISOBUTYRYLCICLESONIDE
1659, 2pixA, 0.7167, 2.87, 0.147, 248, 218, AR LBD WITH SMALL MOLECULE
1660, 5kccB, 0.7166, 2.85, 0.189, 227, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE (OBHS-N)
1661, 5dweB, 0.7166, 2.77, 0.185, 229, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-CHLORO-SUBSTITUTED TRIARYL-IMINE ANALOG 44 -[(2- CHLOROPHENYL)CARBONIMIDOYL]DIPHENOL
1662, 2aaxA, 0.7166, 3.26, 0.172, 261, 221, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE
1663, 3rljA, 0.7165, 2.92, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-22
1664, 5l7eA, 0.7164, 2.61, 0.178, 243, 214, MCR IN COMPLEX WITH LIGAND
1665, 4pp3A, 0.7164, 2.26, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 6-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1666, 1xnnA, 0.7163, 2.84, 0.143, 247, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH (3A-ALPHA-4- ALPHA 7-ALPHA-7A-ALPHA-)-3A477A-TETRAHYDRO-2-(4-NITRO- 1-NAPHTHALENYL)-47-ETHANO-1H-ISOINDOLE-13(2H)-DIONE.
1667, 5u2bB, 0.7161, 2.90, 0.194, 228, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1668, 4is8A, 0.7161, 2.70, 0.186, 230, 215, DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS
1669, 5unjA, 0.7159, 2.69, 0.186, 227, 215, STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOG 1 IN COMPLEX WITH PGC1A AND RJW100
1670, 2yjdA, 0.7159, 2.61, 0.173, 223, 214, STAPLED PEPTIDE BOUND TO ESTROGEN RECEPTOR BETA
1671, 3b5rA, 0.7158, 2.92, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM C-31
1672, 2aa6A, 0.7157, 3.22, 0.164, 260, 220, MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE
1673, 4pohA, 0.7156, 2.27, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 8-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1674, 4n1yC, 0.7156, 2.84, 0.166, 224, 217, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1675, 3b65A, 0.7156, 2.92, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-24
1676, 2aaxB, 0.7156, 3.34, 0.163, 257, 221, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE
1677, 4ok1A, 0.7155, 3.03, 0.146, 249, 219, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1678, 1fbyB, 0.7155, 2.12, 0.240, 212, 208, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
1679, 5w4vB, 0.7154, 2.32, 0.217, 209, 207, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1680, 2nw4A, 0.7154, 2.90, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH BMS-564929
1681, 2ab2B, 0.7153, 3.19, 0.159, 259, 220, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE
1682, 3wfgA, 0.7152, 2.85, 0.170, 249, 218, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2E
1683, 3v49A, 0.7152, 2.83, 0.148, 244, 216, STRUCTURE OF AR LBD WITH ACTIVATOR PEPTIDE AND SARM INHIBITOR 1
1684, 3b66A, 0.7151, 2.93, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-21
1685, 5tmmA, 0.7149, 2.80, 0.191, 223, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1686, 5t8eA, 0.7149, 3.00, 0.147, 249, 218, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS). PART II: OPTIMIZATION OF 4-(PYRROLIDIN- 1-YL)BENZONITRILE DERIVATIVES
1687, 5w4vA, 0.7148, 2.34, 0.213, 209, 207, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1688, 2yhdA, 0.7148, 2.93, 0.147, 249, 218, HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH AF2 SMALL MOLECULE INHIBITOR
1689, 4hlwA, 0.7147, 2.84, 0.148, 244, 216, TARGETING THE BINDING FUNCTION 3 (BF3) SITE OF THE HUMAN ANDROGEN RECEPTOR THROUGH VIRTUAL SCREENING. 2. DEVELOPMENT OF 2-((2- PHENOXYETHYL) THIO)-1H-BENZOIMIDAZOLE DERIVATIVES.
1690, 4is8B, 0.7145, 2.92, 0.189, 230, 217, DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS
1691, 2pnuA, 0.7145, 2.89, 0.147, 245, 217, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH EM-5744
1692, 2zxzA, 0.7144, 2.21, 0.239, 213, 209, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1693, 1oshA, 0.7143, 2.58, 0.286, 216, 210, A CHEMICAL GENETIC AND STRUCTURAL ANALYSIS OF THE NUCLEAR BILE ACID RECEPTOR FXR
1694, 4oktA, 0.7142, 3.07, 0.146, 248, 219, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1695, 2q7lA, 0.7142, 3.09, 0.151, 247, 218, THE ANDROGEN RECEPTOR PROSTATE CANCER MUTANT H874Y LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND A TIF2 BOX3 COACTIVATOR PEPTIDE 740-753
1696, 1u9eA, 0.7142, 2.64, 0.168, 223, 214, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
1697, 1i38A, 0.7142, 2.80, 0.147, 247, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH DIHYDROTESTOSTERONE
1698, 5tlmA, 0.7141, 2.77, 0.191, 226, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 4  -(THIOPHENE-235-TRIYL)TRIPHENOL
1699, 4udaA, 0.7141, 2.81, 0.172, 241, 215, MR IN COMPLEX WITH DEXAMETHASONE
1700, 2ihqA, 0.7141, 2.95, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMIAN COMPLEX WITH AN N-ARYL- HYDROXYBICYCLOHYDANTOIN
1701, 5dmcA, 0.7140, 2.76, 0.191, 223, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A NITRILE-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 33-BIS(4- HYDROXYPHENYL)-2-PHENYLPROP-2-ENENITRILE
1702, 2ab2A, 0.7140, 3.12, 0.174, 259, 219, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE
1703, 5toaA, 0.7139, 2.84, 0.158, 230, 215, CRYSTAL STRUCTURE OF ER BETA BOUND TO ESTRADIOL
1704, 2aa5A, 0.7138, 3.06, 0.165, 255, 218, MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE
1705, 4pldA, 0.7137, 2.84, 0.170, 239, 218, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN TIF-2
1706, 2aa2A, 0.7136, 3.14, 0.164, 252, 219, MINERALOCORTICOID RECEPTOR WITH BOUND ALDOSTERONE
1707, 5t8jA, 0.7134, 3.02, 0.147, 249, 218, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS). PART II: OPTIMIZATION OF 4-(PYRROLIDIN- 1-YL)BENZONITRILE DERIVATIVES
1708, 2aa6B, 0.7134, 3.14, 0.178, 259, 219, MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE
1709, 5tlmB, 0.7133, 2.80, 0.190, 227, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 4  -(THIOPHENE-235-TRIYL)TRIPHENOL
1710, 5mwyA, 0.7133, 2.74, 0.172, 244, 215, THE STRUCTURE OF MR IN COMPLEX WITH EPLERENONE.
1711, 5mwpA, 0.7133, 2.69, 0.173, 243, 214, THE STRUCTURE OF MR IN COMPLEX WITH AZD9977.
1712, 5mk4C, 0.7133, 2.31, 0.238, 215, 210, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 7 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1713, 1mv9A, 0.7133, 2.21, 0.245, 214, 208, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE EICOSANOID DHA (DOCOSA HEXAENOIC ACID) AND A COACTIVATOR PEPTIDE
1714, 5lyqA, 0.7131, 2.21, 0.245, 212, 208, CRYSTAL STRUCTURE OF THE RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC SPIROKETAL AGONIST AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1715, 2q7jA, 0.7131, 2.91, 0.153, 247, 216, THE WILD TYPE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND A TIF2 BOX 3 COACTIVATOR PEPTIDE 740-753
1716, 4ivyA, 0.7129, 3.01, 0.180, 229, 217, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 7A
1717, 5v8qA, 0.7128, 3.02, 0.147, 249, 218, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS): PART III
1718, 5kcuB, 0.7128, 2.80, 0.196, 227, 214, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL ALPHA-NAPHTHYL OBHS-N DERIVATIVE
1719, 5cj6A, 0.7128, 2.86, 0.148, 244, 216, CRYSTAL STRUCTURE OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR BOUND TO THE LIGAND BINDING DOMAIN OF THE HUMAN ANDROGEN RECEPTOR
1720, 3olsB, 0.7128, 2.82, 0.172, 224, 215, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1721, 5l11A, 0.7127, 3.07, 0.192, 234, 219, HUMAN LIVER RECEPTOR HOMOLOGUE-1 (LRH-1) BOUND TO RJW100 AND A FRAGMENT OF TIF-2
1722, 3r5mC, 0.7127, 2.29, 0.234, 213, 209, CRYSTAL STRUCTURE OF RXRALPHALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1723, 3b67A, 0.7127, 2.95, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM C-23
1724, 5uanA, 0.7125, 2.21, 0.226, 278, 208, CRYSTAL STRUCTURE OF MULTI-DOMAIN RAR-BETA-RXR-ALPHA HETERODIMER ON DNA
1725, 2ylyA, 0.7125, 2.51, 0.170, 219, 212, SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS.
1726, 4znuB, 0.7123, 2.89, 0.185, 226, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHYL-SUBSTITUTED OBHS DERIVATIVE
1727, 1r5kA, 0.7123, 2.96, 0.181, 236, 216, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
1728, 3b68A, 0.7122, 2.96, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-4
1729, 3omqB, 0.7121, 2.82, 0.172, 224, 215, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1730, 5vo4A, 0.7120, 2.99, 0.147, 245, 217, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH 5-(2-FLUORO-4-HYDROXYPHENYL)-1-METHYL-1H-PYRROLE-2- CARBONITRILE
1731, 3ompB, 0.7119, 2.82, 0.172, 224, 215, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1732, 2aa5B, 0.7117, 3.28, 0.159, 255, 220, MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE
1733, 4ofrA, 0.7116, 2.92, 0.148, 243, 216, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1734, 5u2bD, 0.7115, 2.80, 0.191, 226, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1735, 3omoB, 0.7115, 2.83, 0.172, 224, 215, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1736, 1mvcA, 0.7114, 2.23, 0.245, 212, 208, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1737, 1mznG, 0.7110, 2.24, 0.245, 212, 208, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1738, 5dxgB, 0.7109, 2.63, 0.192, 219, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P5
1739, 1mznC, 0.7108, 2.25, 0.245, 212, 208, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1740, 5ji0A, 0.7106, 2.51, 0.231, 216, 212, PPARGAMMA-RXRALPHA(S427F) HETERODIMER IN COMPLEX WITH SRC-1 ROSIGLITAZONE AND 9-CIS-RETANOIC ACID
1741, 3e94A, 0.7106, 2.18, 0.242, 211, 207, CRYSTAL STRUCTURE OF RXRALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN AND A COACTIVATOR FRAGMENT
1742, 5tmmB, 0.7105, 2.72, 0.183, 222, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1743, 5tm1A, 0.7105, 2.69, 0.188, 220, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1744, 3kwyA, 0.7104, 2.21, 0.246, 210, 207, CRYSTAL STRUCTURE OF RXRALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN AND A COACTIVATOR FRAGMENT
1745, 3fugA, 0.7102, 2.19, 0.242, 211, 207, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST 3-[4-HYDROXY-3-(35 588-PENTAMETHYL-5678-TETRAHYDRONAPHTHALEN-2-YL)- PHENYL]ACRYLIC ACID
1746, 2ao6A, 0.7101, 2.87, 0.149, 242, 215, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TIF2(III) 740-753 PEPTIDE AND R1881
1747, 2q1vA, 0.7100, 2.88, 0.144, 244, 215, ANCESTRAL CORTICOID RECEPTOR IN COMPLEX WITH CORTISOL
1748, 2p1vA, 0.7100, 2.20, 0.242, 211, 207, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -PROPOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1749, 4oedA, 0.7099, 2.85, 0.149, 242, 215, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1750, 5mk4A, 0.7098, 2.32, 0.234, 214, 209, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 7 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1751, 1xowA, 0.7098, 2.86, 0.149, 243, 215, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH AN ANDROGEN RECEPTOR NH2- TERMINAL PEPTIDE AR20-30 AND R1881
1752, 4oilA, 0.7097, 2.84, 0.149, 242, 215, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1753, 3k23A, 0.7097, 2.68, 0.169, 245, 213, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
1754, 3gytA, 0.7097, 3.11, 0.174, 242, 219, NUCLEAR RECEPTOR DAF-12 FROM PARASITIC NEMATODE STRONGYLOIDES STERCORALIS IN COMPLEX WITH ITS PHYSIOLOGICAL LIGAND DAFACHRONIC ACID DELTA 4
1755, 1r5kB, 0.7097, 3.14, 0.189, 235, 217, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
1756, 2p1tA, 0.7096, 2.21, 0.242, 211, 207, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -METHOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1757, 3vhuA, 0.7095, 3.12, 0.165, 249, 218, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH SPIRONOLACTONE
1758, 2oz7A, 0.7095, 3.02, 0.142, 249, 218, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR T877A MUTANT LIGAND- BINDING DOMAIN WITH CYPROTERONE ACETATE
1759, 3d24C, 0.7094, 2.48, 0.186, 216, 210, CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN OF ESTROGEN- RELATED RECEPTOR ALPHA (ERRALPHA) IN COMPLEX WITH THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR COACTIVATOR- 1ALPHA BOX3 PEPTIDE (PGC-1ALPHA)
1760, 4oeaA, 0.7093, 2.86, 0.149, 242, 215, CRYSTAL STRUCTURE OF AR-LBD
1761, 1r5kC, 0.7093, 3.10, 0.190, 235, 216, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
1762, 4ofuA, 0.7090, 2.78, 0.150, 241, 214, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1763, 4oc7A, 0.7090, 2.32, 0.244, 213, 209, RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH (E)-3-(3 -ALLYL-6- HYDROXY-[11 -BIPHENYL]-3-YL)ACRYLIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF2
1764, 2amaA, 0.7090, 2.87, 0.149, 243, 215, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH DIHYDROTESTOSTERONE
1765, 4oghA, 0.7089, 2.80, 0.150, 242, 214, CRYSTAL STRUCTURE OF T877A-AR-LBD
1766, 3pcuA, 0.7089, 2.22, 0.242, 211, 207, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH LX0278 AND SRC1 PEPTIDE
1767, 2q1hA, 0.7089, 2.91, 0.144, 244, 215, ANCESTRAL CORTICOID RECEPTOR IN COMPLEX WITH ALDOSTERONE
1768, 4oezA, 0.7088, 2.86, 0.149, 242, 215, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1769, 1xq3A, 0.7087, 2.87, 0.149, 243, 215, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH R1881
1770, 4oiuA, 0.7085, 2.84, 0.149, 242, 215, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1771, 5u2bE, 0.7084, 2.76, 0.188, 221, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1772, 5mkjA, 0.7084, 2.23, 0.242, 211, 207, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 9 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1773, 4oh5A, 0.7082, 2.78, 0.150, 242, 214, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1774, 5dkeA, 0.7081, 2.67, 0.189, 221, 212, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-NAPHTHYL-SUBSTITUTED METHYL CIS-DIARYL-ETHYLENE COMPOUND 44 -[2-(NAPHTHALEN-2-YL)PROP-1-ENE-11-DIYL]DIPHENOL
1775, 4oeyA, 0.7078, 2.80, 0.150, 241, 214, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1776, 2q7kA, 0.7078, 2.79, 0.150, 242, 214, THE ANDROGEN RECEPTOR PROSTATE CANCER MUTANT H874Y LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND AN AR 20-30 PEPTIDE
1777, 5dxpA, 0.7076, 2.63, 0.184, 222, 212, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 4-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(PHENYL)METHYL]PHENOL
1778, 2q3yA, 0.7076, 2.90, 0.158, 244, 215, ANCESTRAL CORTICIOD RECEPTOR IN COMPLEX WITH DOC
1779, 4olmA, 0.7074, 2.75, 0.150, 240, 213, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1780, 4k7aA, 0.7074, 2.88, 0.144, 242, 215, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH MINOXIDIL
1781, 5dvsB, 0.7072, 2.74, 0.188, 223, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-METHYL-SUBSTITUTED TRIARYL-IMINE 44 -[(2-METHYLPHENYL) CARBONIMIDOYL]DIPHENOL
1782, 4ql8A, 0.7072, 2.79, 0.150, 240, 214, CRYSTAL STRUCTURE OF ANDROGEN RECEPTOR IN COMPLEX WITH THE LIGAND
1783, 2ax6A, 0.7072, 3.00, 0.148, 242, 216, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT IN COMPLEX WITH HYDROXYFLUTAMIDE
1784, 2ovmA, 0.7071, 3.18, 0.144, 243, 216, PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE FROM THE CO-REPRESSOR NCOR
1785, 2abiC, 0.7071, 2.59, 0.180, 234, 211, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1786, 1rdtA, 0.7071, 2.22, 0.237, 211, 207, CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER
1787, 5mj5A, 0.7069, 2.35, 0.244, 213, 209, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETICHONOKIOL DERIVATIVE 3 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1788, 1xpcA, 0.7067, 3.10, 0.181, 245, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 19
1789, 5ec9A, 0.7065, 2.16, 0.248, 210, 206, RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH CHIRAL DIHYDROBENZOFURAN BENZOIC ACID 9A AND A FRAGMENT OF THE COACTIVATOR TIF2
1790, 1xp9A, 0.7065, 3.07, 0.172, 245, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 18
1791, 4xi3C, 0.7063, 3.05, 0.173, 236, 214, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1792, 1s9qA, 0.7063, 2.79, 0.219, 224, 210, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
1793, 2p1uA, 0.7062, 2.27, 0.242, 211, 207, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -ETHOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1794, 1yimA, 0.7062, 3.07, 0.172, 245, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 4
1795, 1xp6A, 0.7062, 3.10, 0.177, 245, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 16
1796, 3dzyA, 0.7061, 2.38, 0.236, 302, 208, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH ROSIGLITAZONE 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1797, 1uhlA, 0.7061, 2.41, 0.229, 214, 210, CRYSTAL STRUCTURE OF THE LXRALFA-RXRBETA LBD HETERODIMER
1798, 1xp1A, 0.7060, 3.12, 0.186, 245, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 15
1799, 5w4vE, 0.7057, 2.33, 0.221, 206, 204, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1800, 5ufwA, 0.7056, 2.99, 0.173, 237, 214, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1154
1801, 5dwgB, 0.7053, 2.69, 0.185, 216, 211, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE TRIARYL-SUBSTITUTED IMINE ANALOG 4-{(E)-(4-HYDROXYPHENYL) [(2-METHYLPHENYL)IMINO]METHYL}BENZENE-13-DIOL
1802, 5ufxA, 0.7052, 3.01, 0.182, 234, 214, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1074
1803, 2ovhA, 0.7052, 3.15, 0.144, 243, 215, PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE FROM THE CO-REPRESSOR SMRT
1804, 2gpvB, 0.7050, 2.59, 0.216, 223, 208, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1805, 2gpvA, 0.7050, 2.69, 0.216, 224, 208, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1806, 5kceA, 0.7049, 2.66, 0.194, 223, 211, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL 2-CHLOROBENZYL OBHS-N DERIVATIVE
1807, 4okwA, 0.7047, 2.77, 0.150, 239, 213, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1808, 1l2jA, 0.7046, 2.87, 0.164, 232, 213, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH (R R)-511-CIS-DIETHYL-561112-TETRAHYDROCHRYSENE-28-DIOL
1809, 4rakA, 0.7042, 2.72, 0.240, 236, 208, CRYSTAL STRUCTURE OF NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2 (LXRB) COMPLEXED WITH PARTIAL AGONIST
1810, 2q7iA, 0.7042, 2.80, 0.150, 241, 213, THE WILD TYPE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND AN AR 20-30 PEPTIDE
1811, 5mmwA, 0.7041, 2.34, 0.245, 212, 208, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 6 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1812, 4ohaA, 0.7041, 2.85, 0.150, 242, 214, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1813, 5w4vC, 0.7040, 2.35, 0.216, 206, 204, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1814, 4ojbA, 0.7039, 2.78, 0.150, 240, 213, CRYSTAL STRUCTURE OF W741L-AR-LBD
1815, 4okbA, 0.7037, 2.79, 0.150, 240, 213, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1816, 4oh6A, 0.7037, 2.89, 0.150, 242, 214, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1817, 2abiB, 0.7037, 2.67, 0.175, 234, 211, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1818, 5q0lA, 0.7036, 3.23, 0.284, 221, 215, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1819, 3up0A, 0.7036, 3.34, 0.145, 242, 221, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-DELTA7-DAFACHRONIC ACID
1820, 2gpuA, 0.7034, 2.78, 0.205, 222, 210, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN
1821, 1s9pB, 0.7033, 2.72, 0.214, 217, 210, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1822, 4oarA, 0.7032, 2.98, 0.150, 241, 213, PROGESTERONE RECEPTOR WITH BOUND ULIPRISTAL ACETATE AND A PEPTIDE FROM THE CO-REPRESSOR SMRT
1823, 2qzoA, 0.7032, 3.09, 0.186, 227, 215, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH WAY-169916
1824, 2gpvC, 0.7030, 2.53, 0.217, 223, 207, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1825, 1xiuA, 0.7029, 2.44, 0.237, 221, 207, CRYSTAL STRUCTURE OF THE AGONIST-BOUND LIGAND-BINDING DOMAIN OF BIOMPHALARIA GLABRATA RXR
1826, 2iogA, 0.7028, 3.05, 0.173, 243, 214, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 11F
1827, 1ya3A, 0.7028, 2.52, 0.181, 233, 210, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1828, 1a52A, 0.7028, 2.92, 0.179, 239, 212, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
1829, 5q0lC, 0.7027, 3.23, 0.284, 220, 215, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1830, 4okxA, 0.7027, 2.80, 0.150, 240, 213, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1831, 2ewpB, 0.7027, 2.69, 0.210, 224, 210, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1832, 3rllA, 0.7026, 2.76, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE T877A ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH (S)-N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-(4- CYANONAPHTHALEN-1-YLOXY)-2-HYDROXY-2-METHYLPROPANAMIDE
1833, 2axaA, 0.7026, 2.76, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH S-1
1834, 5hcvA, 0.7025, 2.80, 0.174, 236, 213, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1835, 5fqpA, 0.7025, 3.03, 0.168, 242, 214, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 1.
1836, 6c42A, 0.7024, 2.96, 0.184, 234, 212, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1156
1837, 5tm4B, 0.7023, 2.68, 0.186, 218, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG 5-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)PENTANOIC ACID
1838, 3up0B, 0.7023, 3.33, 0.140, 242, 221, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-DELTA7-DAFACHRONIC ACID
1839, 2ax7A, 0.7018, 2.77, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT IN COMPLEX WITH S-1
1840, 1y9rA, 0.7016, 2.64, 0.180, 239, 211, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1841, 5krkB, 0.7015, 2.76, 0.190, 221, 211, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((5-BROMO-23-DIHYDRO-1H-INDEN-1-YLIDENE) METHYLENE)DIPHENOL
1842, 2ax8A, 0.7014, 2.77, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN W741L MUTANT IN COMPLEX WITH S-1
1843, 1qkmA, 0.7014, 2.91, 0.160, 230, 213, HUMAN OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST GENISTEIN
1844, 5tm2A, 0.7013, 2.67, 0.195, 217, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1845, 1s9pA, 0.7013, 2.67, 0.215, 215, 209, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1846, 2oaxF, 0.7011, 3.02, 0.178, 238, 214, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1847, 3os8B, 0.7010, 3.10, 0.168, 240, 214, ESTROGEN RECEPTOR
1848, 3e00A, 0.7009, 2.23, 0.239, 289, 205, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH GW9662 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1849, 1sj0A, 0.7009, 3.08, 0.188, 243, 213, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE ANTAGONIST LIGAND 4-D
1850, 1s9pC, 0.7009, 2.70, 0.215, 219, 209, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1851, 1z95A, 0.7008, 2.77, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN W741L MUTANT COMPLEX WITH R-BICALUTAMIDE
1852, 3os8A, 0.7007, 3.10, 0.168, 240, 214, ESTROGEN RECEPTOR
1853, 3osaB, 0.7004, 3.22, 0.167, 239, 215, ESTROGEN RECEPTOR
1854, 3osaA, 0.7003, 3.22, 0.167, 239, 215, ESTROGEN RECEPTOR
1855, 5w9dA, 0.7002, 3.01, 0.178, 242, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S C417S C530S MUTANT IN COMPLEX WITH ENDOXIFEN
1856, 2oaxA, 0.7002, 2.69, 0.176, 233, 210, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1857, 2ax9A, 0.7001, 2.79, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH R-3
1858, 1a52B, 0.7001, 2.95, 0.179, 240, 212, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
1859, 5jy3A, 0.6999, 2.47, 0.254, 228, 205, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
1860, 2qxsA, 0.6999, 3.19, 0.177, 236, 215, CRYSTAL STRUCTURE OF ANTAGONIZING MUTANT 536S OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO RALOXIFENE
1861, 3dzuA, 0.6998, 2.21, 0.234, 289, 205, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH BVT.13 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1862, 1xnxB, 0.6995, 3.06, 0.203, 232, 212, CRYSTAL STRUCTURE OF CONSTITUTIVE ANDROSTANE RECEPTOR
1863, 5u2bF, 0.6993, 2.74, 0.190, 225, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1864, 4xi3B, 0.6990, 3.01, 0.170, 233, 212, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1865, 5ufxB, 0.6988, 3.28, 0.182, 231, 214, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1074
1866, 3up3A, 0.6988, 3.13, 0.142, 242, 218, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-CHOLESTENOIC ACID
1867, 2ewpA, 0.6988, 2.75, 0.205, 224, 210, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1868, 5fqvA, 0.6986, 3.01, 0.175, 233, 212, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 5.
1869, 2ewpC, 0.6985, 2.68, 0.206, 223, 209, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1870, 3d24A, 0.6984, 2.44, 0.189, 209, 206, CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN OF ESTROGEN- RELATED RECEPTOR ALPHA (ERRALPHA) IN COMPLEX WITH THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR COACTIVATOR- 1ALPHA BOX3 PEPTIDE (PGC-1ALPHA)
1871, 5w4vD, 0.6983, 2.28, 0.219, 203, 201, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1872, 6chwA, 0.6980, 3.21, 0.172, 246, 215, ESTROGEN RECEPTOR ALPHA Y537S COVALENTLY BOUND TO ANTAGONIST H3B-5942.
1873, 1ya3C, 0.6980, 2.47, 0.184, 232, 207, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1874, 3os9A, 0.6979, 2.92, 0.171, 233, 210, ESTROGEN RECEPTOR
1875, 2abiA, 0.6979, 2.46, 0.174, 230, 207, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1876, 5fqsA, 0.6978, 3.02, 0.175, 233, 212, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 3.
1877, 1y9rB, 0.6978, 2.76, 0.171, 238, 210, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1878, 1pq6C, 0.6978, 2.35, 0.252, 208, 202, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
1879, 1vjbB, 0.6977, 2.51, 0.220, 210, 205, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
1880, 5ufwB, 0.6973, 3.21, 0.178, 229, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1154
1881, 2jj3B, 0.6972, 2.90, 0.161, 226, 211, ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
1882, 4iuiB, 0.6971, 2.71, 0.186, 221, 210, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A
1883, 5wzxB, 0.6970, 2.79, 0.276, 212, 210, STRUCTURAL BASIS FOR A PENTACYCLIC OLEANANE-TYPE TRITERPENOID AS A LIGAND OF FXR
1884, 5fqtA, 0.6970, 3.03, 0.175, 233, 212, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 4.
1885, 5w9dB, 0.6969, 3.11, 0.188, 237, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S C417S C530S MUTANT IN COMPLEX WITH ENDOXIFEN
1886, 5hcvC, 0.6969, 2.64, 0.177, 229, 209, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1887, 5hjpC, 0.6968, 2.22, 0.235, 216, 204, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1888, 2ouzA, 0.6966, 3.29, 0.167, 246, 215, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA-LASOFOXIFENE COMPLEX
1889, 5w9cA, 0.6965, 2.95, 0.171, 233, 211, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1890, 5hcvB, 0.6962, 2.63, 0.177, 232, 209, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1891, 1qktA, 0.6962, 3.18, 0.173, 248, 214, MUTANT ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
1892, 5jy3C, 0.6961, 2.72, 0.252, 231, 206, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
1893, 3h0aA, 0.6961, 2.32, 0.238, 210, 206, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID CO-ACTIVATOR PEPTIDE AND A PARTIAL AGONIST
1894, 1ya3B, 0.6961, 2.45, 0.179, 230, 207, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1895, 5kyjB, 0.6960, 2.31, 0.234, 217, 205, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1896, 5aauB, 0.6959, 2.52, 0.180, 222, 206, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
1897, 2ayrA, 0.6954, 3.27, 0.172, 246, 215, A SERM DESIGNED FOR THE TREATMENT OF UTERINE LEIOMYOMA WITH UNIQUE TISSUE SPECIFICITY FOR UTERUS AND OVARIES IN RATS
1898, 6chzA, 0.6951, 3.29, 0.172, 246, 215, ESTROGEN RECEPTOR ALPHA Y537S BOUND TO ANTAGONIST H3B-9224.
1899, 2ewpD, 0.6951, 2.68, 0.212, 221, 208, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1900, 5hjpA, 0.6947, 2.18, 0.236, 215, 203, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1901, 2oaxD, 0.6947, 2.86, 0.175, 234, 211, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1902, 1qknA, 0.6946, 2.83, 0.163, 228, 208, RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH ANTAGONIST RALOXIFENE
1903, 1yinA, 0.6945, 3.05, 0.175, 241, 211, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 3F
1904, 3dt3B, 0.6942, 3.10, 0.179, 240, 212, HUMAN ESTROGEN RECEPTOR ALPHA LBD WITH GW368
1905, 5w4vF, 0.6941, 2.29, 0.220, 202, 200, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1906, 2jj3A, 0.6937, 2.86, 0.162, 223, 210, ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
1907, 3os8C, 0.6936, 2.69, 0.178, 234, 208, ESTROGEN RECEPTOR
1908, 3ertA, 0.6936, 3.25, 0.182, 246, 214, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
1909, 1xb7A, 0.6936, 2.68, 0.183, 215, 208, X-RAY STRUCTURE OF ERRALPHA LBD IN COMPLEX WITH A PGC- 1ALPHA PEPTIDE AT 2.5A RESOLUTION
1910, 2oaxC, 0.6934, 2.76, 0.176, 233, 210, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1911, 5i4vB, 0.6933, 2.30, 0.235, 215, 204, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
1912, 2i0gB, 0.6933, 2.91, 0.162, 222, 210, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1913, 5w9cB, 0.6932, 3.10, 0.179, 234, 212, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1914, 4xi3A, 0.6929, 2.92, 0.177, 230, 209, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1915, 2yatA, 0.6928, 2.68, 0.197, 227, 208, CRYSTAL STRUCTURE OF ESTRADIOL DERIVED METAL CHELATE AND ESTROGEN RECEPTOR-LIGAND BINDING DOMAIN COMPLEX
1916, 3os8D, 0.6927, 2.74, 0.173, 230, 208, ESTROGEN RECEPTOR
1917, 2z4bB, 0.6926, 2.95, 0.171, 224, 210, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1918, 2i0gA, 0.6923, 2.84, 0.163, 221, 209, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1919, 1ndeA, 0.6919, 3.23, 0.156, 231, 212, ESTROGEN RECEPTOR BETA WITH SELECTIVE TRIAZINE MODULATOR
1920, 2z4bA, 0.6918, 2.84, 0.163, 221, 209, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1921, 5wzxA, 0.6917, 2.79, 0.284, 210, 208, STRUCTURAL BASIS FOR A PENTACYCLIC OLEANANE-TYPE TRITERPENOID AS A LIGAND OF FXR
1922, 2oaxE, 0.6917, 2.56, 0.174, 234, 207, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1923, 5kyjF, 0.6916, 2.34, 0.235, 218, 204, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1924, 2gpvD, 0.6916, 2.51, 0.227, 209, 203, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1925, 1vjbA, 0.6911, 2.63, 0.216, 208, 204, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
1926, 2p7zA, 0.6909, 2.37, 0.218, 207, 202, ESTROGEN RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXY- TAMOXIFEN
1927, 1dkfA, 0.6908, 2.52, 0.224, 217, 205, CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
1928, 5kyaB, 0.6906, 2.31, 0.236, 216, 203, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1929, 2gpvE, 0.6905, 2.43, 0.223, 208, 202, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1930, 5e15A, 0.6903, 2.62, 0.189, 218, 206, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1931, 3os9B, 0.6902, 2.88, 0.179, 228, 207, ESTROGEN RECEPTOR
1932, 2ylyB, 0.6902, 2.67, 0.155, 221, 206, SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS.
1933, 3r2aD, 0.6901, 2.57, 0.232, 219, 203, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
1934, 5kyaF, 0.6897, 2.30, 0.236, 217, 203, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1935, 5i4vF, 0.6897, 2.31, 0.236, 218, 203, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
1936, 3dt3A, 0.6895, 3.00, 0.181, 236, 210, HUMAN ESTROGEN RECEPTOR ALPHA LBD WITH GW368
1937, 2qtuB, 0.6893, 2.97, 0.172, 222, 209, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1938, 2giuA, 0.6890, 2.86, 0.168, 225, 208, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 45
1939, 3r29B, 0.6887, 2.60, 0.241, 212, 203, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2
1940, 2qtuA, 0.6885, 2.89, 0.173, 219, 208, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1941, 2gpvF, 0.6885, 2.51, 0.223, 208, 202, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1942, 5uc3A, 0.6884, 2.95, 0.164, 232, 207, NUCLEAR RECEPTOR
1943, 1g2nA, 0.6883, 2.63, 0.176, 246, 204, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE ULTRASPIRACLE PROTEIN USP THE ORTHOLOG OF RXRS IN INSECTS
1944, 5accA, 0.6880, 3.16, 0.186, 228, 210, A NOVEL ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATOR AZD9496 DRIVES TUMOUR GROWTH INHIBITION IN ESTROGEN RECEPTOR POSITIVE AND ESR1 MUTANT MODELS
1945, 5mkuA, 0.6879, 2.35, 0.236, 208, 203, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 4 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1946, 3a9eA, 0.6874, 2.18, 0.230, 218, 200, CRYSTAL STRUCTURE OF A MIXED AGONIST-BOUND RAR-ALPHA AND ANTAGONIST- BOUND RXR-ALPHA HETERODIMER LIGAND BINDING DOMAINS
1947, 5fqrA, 0.6872, 3.18, 0.186, 228, 210, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 2.
1948, 2oaxB, 0.6871, 2.58, 0.175, 233, 206, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1949, 3r2aA, 0.6868, 2.45, 0.233, 211, 202, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
1950, 1r1kA, 0.6868, 2.62, 0.176, 241, 204, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO PONASTERONE A
1951, 1s9qB, 0.6867, 2.46, 0.219, 216, 201, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
1952, 3ixpA, 0.6865, 2.59, 0.176, 242, 204, CRYSTAL STRUCTURE OF THE ECDYSONE RECEPTOR BOUND TO BYI08346
1953, 5uc3B, 0.6863, 3.07, 0.163, 231, 208, NUCLEAR RECEPTOR
1954, 6c42B, 0.6862, 3.02, 0.179, 225, 207, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1156
1955, 2pogA, 0.6862, 2.93, 0.183, 233, 208, BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR B AGONISTS (SERBAS). PART 2: STRUCTURE ACTIVITY RELATIONSHIP STUDIES ON THE BENZOPYRAN SCAFFOLD.
1956, 2qxsB, 0.6860, 2.85, 0.179, 225, 207, CRYSTAL STRUCTURE OF ANTAGONIZING MUTANT 536S OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO RALOXIFENE
1957, 1m7wC, 0.6859, 2.57, 0.222, 220, 203, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1958, 3uucD, 0.6857, 3.33, 0.185, 231, 211, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
1959, 3uucC, 0.6856, 3.00, 0.188, 228, 207, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
1960, 5w9cD, 0.6853, 2.98, 0.178, 227, 208, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1961, 5w9cC, 0.6853, 2.77, 0.175, 228, 206, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1962, 1m7wB, 0.6853, 2.42, 0.219, 218, 201, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1963, 1r20A, 0.6851, 2.65, 0.176, 239, 204, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO THE SYNTHETIC AGONIST BYI06830
1964, 3r29A, 0.6850, 2.48, 0.243, 212, 202, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2
1965, 3r2aB, 0.6848, 2.36, 0.230, 217, 200, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
1966, 2r40A, 0.6848, 2.55, 0.182, 238, 203, CRYSTAL STRUCTURE OF 20E BOUND ECR/USP
1967, 3osaC, 0.6847, 2.66, 0.176, 230, 205, ESTROGEN RECEPTOR
1968, 3gyuA, 0.6845, 3.16, 0.179, 234, 212, NUCLEAR RECEPTOR DAF-12 FROM PARASITIC NEMATODE STRONGYLOIDES STERCORALIS IN COMPLEX WITH ITS PHYSIOLOGICAL LIGAND DAFACHRONIC ACID DELTA 7
1969, 1hg4E, 0.6845, 2.30, 0.193, 240, 202, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1970, 2q70A, 0.6841, 3.17, 0.190, 235, 210, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLXED TO A BENZOPYRAN LIGAND
1971, 5z12C, 0.6839, 2.13, 0.231, 203, 199, A STRUCTURE OF FXR/RXR 
1972, 4xi3D, 0.6839, 2.71, 0.176, 219, 204, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1973, 1hg4D, 0.6838, 2.69, 0.184, 238, 206, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1974, 3osaD, 0.6833, 2.72, 0.171, 226, 205, ESTROGEN RECEPTOR
1975, 1hg4A, 0.6833, 2.32, 0.188, 240, 202, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1976, 2jfaA, 0.6832, 2.78, 0.185, 221, 205, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY- SELECTED COREPRESSOR PEPTIDE
1977, 1hg4B, 0.6832, 2.32, 0.188, 240, 202, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1978, 4ummF, 0.6831, 2.62, 0.172, 241, 203, THE CRYO-EM STRUCTURE OF THE PALINDROMIC DNA-BOUND USP-ECR NUCLEAR RECEPTOR REVEALS AN ASYMMETRIC ORGANIZATION WITH ALLOSTERIC DOMAIN POSITIONING
1979, 5dvvB, 0.6828, 2.52, 0.192, 210, 203, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-IMINE ANALOG 44 -(PHENYLCARBONIMIDOYL)DIPHENOL
1980, 1hg4C, 0.6826, 2.68, 0.184, 238, 206, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1981, 5aauA, 0.6824, 2.90, 0.175, 229, 206, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
1982, 2i0jB, 0.6824, 2.89, 0.194, 227, 206, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1983, 5dvvA, 0.6819, 2.43, 0.194, 209, 201, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-IMINE ANALOG 44 -(PHENYLCARBONIMIDOYL)DIPHENOL
1984, 1hg4F, 0.6819, 2.34, 0.193, 240, 202, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1985, 1uomA, 0.6818, 3.07, 0.184, 231, 207, THE STRUCTURE OF ESTROGEN RECEPTOR IN COMPLEX WITH A SELECTIVE AND POTENT TETRAHYDROISOCHIOLIN LIGAND.
1986, 3k6pA, 0.6812, 3.23, 0.175, 226, 211, ESTROGEN RELATED RECEPTOR ALPHA IN COMPLEX WITH AN ETHER BASED LIGAND
1987, 2i0jC, 0.6808, 2.93, 0.176, 223, 205, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1988, 5aavA, 0.6805, 2.91, 0.180, 232, 205, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
1989, 2iokA, 0.6803, 3.05, 0.197, 227, 208, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 1D
1990, 1nhzA, 0.6803, 3.22, 0.168, 239, 208, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF GLUCOCORTICOID RECEPTOR
1991, 4wvdA, 0.6802, 2.90, 0.271, 210, 203, IDENTIFICATION OF A NOVEL FXR LIGAND THAT REGULATES METABOLISM
1992, 4wvdB, 0.6801, 2.89, 0.281, 208, 203, IDENTIFICATION OF A NOVEL FXR LIGAND THAT REGULATES METABOLISM
1993, 2iokB, 0.6798, 3.15, 0.192, 228, 208, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 1D
1994, 4q50F, 0.6796, 3.09, 0.184, 220, 207, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
1995, 1l2jB, 0.6796, 2.76, 0.172, 223, 203, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH (R R)-511-CIS-DIETHYL-561112-TETRAHYDROCHRYSENE-28-DIOL
1996, 2i0jA, 0.6794, 2.98, 0.180, 221, 205, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1997, 2bj4A, 0.6790, 2.68, 0.187, 218, 203, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
1998, 4iuiA, 0.6787, 2.66, 0.192, 211, 203, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A
1999, 2jf9A, 0.6787, 2.97, 0.171, 215, 205, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
2000, 5tm9A, 0.6786, 2.97, 0.176, 215, 205, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-3-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)ACRYLIC ACID
2001, 2fszB, 0.6778, 3.04, 0.157, 227, 204, A SECOND BINDING SITE FOR HYDROXYTAMOXIFEN WITHIN THE COACTIVATOR-BINDING GROOVE OF ESTROGEN RECEPTOR BETA
2002, 2r6yA, 0.6777, 2.96, 0.184, 232, 206, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SERM
2003, 3uucB, 0.6776, 3.34, 0.187, 229, 208, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
2004, 2i0jD, 0.6776, 2.87, 0.191, 225, 204, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
2005, 5tnbC, 0.6771, 3.13, 0.165, 229, 206, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2006, 1errA, 0.6763, 3.23, 0.183, 224, 208, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
2007, 3tx7B, 0.6759, 2.52, 0.175, 218, 200, CRYSTAL STRUCTURE OF LRH-1/BETA-CATENIN COMPLEX
2008, 3h52B, 0.6759, 2.28, 0.177, 249, 198, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2009, 2jfaB, 0.6758, 2.91, 0.186, 222, 204, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY- SELECTED COREPRESSOR PEPTIDE
2010, 2r6wA, 0.6757, 2.95, 0.185, 229, 205, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO A SERM
2011, 5ak2A, 0.6754, 2.99, 0.181, 228, 204, OXYPHENYLPROPENOIC ACIDS AS ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS.
2012, 4b7wC, 0.6754, 2.24, 0.227, 202, 198, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2013, 4b7wA, 0.6754, 2.24, 0.227, 202, 198, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2014, 2fszA, 0.6753, 2.86, 0.159, 223, 201, A SECOND BINDING SITE FOR HYDROXYTAMOXIFEN WITHIN THE COACTIVATOR-BINDING GROOVE OF ESTROGEN RECEPTOR BETA
2015, 1lbdA, 0.6753, 3.48, 0.217, 238, 212, LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA
2016, 5tm9B, 0.6741, 2.81, 0.182, 211, 203, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-3-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)ACRYLIC ACID
2017, 5tnbD, 0.6737, 2.83, 0.178, 227, 202, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2018, 4q50G, 0.6737, 3.02, 0.195, 219, 205, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2019, 4q50E, 0.6736, 2.94, 0.192, 218, 203, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2020, 2r6wB, 0.6731, 2.94, 0.191, 223, 204, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO A SERM
2021, 3uucA, 0.6727, 3.11, 0.191, 220, 204, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
2022, 1hj1A, 0.6727, 2.39, 0.168, 204, 196, RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PURE ANTIOESTROGEN ICI164384
2023, 2r6yB, 0.6726, 2.92, 0.197, 221, 203, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SERM
2024, 2jf9C, 0.6725, 2.92, 0.183, 214, 202, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
2025, 1xqcC, 0.6725, 2.96, 0.196, 224, 204, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2026, 4q50H, 0.6720, 2.90, 0.182, 218, 203, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2027, 2ewpE, 0.6718, 2.56, 0.205, 214, 200, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
2028, 5tnbA, 0.6714, 3.11, 0.176, 227, 204, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2029, 5tn9C, 0.6708, 3.13, 0.172, 224, 204, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2030, 2bj4B, 0.6704, 3.11, 0.176, 221, 204, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
2031, 3h52A, 0.6701, 2.53, 0.157, 247, 198, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2032, 5ak2B, 0.6700, 2.54, 0.182, 210, 198, OXYPHENYLPROPENOIC ACIDS AS ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS.
2033, 2aclC, 0.6699, 2.24, 0.241, 215, 195, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2034, 1xqcA, 0.6698, 3.01, 0.191, 224, 204, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2035, 1g1uD, 0.6691, 3.45, 0.220, 229, 209, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2036, 4q50C, 0.6688, 2.97, 0.183, 220, 202, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2037, 2qe4A, 0.6688, 2.63, 0.176, 207, 199, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
2038, 1errB, 0.6684, 3.07, 0.186, 222, 204, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
2039, 5tlpB, 0.6681, 2.68, 0.186, 207, 199, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-BSC ANALOG 3-FLUOROPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE AND 3-METHYL-6-PHENYL-3H- IMIDAZO[45-B]PYRIDIN-2-AMINE
2040, 2q70B, 0.6681, 2.60, 0.192, 211, 198, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLXED TO A BENZOPYRAN LIGAND
2041, 2pogB, 0.6680, 2.60, 0.187, 211, 198, BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR B AGONISTS (SERBAS). PART 2: STRUCTURE ACTIVITY RELATIONSHIP STUDIES ON THE BENZOPYRAN SCAFFOLD.
2042, 2jf9B, 0.6680, 2.82, 0.189, 209, 201, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
2043, 1g5yD, 0.6675, 3.38, 0.216, 229, 208, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2044, 2aclE, 0.6669, 2.29, 0.241, 214, 195, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2045, 5tn9A, 0.6668, 2.95, 0.164, 222, 201, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2046, 1xqcD, 0.6664, 3.02, 0.194, 221, 201, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2047, 2aclA, 0.6661, 2.31, 0.231, 214, 195, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2048, 1xqcB, 0.6660, 2.95, 0.189, 221, 201, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2049, 2aclG, 0.6659, 2.37, 0.231, 214, 195, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2050, 2qe4B, 0.6649, 2.56, 0.188, 204, 197, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
2051, 4oivB, 0.6648, 2.96, 0.269, 218, 201, STRUCTURAL BASIS FOR SMALL MOLECULE NDB AS A SELECTIVE ANTAGONIST OF FXR
2052, 3os9C, 0.6645, 2.59, 0.178, 221, 197, ESTROGEN RECEPTOR
2053, 4q50D, 0.6632, 2.89, 0.195, 216, 200, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2054, 3r2aC, 0.6622, 2.57, 0.246, 203, 195, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
2055, 1g1uA, 0.6622, 3.51, 0.221, 228, 208, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2056, 1h9uC, 0.6619, 2.15, 0.245, 201, 192, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2057, 1h9uD, 0.6618, 2.16, 0.245, 201, 192, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2058, 1h9uA, 0.6618, 2.16, 0.245, 201, 192, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2059, 1g5yA, 0.6618, 3.53, 0.221, 228, 208, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2060, 4lsjA, 0.6617, 2.19, 0.187, 244, 193, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN BOUND TO A DIBENZOXAPINE SULFONAMIDE
2061, 4dorA, 0.6616, 2.95, 0.199, 216, 201, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN SHP BOX1
2062, 1h9uB, 0.6615, 2.16, 0.245, 201, 192, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2063, 3fc6A, 0.6613, 2.34, 0.237, 207, 194, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
2064, 5tn9D, 0.6574, 2.74, 0.179, 219, 196, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2065, 1g5yB, 0.6574, 3.17, 0.234, 229, 201, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2066, 1g5yC, 0.6564, 3.25, 0.239, 226, 201, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2067, 4q50B, 0.6562, 2.93, 0.193, 209, 197, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2068, 4q50A, 0.6559, 2.75, 0.184, 210, 196, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2069, 3kfcC, 0.6558, 1.94, 0.276, 186, 185, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
2070, 5aavB, 0.6557, 2.79, 0.196, 209, 194, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
2071, 2nxxB, 0.6552, 3.53, 0.187, 228, 208, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2072, 2pjlA, 0.6551, 3.16, 0.151, 218, 205, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC INVERSE AGONIST REVEALS ITS NOVEL MOLECULAR MECHANISM
2073, 5tnbB, 0.6550, 2.88, 0.179, 215, 196, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2074, 2pjlB, 0.6548, 3.24, 0.150, 218, 206, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC INVERSE AGONIST REVEALS ITS NOVEL MOLECULAR MECHANISM
2075, 2nxxA, 0.6544, 3.50, 0.187, 224, 208, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2076, 5tn9B, 0.6541, 2.62, 0.175, 211, 194, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2077, 1g1uC, 0.6538, 3.22, 0.241, 226, 199, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2078, 3fc6C, 0.6529, 2.07, 0.243, 202, 189, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
2079, 3h52D, 0.6527, 2.58, 0.154, 234, 195, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2080, 2nxxD, 0.6525, 3.34, 0.189, 227, 206, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2081, 2nxxC, 0.6525, 3.34, 0.189, 225, 206, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2082, 3os9D, 0.6515, 2.70, 0.180, 208, 194, ESTROGEN RECEPTOR
2083, 6b0fA, 0.6513, 2.63, 0.176, 204, 193, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
2084, 1g1uB, 0.6512, 3.17, 0.237, 229, 198, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2085, 3n00A, 0.6484, 2.16, 0.342, 184, 184, CRYSTAL STRUCTURE OF A DELETION MUTANT OF HUMAN REVERBA LIGAND BINDING DOMAIN BOUND WITH AN NCOR ID1 PEPTIDE DETERMINED TO 2.60A
2086, 2xhsA, 0.6463, 3.83, 0.144, 232, 209, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF FUSHI TARAZU FACTOR 1 OF DROSOPHILA MELANOGASTER.
2087, 3falC, 0.6449, 2.03, 0.242, 198, 186, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
2088, 4oivA, 0.6427, 3.03, 0.278, 210, 194, STRUCTURAL BASIS FOR SMALL MOLECULE NDB AS A SELECTIVE ANTAGONIST OF FXR
2089, 3falA, 0.6420, 1.92, 0.250, 196, 184, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
2090, 4mddA, 0.6419, 2.89, 0.155, 247, 193, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR BOUND TO A NON- STEROIDAL ANTAGONIST REVEALS REPOSITIONING AND PARTIAL DISORDERING OF ACTIVATION FUNCTION HELIX 12
2091, 2q60D, 0.6375, 2.74, 0.221, 197, 190, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2092, 2q60A, 0.6374, 2.70, 0.226, 198, 190, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2093, 3cjwA, 0.6364, 2.95, 0.223, 207, 193, CRYSTAL STRUCTURE OF THE HUMAN COUP-TFII LIGAND BINDING DOMAIN
2094, 2q60C, 0.6348, 2.42, 0.226, 203, 186, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2095, 4b7wD, 0.6343, 2.17, 0.228, 200, 184, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2096, 4b7wB, 0.6343, 2.17, 0.228, 200, 184, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2097, 5tbpC, 0.6331, 3.11, 0.240, 213, 192, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2098, 3h52C, 0.6328, 2.82, 0.172, 237, 192, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2099, 5uc1B, 0.6319, 3.17, 0.170, 205, 194, STRUCTURAL ANALYSIS OF GLUCOCORTICOID RECEPTOR BETA LIGAND BINDING DOMAIN COMPLEXED WITH GLUCOCORTICOID ANTAGONIST RU-486: IMPLICATION OF HELIX 12 IN ANTAGONISM
2100, 5tbpB, 0.6318, 3.08, 0.241, 213, 191, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2101, 5uc1A, 0.6305, 3.10, 0.171, 205, 193, STRUCTURAL ANALYSIS OF GLUCOCORTICOID RECEPTOR BETA LIGAND BINDING DOMAIN COMPLEXED WITH GLUCOCORTICOID ANTAGONIST RU-486: IMPLICATION OF HELIX 12 IN ANTAGONISM
2102, 3eybB, 0.6296, 2.70, 0.246, 199, 187, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2103, 3eybC, 0.6294, 2.71, 0.246, 199, 187, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2104, 3eybA, 0.6293, 2.70, 0.241, 199, 187, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2105, 3eybD, 0.6291, 2.71, 0.246, 199, 187, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2106, 4ozrE, 0.6284, 2.71, 0.241, 197, 187, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (METHYLENE LACTAM CRYSTAL)
2107, 4mddB, 0.6247, 2.40, 0.164, 220, 183, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR BOUND TO A NON- STEROIDAL ANTAGONIST REVEALS REPOSITIONING AND PARTIAL DISORDERING OF ACTIVATION FUNCTION HELIX 12
2108, 2q60B, 0.6227, 2.65, 0.228, 198, 184, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2109, 4n5gB, 0.6219, 2.82, 0.249, 209, 185, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2110, 2gl8D, 0.6211, 2.62, 0.251, 195, 183, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2111, 5t97B, 0.6205, 2.47, 0.181, 191, 182, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- (4-{(1R)-6-HYDROXY-1-METHYL-2-[4-(PROPAN-2 -YL)PHENYL]-1234- TETRAHYDROISOQUINOLIN-1-YL}PHENYL)PROP-2-ENOIC ACID
2112, 2v0vA, 0.6205, 2.19, 0.363, 181, 179, CRYSTAL STRUCTURE OF REV-ERB BETA
2113, 4zo1B, 0.6199, 2.89, 0.246, 199, 187, CRYSTAL STRUCTURE OF THE T3-BOUND TR-BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH RXR-ALPHA
2114, 2gl8C, 0.6194, 2.43, 0.260, 194, 181, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2115, 2v0vD, 0.6187, 2.20, 0.356, 179, 177, CRYSTAL STRUCTURE OF REV-ERB BETA
2116, 4n5gC, 0.6183, 2.95, 0.247, 209, 186, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2117, 2gl8A, 0.6165, 2.48, 0.250, 190, 180, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2118, 2gl8B, 0.6160, 2.40, 0.256, 192, 180, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2119, 2v0vB, 0.6154, 2.25, 0.354, 181, 178, CRYSTAL STRUCTURE OF REV-ERB BETA
2120, 5t92A, 0.6149, 2.21, 0.185, 183, 178, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- {4-[(1R)-2-(4-FLUOROPHENYL)-6-HYDROXY-1-METHY L-1234- TETRAHYDROISOQUINOLIN-1-YL]PHENYL}PROP-2-ENOIC ACID
2121, 6b0fB, 0.6137, 2.40, 0.179, 185, 179, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
2122, 2v0vC, 0.6128, 1.98, 0.366, 179, 175, CRYSTAL STRUCTURE OF REV-ERB BETA
2123, 3p0uA, 0.6091, 3.45, 0.173, 222, 191, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN TESTICULAR RECEPTOR 4
2124, 4n73A, 0.6063, 2.86, 0.352, 198, 182, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN (LBD) OF REV-ERB BETA BOUND TO COBALT PROTOPORPHYRIN IX
2125, 3p0uB, 0.6056, 3.32, 0.175, 216, 189, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN TESTICULAR RECEPTOR 4
2126, 5t92B, 0.6033, 2.44, 0.198, 183, 177, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- {4-[(1R)-2-(4-FLUOROPHENYL)-6-HYDROXY-1-METHY L-1234- TETRAHYDROISOQUINOLIN-1-YL]PHENYL}PROP-2-ENOIC ACID
2127, 5t97A, 0.5941, 2.23, 0.186, 177, 172, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- (4-{(1R)-6-HYDROXY-1-METHYL-2-[4-(PROPAN-2 -YL)PHENYL]-1234- TETRAHYDROISOQUINOLIN-1-YL}PHENYL)PROP-2-ENOIC ACID
2128, 3nsqB, 0.5897, 2.67, 0.263, 199, 175, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD COMPLEXED WITH ANTAGONIST DANTHRON
2129, 4n5gA, 0.5877, 3.02, 0.258, 196, 178, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2130, 2v7cB, 0.5874, 1.85, 0.380, 168, 166, CRYSTAL STRUCTURE OF REV-ERB BETA
2131, 5tbpD, 0.5872, 2.96, 0.267, 198, 176, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2132, 5tbpA, 0.5871, 2.95, 0.261, 198, 176, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2133, 5gymB, 0.5870, 2.85, 0.263, 196, 175, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2134, 4n5gD, 0.5869, 2.98, 0.267, 196, 176, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2135, 4n8rD, 0.5861, 2.91, 0.254, 197, 177, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2136, 4n8rA, 0.5846, 2.92, 0.260, 197, 177, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2137, 4oztU, 0.5839, 2.98, 0.219, 195, 178, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (PONA CRYSTAL)
2138, 4n8rB, 0.5835, 2.93, 0.263, 198, 175, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2139, 5gymA, 0.5808, 2.88, 0.260, 193, 173, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2140, 4n8rC, 0.5803, 3.01, 0.263, 196, 175, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2141, 3cqvA, 0.5800, 2.71, 0.355, 188, 172, CRYSTAL STRUCTURE OF REVERB BETA IN COMPLEX WITH HEME
2142, 5gymD, 0.5799, 2.80, 0.262, 192, 172, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2143, 1z5xU, 0.5775, 3.01, 0.239, 193, 176, HEMIPTERAN ECDYSONE RECEPTOR LIGAND-BINDING DOMAIN COMPLEXED WITH PONASTERONE A
2144, 5gymF, 0.5773, 2.86, 0.262, 195, 172, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2145, 5gymC, 0.5770, 3.01, 0.259, 190, 174, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2146, 3nsqA, 0.5757, 2.68, 0.263, 193, 171, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD COMPLEXED WITH ANTAGONIST DANTHRON
2147, 5gymG, 0.5752, 2.92, 0.262, 192, 172, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2148, 3nspA, 0.5752, 2.69, 0.263, 193, 171, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD
2149, 4ozrU, 0.5746, 2.92, 0.220, 196, 173, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (METHYLENE LACTAM CRYSTAL)
2150, 3nspB, 0.5743, 2.52, 0.266, 190, 169, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD
2151, 5gymE, 0.5726, 2.51, 0.268, 191, 168, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2152, 5gymH, 0.5721, 2.92, 0.263, 192, 171, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2153, 2v7cA, 0.5540, 1.93, 0.391, 159, 156, CRYSTAL STRUCTURE OF REV-ERB BETA
2154, 3f5cB, 0.5451, 3.36, 0.192, 183, 172, STRUCTURE OF DAX-1:LRH-1 COMPLEX
2155, 3f5cC, 0.5348, 3.29, 0.183, 181, 169, STRUCTURE OF DAX-1:LRH-1 COMPLEX
